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SUMMARY OF THE DISSERTATION 
 
 
    This thesis is aimed at exploring the application of gold nanoparticles in cancer cell 
diagnostics and therapy. Cancer is a public leading cause of death in the world. Searching 
for efficient method of diagnostics of cancer and selective therapy are extremely active 
field today. With the great development of nanotechnology, various nanoparticles in 
different structures, shapes and composites provides good potential for their application 
in cancer diagnostics and therapy. Compared to other nanoparticles, gold nanoparticles 
have great advantages in cancer applications due to their easy preparation, efficient 
bioconjugation, potential noncytotoxicity, tunable and enhanced scattering and absorption 
properties.  The strong scattering of gold nanoparticles provides an opportunity for their 
use in cancer cell imaging. Their strong absorption provides a possibility for them to be 
used in photothermal therapy. In this thesis, we will show that both gold nanospheres and 
gold nanorods can be used as molecular contrast agents for dual efficient cancer 
diagnostics and selective photothermal therapy. 
    Gold nanospheres of 40 nm in diameter were synthesized by the citrate reduction 
method. The nanospheres were conjugated to anti-epidermal growth factor receptor (anti-
EGFR) monoclonal antibodies and then incubated with a nonmalignant epithelial cell line 
(HaCat) and two malignant oral epithelial cell lines (HOC 313 clone 8 and HSC 3). The 
cells were imaged under dark field at 100x using an inverted IX70 Olympus microscope. 
The absorption spectra of gold nanoparticles on single cells were measured using a 
SEE1100 micro-spectrometer. The dark field light scattering images show distinct 
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difference between the cancerous and noncancerous cells due to the overexpression of the 
EGFR on the cancer cells. The anti-EGFR antibody conjugated nanoparticles specifically 
and homogeneously bind to the surface of the cancer cells with higher affinity than to the 
noncancerious cells. The peak position of the surface plasmon absorption spectra of gold 
nanoparticles also show difference between cancer and noncancer cells due to the 
difference in the dielectric constant of the surrounding environment on the surface of the 
gold nanoparticles. 
    After the incubation with anti-EGFR/gold conjugates, the cells were exposed to a cw 
argon ion laser at 514 nm. Due to the overloading of gold nanoparticles on the cancer 
cells, it is found that the malignant cells require less than half the laser energy to be killed 
than the healthy cells. No photothermal destruction is observed for all types of cells in the 
absence of nanoparticles at four times the energy required to kill the malignant cells with 
ant-EGFR/Au. This demonstrates that gold nanospheres can be used as a novel class of 
selective photothermal agents using a cw laser at low powers in the visible region. 
    By oven-heating experiment, it is found that cells without nanoparticles are thermally 
destroyed between 70 – 80 oC. This temperature is found to be in agreement with the 
calculation results by Prashant (another member in our group) from the amount of gold 
loading at the threshold laser power.  
    For clinical application of treating cancer in vivo under the skin, it is necessary to use 
nanoparticles absorbing in the near infrared (NIR) region of the radiation spectrum to 
minimize the light extinction by intrinsic chromophores in native tissue. Gold nanorods 
with suitable aspect ratios (length divided by width) can be synthesized which absorb and 
 xxiv
scatter strongly laser light in the NIR region (650-900 nm). Thus gold nanorods were 
synthesized by the seed-mediated growth method and conjugated to anti-epidermal 
growth factor receptor (anti-EGFR) monoclonal antibodies and incubated in cell cultures 
with the cancer and healthy cells. Like the nanospheres, the anti-EGFR antibody 
conjugated nanorods bind specifically to the surface of the malignant type cells with a 
much higher affinity due to the overexpressed EGFR on the cytoplasmic membrane of 
the malignant cells. As a result, they strongly scattered red light from gold nanorods in 
dark field using a laboratory microscope, the malignant cells are clearly visualized and 
distinguished from the nonmalignant cells.  
It is found that malignant cells require half the laser energy to be photothermally 
destroyed than the nonmalignant cells if exposed to a continuous Ti:Sapphire laser at 800 
nm. Compared to other contrast agents for photothermal therapy in NIR region such as 
Si/Au nanoshell and carbon nanotubes, solid gold nanorods have several advantages. The 
synthesis of gold nanorods with various aspect ratios, which enable tunable absorption 
wavelength in NIR is quite simple and well-established. The size of the nanorods needed 
is quite small and is potentially useful in applications such as drug delivery and gene 
therapy. In addition, the biosafety of gold nanorods has been proven is well known and 
they have been used in vivo since the 1950’s. Recently the noncytotoxicity of gold 
nanoparticles in human cells has been studied in detail by Wyatt et al.  
    The addition of gold nanoparticles is found to quench the NADH fluorescence 
intensities but has no effect on the fluorescence lifetime. This suggested that the 
fluorescence quenching is not due to coupling with the excited state, but due to changing 
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the ground state of NADH. In support of this, the intensity of the 340 nm absorption band 
of NADH is found to decrease while that of the 260 nm band of NAD+ is found to 
increase as the concentration of gold nanoparticles increase. This conversion reaction is 
further supported by nuclear magnetic resonance and mass spectroscopy. The linear 
dependence of the initial reaction rate of NADH on the concentration of gold 
nanoparticles gives strong support that the conversion of NADH to NAD+ is occurring on 





CHAPTER 1  
INTRODUCTION 
 
    When the size of a material is reduced to the nanometer length scale (which is the 
length scale of the electronic motion that determines the material’s properties), its 
electronic and thus chemical properties change tremendously. In semiconductor 
nanoparticles, the property change results from quantum confinement of the electronic 
motion (1). In metals, the properties of the surface become dominant and give 
nanoparticles new properties (2). In noble metals the coherent collective oscillation of 
electrons in the conduction band induces large surface electric fields which greatly 
enhance the radiative properties of gold and silver nanoparticles when they interact with 
resonant electromagnetic radiation (3). This makes the absorption crossection of these 
nanoparticles orders of magnitude stronger than the strongest absorbing molecules (4) 
and the scattered light becomes orders of magnitude more intense than the fluorescence 
of organic dyes (5). These unique properties provides great potential for the nanoparticles 
to be used in many applications, such as biochemical sensors (6), biological imaging and 
medial therapeutics (7-12) as well as in catalysis because of their high surface-to-volume 
ratios (13-14).   
1.1 Important properties of gold nanoparticles 
1.1.1 Surface plasmon absorption property of gold nanoparticles 
        Gold nanoparticles show a strong absorption band in the visible region when the 
frequency of the electromagnetic field is resonant with the coherent electron motion, 
which is called surface plasmon resonance absorption (15). The surface plasmon 
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absorption results from the dipole oscillations of the free electrons with respect to the 
ionic core of a spherical nanoparticle (16). A net charge difference is shown on the 
nanoparticle surface when interaction with an electric field which results in a polarization 
of the electrons with respect to the ionic core of a nanoparticle (see Figure 1).  
 
 
Figure 1-1: A scheme of surface plasmon absorption of 
spherical nanoparticles illustrating the excitation of the 
dipole surface plasmon oscillation (16). 
This induces a dipolar oscillation of all the electrons in the same phase. When the 
frequency of the electromagnetic field becomes resonant with the coherent electron 
motion, a strong absorption band around 520 nm in the spectrum is observed (Figure 1-2), 
which is the origin of the observed brilliant color of the nanoparticles in solution.  















Wavelength (nm)  
Figure 1-2: Typical surface plasmon absorption spectrum of spherical 
nanoparticles. Strong absorption band around 520 nm in the spectrum is the 
origin of the observed red color of the nanoparticle solution.  
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        Mie (17) is the first to explain the surface plasmon resonance behavior of the 
spherical metal nanoparticles. He solved maxwell’s equation for an electromagnetic light 
wave interactiong with a small sphere. For nanoparticles much smaller than the 
wavelength (< 20nm), only the dipole oscillation contributes significantly to the 
extinction cross section and thus Mie’s theory reduced to the following equation:  
 
(1-1)
Where V is the particle volume, x is the angular frequency of the exciting light, c is the 
speed of light, and εm and ε(ω) = ε1(ω) + i ε2(ω) are the dielectric functions of the 
surrounding medium and the material itself respectively. The resonance condition if 
fulfilled when is ε1(ω) = -2 εm  if ε2 is small or weakly dependent on ω. But for larger 
nanoparticles, the light can not polarize the nanoparticles homogeneously and retardation 
effects lead to the excitation of higher-order modes (2).  
    From equation (1-1), it can be seen that the peak intensity and position of the surface 
plasmon absorption band is dependent on the size and shape of the metal nanoparticles as 
well as the dielectric constant of the metals as well as the medium surrounding the 
particles (18). As the size increases, the absorption maximum is red shifted slightly (See 
Figure 1-3). The bandwidth also changes when the sizes changes. Link and El-Sayed (4) 
have shown that the bandwidth decreases with the increase of the nanoparticles size when 
the nanoparticles are less than 20 nm in diameter (Figure 1-4, left) and the bandwidth 
increases with the increase of the nanoparticle size when the nanoparticles are larger than 
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20 nm. He also found that the absorption coefficient is linearly dependent on the volume 









































Figure 1-3: Surface plasmon absorption spectra (left) and TEM (right) of 
spherical gold nanoparticles in different sizes. The surface plasmon absorption 







Figure 1-4: Left: the relationship of the absorption bandwidth with the size of the 
nanoparticles; Right: the relationship of the absorption coefficient with the size of the 
nanoparticles (4). The bandwidth increases with decreasing nanoparticle radius in the 
intrinsic size region and also with increasing radius in the extrinsic size region as 
predicted by Mie theory.  The extinction coefficients of these gold nanoparticles against 
their volume show a linear dependence (4).  
    When the shape of the nanoparticles changes from nanosphere to nanorods, the surface 
plasmon absorption spectrum also changes. Figure 1-5 shows a typical absorption 
spectrum of nanorods. The surface plasmon absorption of gold nanorods have two bands: 
a strong long wavelength band in the near infrared region due to the longitudinal 
oscillation of electrons and a weak short wavelength band in the visible region around 
520 nm due to the transverse electronic oscillation.  
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Figure 1-5: Typical surface plasmon absorption spectrum of gold 
nanorods.  The strong long wavelength band in the near infrared region 
around 800 nm is due to the longitudinal oscillation of electrons and the 
weak short wavelength band in the visible region around 520 nm is due to 






























    The optical absorption spectrum of gold nanorods with aspect ratio R can be modeled 
using an extension of the Mie theory. Within the dipole approximation according to the 
Gans (19) treatment, the extinction cross-section rext for elongated ellipsoids is given by 
the following equation (20): 
(1-2)
 
Where Pj are the depolarization factors along the three axes A, B and C of the nanorod. 
with A > B = C, defined as 
 
(1-3)




    Different from spherical nanoparticles, the absorption spectrum of the gold nanorods is 
very sensitive to the aspect ratio (length/width). Figure 1-6 shows experimentally how the 
absorption maximum of the nanorods shifted with the aspect ratios. When the aspect ratio 
increases, the absorption maximum of the longitudinal band is greatly red shifted. The 
absorption difference of the longitudinal band caused the color difference of the nanorod 
solution. For short nanorods with the longitudinal maximum lower than 700 nm, the 
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nanorods appear in blue color. When the longitudinal maximum is between 700 nm and 
800nm, the solution appears in deep red color and the nanorods with longitudinal 
maximum larger than 800 nm, the nanorods appears in pink color. Figure 1-7 shows 
theoretically the changes of the absorption intensity and the position with the change of 
the dimension of the nanorods (21) according to equation (1-2). From Figure 1-7, it can 
























































Figure 1-6: The absorption spectra of gold rods of different aspect ratios (left) 







Figure 1-7: Calculated absorption spectra of elongated ellipsoids with 
varying aspect ratios R according to equation (1-2). (21). 
 
From the inset of Figure 1-7, it can be seen that the absorption maximum of the 
longitudinal band is linearly dependant on the aspect ratio of the nanorods while there is 
no change on the transverse band. This gives a simple guess of the aspect ratio according 
to the known absorption maximum without TEM experiments. 
Due to the strong surface plasmon absorption, gold nanoparticles offer great potential 
in photothermal therapy applications. It has been found that the strong absorbed radiation 
is converted efficiently into heat on a picosecond time domain due to electron-phonon 
and phonon-phonon processes (18). Thus, upon the laser irradiation at the surface 
plasmon absorption band, the nanoparticles absorb photon energy and then immediately 
transfer into heat energy. If the nanoparticles are incorporated or incubated with 
biomolecules, cells or tissues, this heat energy will cause the sharp increase on the local 
temperature around the nanoparticles and thus cause the damage of the surrounding 
materials. This photothermal destruction can be used for disease or cancer therapy. 
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Compared to the strongly absorbing Rhodimine 6G (ε = 1.16 x 105 M-1 cm-1 at 530 nm 
(22)) dye molecules, gold nanoparticles absorb about 103 stronger (for nanospheres of 40 
nm in diameter, ε = 2.74 x 109 M-1 cm-1 at 530 nm, (4)). Thus gold nanoparticles provide 
a novel class of photo-absorber in medical applications.   
    For clinical application of treating cancer in vivo under the skin, one need to use near 
infrared (NIR) laser light which has larger penetration depth. Light in the region between 
650 – 900 nm has a penetration depth of at least several centimeters depending on the 
types of the tissue (23). From Figure 1-6 we can see that the gold nanorods absorb 
strongly in the NIR region. This offers the great opportunity for the nanorods to be used 
as the photo-absorbers in NIR and realize photothermal therapy. 
1.1.2 Surface plasmon light scattering property of gold nanoparticles 
    It is known that gold particle suspensions scatter colored light when illuminated by a 
beam of white light (24). The light-scattering gold nanoparticle suspensions have the 
same appearance as fluorescent solutions as shown in Figure 1-8 (5).  
    The light scattering is sensitive to the size, shape and the composite of the 
nanoparticles. Nanoparticles with 58 nm in diameter scatter green light while 78 nm  in 
diameter scatter yellow light (Figure 1-8, b and c) while gold nanorods scatter red light 
under illumination of a beam of white light (Figure 1-9, (25)). Figure 1- 10 shows how 
the scattered light is different for compositions and shapes (26). 
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Figure 1-8:  a: the gold nanoparticles of different sizes irradiated by a beam 
of white light, b: the light scattering imaging of 58 nm gold nanoparticles, c: 
the light scattering imaging of 78 nm gold nanoparticles (5).  
 
Figure 1-9: True color photograph of a sample of gold nanorods (red) and 
60 nm nanospheres (green) in dark-field illumination (inset upper left). 
Bottom right: TEM images of a dense ensemble of nanorods and a single 
nanosphere (25).  
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                            Silver nanoprisms    gold nanorods   gold nanospheres 
   
                                  , 
 
Figure 1-10: Light scattering of silver nanoprisms, gold nanorods, 
and gold nanospheres (26).  
    Juan Yguerabide and Evangelina E. Yguerabide (5) have presented the theory of the 
light-scattering properties. The light scattering intensity is described by equation (1-5), 
which depends on the detection direction of the scattered light. The light scattering cross 





Where a is the particle radius, nmed is the refractive index of the medium surrounding the 
particle, I0 is the intensity of the incident monochromatic light, m is the relative refractive 
index of the bulk particle material, α is the angle between the detection direction r and 
the incident beam, λ0 is the wavelength of the incident beam and Im is the imaginary part 
of the complex expression within the parenthesis.  
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    From equation (1-5 and 1-6), we can see that the light scattering power is proportional 
to the sixth power of the particle radius. Thus by changing the size of the nanoparticles, 
the strength and the light scattering profile can be tuned. Figure 1-11 shows the 
normalized light scattering profile of the gold nanospheres in different sizes and Table 1-
1 shows the relative strength of the light scattering of these particles. Thus, by changing 
the size of the gold nanoparticles, light scattering color and power can be tuned. 
 
Figure 1-11: Calculated light scattering cross section vs wavelength for homogeneous, 
spherical gold particles with different diameters (23). 
 
Table 1-1: Comparison of calculated intensity of light Scattered at 90° by gold particles 
illuminated with monochromatic (I u) and white unpolarized Light (I u, INT) (19). 
 
    Lu et al. (27) theoretically derived the resonant light scattering cross section of gold 









           
(1-10)
           
(1-11)
Where a is the half of rod length, b is half of the rod width, ε1 and ε2 are the dielectric 
functions for the ellipsoid and embedding regions, respectively. Figure 1-12 shows the 
numerical calculation results of light scattering spectra of gold nanorods with different 
aspect ratios according to equation (1-7) (27). 
 
 
Figure 1-12: Calculated resonance scattering spectra of gold nanorods 
with varying aspect ratios a/b (27).  
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    Using the light scattering properties, gold nanoparticles offer great potential for 
applications in biomedical imaging. A 60 nm gold nanoparticles is 105 stronger in the 
scattered light than the fluorescence light of a fluorescein molecule. Also, the scattered 
light color and intensity can be tuned by changing the size and shapes of the 
nanoparticles. Compared to fluorescent molecules, the use of gold nanoparticles for 
imaging is simple. There are no photobleach problems which always exist for 
fluorescence molecules. 
    From above introduction, we know that the peak intensity and position of both surface 
plasmon absorption and scattering bands are dependent on the size and shape of the metal 
nanoparticles. Since the total extinction efficiency is equal to the sum of the scattering 
and absorption efficiency, the absorption and scattering percentage will vary depending 
on the size and shape of the nanoparticles. Figure 1-13 shows the calculated size and 
shape dependence of the percentage of the absorption and scattering efficiency (28) using 
Mie theory, separation of variables method and discrete dipole approximation method. 
For a 40 nm nanospheres, the absorption cross section is higher than the light scattering 
cross section. But when the shapes change to spheroid with aspect ration of 2, they are 
equal and when the aspect ration change to 3 for the spheroid nanoparticles, scattering 
cross section dominates. Figure 1-14 shows the percentage of the absorption and 
scattering efficiency for gold nanorods (28) using discrete dipole approximation method. 
It can be see that the absorption and scattering efficiency can be tuned by changing the 
aspect ratio of the nanorods. This tunability between the absorption and scattering 
provides great flexibility for their use in imaging and photothermal therapy. 
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Figure 1-13: Calculated optical extinction, absorption, and 
scattering spectra (a) for a Au sphere with a radius of 40 nm in 
water and for a prolate Au spheroid with an aspect ratio R of (b) 2 
and (c) 3, using different computational methods (29).  
 
 
Figure 1-14: A series of calculated spectra for optical extinction, 
absorption, and scattering efficiencies for Au nanorods with 
different aspect ratios R (28). 
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1.1.3 Catalytic property of gold nanoparticles  
    Gold nanoparitcles have large surface-to-volume ratio compared to bulk materials, thus 
they are attractive to be used as catalysts. Figure 1-15 shows the publication of gold 
catalysis since 1901 from Scienfinder Scholar and Figure 1-16 shows the patens on the 
gold catalysis in the last decades (29). Traditionally gold was thought to be inert in 
catalysis. But within decades, gold nanoparticles have received wide interests due to the 
availability of small size nanoparticles which provides higher percentage of surface 







































































































Figure 1-16: Gold catalysis patents from 1991 to 2005 (29). 
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      The use of supported gold nanoparticles in heterogeneous catalysis accounts for most 
publications. The most reported catalysis is the low-temperature oxidation of carbon 
oxide (29-32), propylene epoxidation (33, 34), combustion of hydrocarbons (35, 36), 
NOx reduction (37, 38), hydrogenation reactions (39) and some other reactions (40-42). 
The activity of the gold nanoparticles depends on the size of the nanoparticles, the 
surface property of the nanoparticles (Au+ might be involved) and the interaction of the 
particle with the supported substrates (43). 
    In homogeneous catalysis colloidal nanoparticles are used. Citrate-stabilized colloidal 
gold nanoparticles have been shown to be an active redox catalyst in the reaction between 
hexacyanoferrate (III) and thiosulfate ions (13, 14, 44) by Freund and Spiro. They found 
that the initial reaction rate is linearly dependent on the concentration of the gold 
nanoparticles. Compared with the theoretical results, they found the reaction is surface 
controlled catalysis, not diffusion controlled. Poly (N-vinyl-2-pyrrolidone) (PVP) capped 
colloidal gold nanoparticles can catalyze the homocoupling of phenylboronic acid in 
water (45). Some other reactions such as thiol oxidation under UV radiation are also 
catalyzed by gold nanoparticles (46). For the colloidal nanoparticle catalysis, the 
stabilizer is most important. Weak stabilizer will not keep the nanoparticle stable during 
reactions while stronger stabilizer will cap the nanoparticle too strongly thus the surface 
activity is limited. So gold nanoparticles prepared in different methods and capped by 






    Cancer is the leading killer in the United States under the age of 85, surpassing heart 
disease in 2004 (48). Currently, one in four deaths in the United States is due to cancer 
(49). Nearly half of all men and a little over one third of all women in the United States 
will develop cancer during their lifetimes (50). Cancer can strike people at any age; 
although about 77% of all cancers are diagnosed in people age of 55 and older (50).   
    Cancer begins when the DNA of a normal cell changes, or "mutates". Most of the time 
when DNA becomes damaged, the body is able to repair it. In cancer cells, the damaged 
DNA is not repaired (51). People can inherit damaged DNA, which accounts for inherited 
cancers. More often, though, a person's DNA becomes damaged by exposure to 
something in the environment, like smoking (52). Cancer usually forms as a tumor. Some 
cancer, like leukemia, does not form tumors. Instead, these cancer cells involve the blood 
and blood-forming organs and circulate through other tissues where they grow. Often, not 
all tumors are cancerous. Benign (noncancerous) tumors do not spread (metastasize) to 
other parts of the body and, with very rare exceptions, are not life threatening (53).  
    Cancer develops when cells in a part of the body begin to grow out of control. 
Although there are many kinds of cancer, they all start because of out-of-control growth 
of abnormal cells. Under normal conditions, the cells in the human body divide and grow 
in an orderly, controlled manner. Cancer occurs when cells grow in an uncontrolled 
manner. Instead of dying, they outlive normal cells and continue to form new abnormal 
cells (54).  
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    The cancer cell is profoundly abnormal cells which can be observed under simple 
optical microscope. Cancer cell’s morphology is different from that of a normal cell. Its 
nucleus is larger and irregular. 
1.2.1 ErbB receptors 
    The growth of cells requires signal transduction between cells. The "conversation" 
between two cells involves a molecular messenger (called a ligand) from the sender and a 
site (called a receptor) on the membrane surface of the cell receiving the signal. When the 
signal is received, it is passed along within the cell. In this way, the message is 
communicated from the outer surface of the cell to the cell's nucleus (55). 
    One of common signaling pathways involve proteins called receptor tyrosine kinases, 
which have three components: An extracellular ligand-binding domain receptor that is 
located outside the cell and receives incoming signals; A transmembrane domain that 
crosses the cell membrane and conveys information from the outside to the inside; An 
intracellular tyrosine kinase domain that adds a phosphate molecule to tyrosine, a type of 
protein. This process initiates an internal messaging cascade and is referred to as 
“phosphorylation” (56).  
    In oncology, the most important tyrosine kinase signaling networks is a group of 
receptors belonging to the "HER" family, also known as the ErbB signaling network (see 
Figure 1-17) (57). The HER family of receptors consists of four main members 
commonly called as HER1/EGFR (ErbB1), HER2 (ErbB2), HER3 (ErbB3) and HER4 
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(ErbB4), which demonstrate homology in their kinase domains, but diverge in their 
extracellular regions and C-terminal tails (see Figure 1-18) (58).  
 
 
Figure 1-17: Her Signaling (57).      
  
    
Figure 1-18: Schematic diagram of the four ErbB family members and 
their ligands. Numbers denote the degree (expressed as a percentage) of 
homology relative to ErbB1/EGFR (58).  
    These receptors are widely expressed in all tissues where they regulate diverse 
functions, including mitogenesis, differentiation, and cell survival. Different ligands and 
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protein-protein interactions contribute to the diverse signaling networks that characterize 
each receptor. Each of these receptors is in some way involved in the development of 
malignant tumors, although some are more involved than others in different cancers. In 
all cells, some level of growth-signal transduction is normal and is part of the regular 
growth cycle. It is the overexpression, or activation, of these signals - or the failure to 
counterbalance or block those signals -- that leads to uncontrollable growth and lead to 
cancer (see Table 1-2) (59). In the case of the HER2, for example, overexpression is the 
 Table 1-2: Her receptors and cancers (59). 






mutation leading to non-stop 
activity 
head and neck, brain, 
bladder, stomach, breast, 
lung, endometrium, cervix, 
vulva, ovary, esophagus, 
stomach, prostate, renal, 
pancreatic, glioblastoma 





coexpression with HER1 




HER3/ErbB3 Coexpression with HER2 
improves the possibility of 
breast cancer 
breast, colon, gast, prostate 
HER4/ErbB4 lower expression in breast and 
prostate tumors relative to 
normal tissue 
breast, prostate, childhood 
medullot 
result of a genetic alteration that generates multiple copies of a gene that encodes a 
growth receptor. Because of the surplus of growth receptor genes in the cell, excessive 
numbers of growth receptors are created that, when activated, enlarge the number growth 
signals stimulating the cell, accelerating cell division and tumor growth. 
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1.2.2. EGFR  
    The epidermal growth factor receptor (EGFR) is a cell surface receptor that directs the 
initiation of processes such as growth, proliferation, apoptosis, adhesion, migration, and 
differentiation, when it is activated by specific growth factors (60-62). Overexpression, or 
increased abundance, of EGFR in cancers was first identified by LICR (Ludwig Institute 
for Cancer Research) investigators who also have done dominant research in the EGFR 
area (63). EGFR is overexpressed (it can also be mutated) with high frequency in most 
cancers (see Table 1-3) (64). EGFR expression in normal cells ranges from 40,000–
100,000 receptors per cell (65). In many cases, the number of EGFRs expressed in 
malignant cells is greater than that expressed in normal cells; up to 2 million EGFRs per 
cell were reported to be demonstrated in human epidermoid carcinoma cells A431 (66).  
    Table 1-3: EGFR overexpression in tumors (64). 
                   Tumor type                         Percentage of tumors overexpressing EGFR
          Cervix/uterus 90% 
Head and Neck 80-100/% 
Renal carcinoma 50-90% 
Esophagael 43-89% 





Pancreatic  30-50% 
Colon 25-77% 
Breast  14-91% 
Gastric 4-33% 
Epidermal growth factor receptor (EGFR) is the prototype member of the type I receptor 
tyrosine kinases (67-69). The EGFR is a 170-kDa plasma membrane glycoprotein 
containing an extracellular ligand-binding domain, a single transmembrane region, a 
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cytoplasmic domain which is composed of a tyrosine kinase domain and a C-terminal tail 
(67, 70, 71). The amino acid sequence of EGFR has been deduced by Ullrich et al. in 
1984 (72). From this information and subsequent structure studies the structure features 
of EGFR has been constructed as in Figure 1-19 (72-76).   
 
Figure 1-19: Structure features of EGFR._ ：canonical sequences for N-
linked glycosylations; : probable sites of N-linked oligosaccharide 
chains, ●: cysteine residues, Y: tyrosine residues, P ~ Y: phosphotyrosine 
residues, T: threonine residues, P ~ T: phosphothreonine residues, K: 
lysine residues, FSBA ~ K: lysine residue covalently labeled with p-
fluorosulfonylbenzoyl adenosine, crosshatched area: membrane-spanning 
region, stippled area: sequences similar to src kinase (76).   
    The extracellular domain of EGFR contains 621 amino acid residues (70) and it folded 
into four domains in three dimension, domain I, II, III and domain IV (77) (see Figure 1-
20). Domain I and III are regions with a relatively large number of canonical sequences 
for N-linked glycosylation and domain II and IV regions containg a high content of 
cysteine [76]. The ligands for EGFR such as EGFRand TGF-α binds to both domain I 
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and III (78). The transmembrane domain is a single polypeptide chain of 22 amino acids 
(79). Immediately adjacent to the transmembrane sequence, there is at the cytoplalsmic 
interface a 13-residue sequence that is highly enriched in basic amino acids (76). The 
tyrosine kinase is located in the endoplasmic domains and the c-terminal regions contains 
the major sites of autophosphorylation.    
   Cell Membrane 
Figure 1-20: Three dimensional structure of the 
extracellular domain of EGFR (77). 
        EGFR realize its function in the initiation of cell growth processes by binding with 
EGF. Upon binding of a specific growth factor ligand to its extracellular ligand-binding 
domain, the EGFR receptor pairs, or ‘dimerizes’, with another ErbB family member (see 
Figure 1-21, 1-22) (80,81). This dimerization may be homodimerization (i.e. EGFR 
dimerizes with another EGFR) or heterodimerization (e.g. EGFR dimerizes with ErbB-2, 
ErbB-3, or ErbB-4) determined by the levels of each receptor, and the particular ligand 
bound to the receptor. After dimerization, the receptors’ intrinsic tyrosine kinase activity 
phosphorylates tyrosine amino acid residues in both receptors. 
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Figure 1-21: EGFR signaling transduction in tumor cells (80). 
 
 
Figure 1-22: Ligand activation of EGFR. A: Structure of unbound 
extrocellular domain (autoinhibited, tethered state); B: Structure of 1:1 
EGF: EGFR extrocellular complex (dimerization-competent state) and C: 
structure of 2:2 EGF: EGFR extrocellular complex (dimerized, activated 
state) (81).  
Various ‘adaptor’ proteins, such as Shc and Grb2, are then recruited to the 
phosphorylated tyrosines, and transduce signals via major cell signaling pathways that are 
comprised of signaling molecules such as the nitogen-activated protein kinase (MAPK), 
































kinase C (PKC), and the p70 S6β kinase, many of which were discovered and/or 
characterized by Ludwig Institute for Cancer Research (LICR) teams (82). The sequential 
activation of these and other molecules transmit signals from the receptor dimers at the 
cell surface through particular pathways to, ultimately, the transcription machinery in the 
nucleus. The final aspect of the EGFR signaling process occurs with the receptor 
undergoing a conformational change (concomitant with ligand binding) that results in the 
exposure of motifs for endocytosis (removal from the cell surface) and degradation. The 
endocytosis of the receptor is the mechanism for down-regulation of signaling from the 
activated EGFR (83-84). 
1.2.3. Cancer diagnostics 
    Conventional cancer diagnostics depends on the cell pathology, such as biopsy, 
endoscopy, and imaging which all looked at the cell appearance under microscope (85, 
86). Biopsy is the only sure way to test for cancer. In biopsy, the doctor removes a 
sample of the tissue on the abnormal area or may removes the whole tumor and then a 
pathologist examines the tissue under microscope.  
    Endoscopy is to look into the body by using a thin, lighted tube. Sample tissue or cells 
can be collected for further examination through the forcep on the tip of the tube. 
    Imaging is to look at the inside of the body using X-ray, or CT (computed tomography), 
ultrasonography and MRI (magnetic resonance imaging). It usually uses a special dye 
that is put into the body to stain certain organs and increase the imaging contrast. X-ray 
imaging is the most common way to make pictures of the inside of the body. CT, 
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sometimes called CAT (computed angled tomography) scan, uses special x-ray 
equipment to obtain image data from different angles around the body and then uses 
computer processing of the information to show a cross-section of body tissues and 
organs.  Ultrasonography uses high-frequency sound wave to enter the body and then use 
the echoes to produce a picture called a sonogram. MRI uses radiofrequency waves and a 
strong magnetic field to provide remarkably clear and detailed pictures of internal organs 
and tissues. The technique has proven very valuable for the diagnosis of a broad range of 
pathologic conditions in all parts of the body including cancer, heart and vascular disease, 
stroke, spinal and joint problems. 
    With the advanced development of molecular biology in the last decade, enormous 
progress has been made to understand the molecular events that accompany maglignant 
transformation and progression by genomics and proteomics (87). Molecular diagnostics 
determines how the genes and proteins in cancer cells and or organism are interacting in a 
cell by expressing these molecular signatures as patterns (88, 89). Compared to the 
conventional pathology methods, these patterns improve the clinical’s ability to 
diagnostics cancers with more accuracy and they assist early cancer detection. However, 
these advances have not yet impacted on diagnostics and staging of the majority of cancer 
cells in real time (90).  
1.2.4. Cancer therapy 
    It is well know that the tradition cancer treatment includes surgery, radiation, hormone 
therapy and more recently chemotherapy, immunotherapy and combines strategies (91). 
Surgery is the oldest form of treatment for cancer. It offers the greatest chance for cure 
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for many types of cancer, especially those that have not yet spread to other parts of the 
body but not for cancers at late phase. It will continue to be an extremely important 
weapon against cancer.  
    Radiation is the second weapon against cancer. Radiation therapy involves treating 
cancer with beams of high-energy particles, or waves (radiation), such as X-rays, gamma 
rays, neutrons or pimesons (92). Radiotherapists often implant radioactive materials or 
radioisotopes into tumors. The particles transfer their energy into electrons which ionize 
the matter they reach such as water and/or the solid constituents of cytoplasm, RNA and 
DNA. This ionization damages the molecules and leads the free radicals to recombine 
with oxygen available in the environment. Thus changes the biological properties of the 
biomolecules such as causing the cell to die or make it impossible to divide. Radiation is 
much more harmful to cancer cells than it is to normal cells. This is because cancer cells 
divide more rapidly than do healthy cells. Cells are more vulnerable to damage when 
they're dividing, making cancer cells to be more susceptible to radiation than normal cells. 
In addition, normal cells can recover from the effects of radiation more easily than cancer 
cells. But still it is nonetheless true that it is impossible to kill a tumor without harming 
the surrounding healthy cells.  
    Hormone therapy changes the internal environment and prevents the growth of cancers 
that are hormone-dependent such as breast and prostate cancers. It is usually called 
androgen deprivation therapy (ADT) or androgen suppression therapy. Controlling cancer 
of the prostate is the triumph of hormone therapy. Androgens, produced mainly in the 
testicles, can actually stimulate prostate cancer cells to grow. Hormone therapy is to 
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lower androgen levels (either by surgery or drugs such as pituitary down-regulators and 
anti-androgens) can usually make prostate cancers shrink or grow more slowly.   
    Chemotherapy is most often used to mean taking medicines, or drugs, to treat cancer, 
especially suitable for those cancers that have been spread out and can not be used by the 
local methods such as surgery and radiation. Normal cells grow and die in a controlled 
way. Cancer cells keep dividing and forming more cells without control. Anticancer 
drugs destroy cancer cells by stopping them from growing or multiplying. They also go 
after and damage any healthy cells that are quickly dividing, whether it's a cancer cell or 
not. Lately emerged photothermal therapy have greatly improved the therapy efficiency 
by  injecting contrast agents such as weak emitting dyes (93, 94) into the tumer sites 
which convert the photoengergy into thermal engery and thus kill the cancer cells. 
Photosensitizers are also been reported for photodynamic therapy which use photoexcited 
molecules to transfer their energy to oxygen forming excited singlet oxygen which 
injures cancer cells (95, 96). 
   With the development of immunology, immunotherapy (also known as biologic therapy) 
is emerged as a more specific cancer treatment method. Immunotherapy is a treatment 
that uses certain parts of the immune system to fight diseases, including cancer. This can 
be done by stimulating your own immune system to work harder or by using an outside 
source, such as manmade immune system proteins (97). Compared to other forms of 
cancer treatment, such as surgery, radiation therapy, or chemotherapy, immunotherapy is 
relatively new. One of the immunotherapy is to use monoclonal antibody which 
specifically target the cancer cells and then block the cancer cell activation or cure the 
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cancer cells by attaching radioactive chemicals on the antibodies (98). Some monoclonal 
antibodies that react with specific antigens on certain types of cancer cells have been used 
in clinical trials (see Table1-4) (64). Compared with side effects of standard 
chemotherapy, the side effects of naked MAbs are usually relatively mild and are often 
related to an "allergic" reaction.  
Table 1-4: Monoclonal antibodies in clinical trials (64).  
MAb Name Trade Name 
Type Used to Treat: Approved in: 
Rituximab Rituxan Anti-CD20 antigen  Non-Hodgkin lymphoma 1997 
Trastuzumab Herceptin Anti-HER2 receptor Breast cancer 1998 
Gemtuzumab 
ozogamicin* Mylotarg 















Anti-CD20 antigen  Non-Hodgkin 
lymphoma 2003 
Cetuximab  Erbitux Anti-EGFR receptor Colorectal cancer 2004 
Bevacizumab Avastin Anti-VEGF receptor Colorectal cancer 2004 
1.3 Nanotechnology in cancer applications 
    With the tremendous development of nanotechnology, a variety of nanostructures with 
different shapes and structures of different composites (1, 4, 99-107) has been provided. 
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These nanostructures demonstrate unique electronic, photonic, catalytic and highly 
controlled and interesting properties as a consequence of the size reduction from bulk to 
nanoscale (16, 18, 108-111). These nanoparticles exhibit similar size dimensions to many 
common biomolecules such as proteins and DNA, thus offer great possibilities for the 
integration of nanotechnology to biotechnology. Typical applications include contrast 
agents for disease diagnostics and therapies (112-115), developing homogenous 
immuassay [116-118] and assembling new materials (119, 120).  
    The use of nanoparticles in medicine is one of the important directions that 
nanotechnology is taking at this time. Their applications in drug delivery [121-123], 
cancer cell diagnostics (124-129) and therapeutics (12, 130, 131) have been active fields 
of research.  
1.3.1 Quantum dots in cancer imaging 
    One of the most widely used nanoparticles in the cancer applications are the 
semiconductor nanocrystals, also referred to as quantum dots, due to their wide 
absorption ranges and unique size dependent fluorescence properties (see Figure 1-23, 
(126), Figure 1-24, (127)). They are highly fluorescent and photobleach resistant (113, 
114). They can be used for imaging cancer cell markers (see Figure 1-25) (125). They 
can provide single excitation for multicolor images, which is not possible for molecular 
fluorophors because of their narrow excitation spectra. But the potential human 





Figure 1-23: The wide absorption spectrum (a) and the narrow emission 









Figure 1-25: Detection of cancer marker Her2 with QD-IgG. (A), (C) 
fixed cells Sk-BR-3 cells were incubated with monoclonal anti-Her2 
antibody and goat anti-mouse IgG conjugated to QDs. (A) QD535-IgG, (c): 
QD630-IgG. (B) and (D) cells were incubated with normal mouse IgG and 
QD-IgG (125).  
 
  1.3.2 Gold nanoshell in cancer imaging and photothermal therapy 
    Another kind of nanoparticles for cancer applications is called gold nanoshell 
nanoparticles (12, 128, 132-135). It contains silica core (about 140 nm in diameter) with 
a thin laser of gold shells (about 10 nm). The absorption band of core-shell particles can 
been tuned by adjusting the ratio of the thickness of the gold shell to the diameter of the 
silica core (Figure 1-26, (132)) and thus enables both strong scattering and absorption 
efficiency. Therefore they can be use as dual imaging/therapy contrast agents (see Figure 





Figure 1-26: The optical tenability of Si/AU core shell nanoparticles by 
changing the ration of the shell to core (132). 
 
   
Figure 1-27: Combined imaging and therapy of SKBr3 breast cancer cells 
using HER2-targeted nanoshells. Scatter-based darkfield imaging of HER2 
expression (top row), cell viability assessed via calcein staining (middle row), 
and silver stain assessment of nanoshell binding (bottom row) (128). 
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Figure 1-28: (a) Gross pathology after in vivo treatment with nanoshells 
and NIR laser reveal hemorrhaging and loss of tissue birefringence 
beneath the apical tissue surface. (b) Silver staining of a tissue section 
reveals the region of localized nanoshells (outlined in red). (c) 
Hematoxylin_eosin staining within the same plane clearly shows tissue 
damage within the area occupied by nanoshells. (d) Likewise, MRTI 
calculations reveal an area of irreversible thermal damage of similar 
dimension to a, b, and c (12). 
1.3.3 Polymer nanoparticles in drug delivery   
    Nanoparticles have become a greatly studied for use in drug delivery for therapeutic 
applications due to their small size which is suited for intravenous delivery.  Polymer has 
several advantages over other nanoparticles such as easy incorporation or incubation of 
the drug with the nanoparticles, the ability to stabilize the drugs in vivo and no side 
effects (especially for the biodegradable polymers) (136-140). Figure 1-29 (141) shows a 
common way of the drug delivery into cells and the later releasing to target. Polymer can 
also be functionized with cancer marker targeting molecules as other nanoparticles. So 
the polymer can specifically target the cancer cells and then release the drugs to the 






Figure 1-29: Intracellular trafficking of nanoparticles. Following their 
uptake, nanoparticles are transported through early endosomes to the 
sorting endosomes. A fraction of nanoparticles recycles back to the cell 
exterior while another fraction is transported to secondary 
endosomes/lysosomes from where nanoparticles escape into the cytoplasm. 
Nanoparticles that escape into the cytoplasm could act as intracellular 
reservoirs for sustained release of the encapsulated therapeutic agent (141). 
 
1.3.4 Gold nanoparticles in cancer imaging    
    Solid gold nanoparticles have been widely interested due to its easy preparation, ready 
bioconjugation and potential noncytotoxicity (143). Various methods for the preparation 
of gold colloids were reported in the 20th century (144). It only takes several minutes to 
synthesize the nanoparticles in a boiling auric solution that is reduced by citrate 
molecules, which is the most popular synthesis method. The sizes of the nanoparticles 
can be easily changed by changing the citrate concentration (145). The citrate capped 
nanoparticles are very stable but the citrate ion can be replaced and functionized with 
various ligands for specific applications. The safety of gold nanoparticles is well-known. 
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Gold nanoparticles have already been used in vivo since the 1950’s as a radiaotracer 
(143).  
    Using the light scattering properties of gold nanoparticles, preliminary studies have 
reported their use as contrast agents for biomedical imaging using multiphoton plasmon 
resonance microscopy (9), third-harmonic microscopy (11), optical coherence 
microscopy (10) and confocal scanning optical microscopy (8) (see Figure 1-30, 1-31).  
 
 
Figure 1-30: SiHa cells labeled with anti-EGFR gold conjugates in (a) 
brightfield (b) in brightfield with laser pointer illumination (8). 
 
 
Figure 1-31: Cervical biopsies labeled with anti-EGFR antibodies/gold 
nanoparticles conjugates: (A) clinically abnormal; (B) clinically normal 
obtained under the same acquisition conditions as (A) (8). 
    Gold nanoparticles have several advantages for imaging application compared to other 
agents. The scattered light is very strong and they are much brighter than chemical 
fluorophores. They are photobleach resistant and can be easily seen in as low as 10-16 M 
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concentration (147). Sokolov (8) have used confocal microscope to detect the scattering 
of anti-EGFR/Au nanoparticles for cervical cancer. Irradiation with a laser will only 
produce single color which is close to the laser wavelength used. When illuminated with 
a beam of white light, gold nanoparticles will scatter light of many colors. The color of 
the light is determined by the absorption spectrum of the nanoparticles which depends on 
the shape and size of the nanoparticles (8). This color dependent scattering property 
provides the potential for imaging studies with a simple white light source.  
    In this thesis, the application of gold nanospheres (129, 130, 148) and nanorods (131) 
in the cancer cell diagnostics and therapy are demonstrated in detail. This includes using 
the surface plasmon absorption band of gold nanoparticles and the strong scattering 
properties for diagnostics of cancer cells from healthy cells, using the particle’s strong 
absorption properties. The efficient energy conversion process from photo energy to local 
heat energy (18) is used for photothermal cancer therapy.  
    The catalytic property of gold nanoparticles for the NADH oxidation to NAD+ is also 
described. In addition, the application of gold nanospheres and nanorods as substrates for 
surface enhanced Raman of small molecules, large biomolecules and living cells is also 
described and demonstrated. Furthermore, some other related studies such as the 
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CHAPTER 2  
DETAILS OF THE DIFFERENT EXPERIMENTS CARRIED OUT  
 
 
2.1 Cell culture 
    One nonmalignant epithelial cell line, HaCaT (human keratinocytes) and two 
malignant epithelial cell lines, HOC 313 clone 8 and HSC 3 (human oral squamous cell 
carcinoma) are obtained from Dr Ivan, a surgeon in Otolaryngology-Head and Neck 
Surgery, Comprehensive Cancer Center, University of California at San Francisco. Dr 
Ivan ships the frozen cells (obtained from Prof Randall Kramer’s lab, where the cells are 
originally extracted from patient tissue and cultured and frozen in liquid nitrogen) in dry 
ice by Fedex. When the frozen cells arrive here, the cells are stored in a -80oC freezer in 
Prof Paul Edmonds’s lab (Department of Biology, Georgia Tech). The chemicals 
involved in the cell culture are listed in Table 2-1.   
 Table 2-1: The chemicals used in the cell culture 
DMEM medium: 
Dulbecco's Modification of Eagle's Medium, 1X with 4.5 g/L, L-glutamine, & sodium pyruvate, 6x500mL, 
Cellgro, Cat No: MT10-013-CV. 
FBS: 
Fetal Bovine Serum, Gem Cell, Cat No: 100-500. 
DPBS buffer:  
Dulbecco's phosphate-Buffered Saline, W/O Calcium and Magnesium, 1X solution, 6x500 mL, Cellgro, 
Cat No: MT21-031-CV. 
Trypsin:  
0.25% Trypsin/2.21 mM EDTA in HBSS without sodium bicarbonate, calcium and magnesium, Porcine 
Paravirus Tested, 6x100mL, Cellgrow, Cat No: MT-25-053-CI. 
15 mL Falcon Centrifuge Tubes: 
17 x 120mm, BD* Falcon* BlueMax* 15mL Graduated Tubes, Qty/pk: 125. Fisher, Cat No: 14-959-49B, 
Falcon No: 352096. 
50 mL Falcon Centrifuge Tubes: 
30x115mm, BD* Falcon* BlueMax* 50mL Graduated Tubes, Qty/pk: 25, Fisher, Cat No: 14-432-22, 
Falcon No: 352070. 
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100 x 20 Tissue Culture plates: 
100 dia, 20mmH, BD Falcon cell culture dishes, Fisher, Cat No: 08-772 E, Falcon No: 353003,  
60 x15 Tissue culture plates: 
60 dia, 15mmH, BD Falcon cell culture dishes, Fisher, Cat No: 08-772B. Falcon No: 353002.   
Multiwell culture plates: 
BD Falcon TM Multiwell culture plates, 12 well flat-bottom with lid, Fisher, Falcon No: 353043, Fisher 
No: 08-772-29. 
Lab marker: 
Black or blue, VWR, Cat No: 52877-150. 
Sterile filter: 
Millex-GV Filter Unit, Millex-GV, 0.22 µm, PVDF 13 mm Ethylene Oxyde, Sterilized, Qty/pk: 100. 
Millipore, Cat No: SLGV013SL. 
Sterile filter, 50 mL 
Steriflip-GP Filter Unit, Steriflip-GP, 0.22 µm, polyethersulfone, gamma irradiated, Qty/Pk: 25, Millipore. 
Cat No: SCGP00525 
Sterile Pipette: 
Falcon* Disposable Polystyrene Serological Pipets, Individually Wrapped in Paper/Plastic, Individually 
wrapped in paper/plastic package. Fisher. 
1 mL pipette, Falcon No: 357522, Cat No: 13-675-15C 
5 mL pippete, Falcon No: 357543, Cat No: 13-675-22 
10 mL pipette, Falcon No: 7551, Cat No: 13-675-20 
25 mL pipette, Falcon No: 357525, Cat No: 13-668-2 
Tweezers: 
DUMONT Electronic, blue epoxy-coated Tweezers, Ted Pella, Inc, Cat No: 5206. 
Cover slips: 
Fisher band cover glasses. Size: 18mm, Circle, NO.2 -0.17 to 0.25 mm thick, Fisher, Cat No: 12-546.   
    Before starting cell culture, the cell culture hood, Biosafety Cabinet (Room 140, 
Department of Biology, Dr Edmonds lab), is sterilized by turning on the UV lights and 
power switch for at least 30 mins. During this time, FBS (stored frozen at -20oC freezer, 
top layer of the common refrigerator) and red DMEM medium (stored cold at 4oC, 
bottom layer of the common refrigerator) are taken out and put in a water bath (set at 
37oC) to be warmed up to 37oC.  After 30 mins, the UV light is turned off and the light is 
turned on to start cell culture experiment. 
    The frozen cells (HaCat, HOC and HSC cells, stored in 2.0 mL cyto tubes)) are taken 
out from the -80oC freezer, warmed up in the water bath until the cells and liquid 
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dissolved. The outside of the tubes is sterilized by spraying with 95% ETOH (obtained 
from stockroom) and the tubes are immediately placed in the Biosafety Hood. Other 
sterile stuff, such as 15 mL centrifuge tubes and 100x20 mm tissue culture plates are also 
placed in the hood to get ready to be used. The warm FBS and DMEM bottles are also 
sterilized by 95 ETOH and placed in the hood. Then 50 mL FBS is transferred to the 500 
mL DMEM bottles with 10 mL sterile disposable pipette to make a 10% FBS DMEM 
medium which is the cell culture medium always used (later referred as medium). The 
remaining FBS is stored frozen again for the next experiments. The cells are transferred 
to the 15 mL centrifuge tubes by 1mL sterile disposable pipette and diluted with  the 
medium prepared above (containing 5% FBS) to 5 to 10 mL. The cells are then 
centrifuged at 0oC or RT, 1000 rpm for 5 mins (Room 310, Edmonds lab). The cells are 
centrifuged down at the tube bottom and the supernatant contained the medium and the 
cell frozen solution (the components are explained later). The supernatant liquid is then 
disposed by the pipette in the hood and the cells are dissolved with the medium. 
    The cell suspension is transferred to the 100x20 mm tissue culture dishes (2 or three 
depending on the cell amount), then the medium solution is added to the dishes to make 
sure to cover at least the dish bottom. The cells are homogenously dispersed in the whole 
dish by gently swirling the dishes. The cell amount can be checked under a microscope 
with 10x or 20 x objectives. The cell dishes are then put in the incubator (5% CO2, 37oC) 
to grow. The live cells fell down and are attached to the dish bottom within 30 mins and 
grow within 8 hrs. Any dead cells just floated in the medium solution. If two many dead 
cells are observed after 8 hrs, the dead cells would have to be removed and rinsed out 
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with DPBS buffer in the hood and new medium is added. In this way, the live cells can 
grow healthier and faster. 
    After 24 hrs, the cells can be cleaved and used for experiments or can be spit into more 
dishes so the cells keep growing. If no cells are needed, the cells can still keep growing 
until it reached 80% confluency (80% percentage of the dish bottom is covered by the 
cells). After 80% confluency, the cells had to be cleaved and separate into more dishes or 
the cells kept growing and the dish bottom would be fully covered by the cells. When the 
cells fully covered the plates, the cells might grow layer by layer, or started to change or 
started to dye. It is not recommended to use the cells if the cells grow full of the dish. 
    The cells are cleaved off the dishes by using trypsin. When the cell dishes are taken out 
of incubator, the medium is sucked out by the pipette, and few mL DPBS buffer is added 
to rinse out the medium. Trypsin is then added to cover the dish bottom and the cell 
dishes are put in the incubator for about 5 mins. The cell dislodgement is checked under 
microscope to make sure all the cells come off the dishes (round cells floating and 
moving in the solution). Few mL medium is then added to the dishes and the cell 
suspension is collected into 15 mL centrifuge tubes. The cells are then centrifuged down 
using above parameters. The cell pellet can be dissolved in medium or DPBS buffer for 
experiment requirement or dissolved into medium to start another round cell culture (spit 
into several tissue culture dishes and let them grow again in the incubator). The cells are 
allowed to grow, split and grow again so that a lot of cells are prepared for. 
    If there are extra cells which are not needed, they can be frozen down and stored for 
later use so that they did not have to be kept growing if we did not have time to take care 
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of them. The frozen solution is composed of 25 mL medium without FBS, 22.5 mL FBS 
and 2.5 mL DMSO. The frozen solution is sterilized by the sterile filter with 50 mL 
centrifuge tubes attached. After the cells are centrifuged down, the cells are dispersed in 
the frozen solution (one mL or seral mL depending on the cell amount). The cells in the 
frozen solution are transferred to the 2 mL cryotubes. The cryotubes are placed into the 
cryto box which had ETOH at its bottom and then put in -80oC freezer. The scheme of 
the cryo-holder is shown in Figure 2-1. The ETOH is used to let the cells freeze slowly in 
the -80oC freezer. If no ethanol solution is present, the cells would freeze too rapidly, 
which can kill the cells. After overnight, the cells can be taken out from the cryo-holder 





                                    Figure 2-1: Scheme of cell frozen holder. 
up to 2 weeks. Some cells would die during long time storage at -80oC. After the cells are 
frozen, the cells are transferred to liquid nitrogen dewar for long time storage (up to 
years). When the cells are needed, they are just taken out of the liquid nitrogen and began 
to be cultured as described above. 
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    In our experiments such as light scattering and photothermal experiments, we need 
grow cells on small glass coverslips. Coverslips need to be coated with collagen for cell 
optimum growth. The coverslips are first cleaned in 30%H2O2: Conc H2SO4 = 1: 3 (v:v) 
solution at 50 to 60oC for 30 mins in our lab, then are placed in ETOH solution and 
transferred to Dr Edmonds lab. The coverslips are then placed in the safety hood and 
sterilized under UV light for 30 mins. One drop of the collagen solution which is 50 
times diluted in DPBS of the pure collagen obtained from Dr Ivan, sterilized with sterile 
filter, is added on top of the coverslip. The coverslips immersed in collagen solution are 
then placed in the incubator for at least 30 mins. The top side of the coverslip is coated 
with collagen which optimizes the cell growth. The extra collagen solution is sucked out 
or rinsed out by the DPBS buffer and the coverslips are ready to use.  Each one of 
coverslips is put in one well of the 12-well cell culture plates. A drop of cell suspension is 
added to each cell well and medium is added to fill half or two third level of the well. The 
culture plates are then placed in the incubator and the cells fell down onto the top side of 
the coverslips and started to grow on the coverslips.  
2.2 Synthesis of gold nanoparticles in different sizes and shapes  
Synthesis of 15 nm gold nanospheres 
    The 15 nm gold nanoparticles are synthesized by the citrate reduction of HAuCl4 (1).  
A 25 mL tri-neck round bottom bottle is cleaned in aqua regia (3 parts HCl, 1 part HNO3) 
and rinsed with DDI water. 100 mL of 1mM HAuCl4 solution (0.04g HAuCl4.3H2O in 
100 mL water) is heated to boiling, refluxed while being stirred (see Figure 2-2). Then 10 
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mL of a 38.8 mM trisodium citrate solution (0.1141 g trisodium citrate in 10 mL water) is 
added quickly.  
 
Figure 2-2: Synthesis of 15 nm gold nanospheres. 
The solution color changed from yellow to black and to deep red. After the color changed, 
the solution is refluxed for an additional 15 min, then the heater is turned off and the 
solution is stirred until it reached cool to room temperature. The nanoparticles made in 
this way typically have average size around 15 nm.  
Synthesis of 20 to 100 nm gold nanospheres 
    The various sizes of larger nanoparticles are synthesized according the method 
described by Frens (2). Basically 50 mL of 0.01% HAuCl4 solution (by weight, Exp: 
0.01g in 100 mL water) is heated to boiling while stirring in a 100 mL beaker (see Figure 
2-3). Then a few hundred µL of 1% (by weight) of trisodium citrate solution is quickly 
added to the auric solution. The solution changed color within several minuets from 
yellow to black and then to red or purple color depending on the sizes of the  
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50 mL, 0.01% 
gold solution
10 mL, 1% 
sodium citrate
 
Figure 2-3: Synthesis of gold nanospheres of different sizes. 
nanoparticles. The color change is slower for larger nanoparticles than for small 
nanoparticles. The amount of citrate solution determines the size of the nanoparticles. 
The approximate amount of citrate and the corresponding sizes of nanoparticles are listed 
in the following table, but each time the amount of citrate may vary within tens of µL. 
But it is true that smaller nanoparticles require more citrate solution and larger 
nanoparticles require less citrate solution. The faster the capping of the nanoparticles by 
the citrate, the smaller the resulting nanoparticles. (see Page 4, Figure 1-3 for the 
absorption and TEM spectra of the samples obtained by this method). 
Table 2-2: Approximate amount of citrate and the corresponding sizes of nanoparticles 
Citrate amount  Surface plasma absorption maximum NPs size 
350 µL  525 nm 30 nm 
330 µL 530 nm 40 nm 
260 µL 535 nm 50 nm 
230 µL 540 nm 60 nm 
210 µL 545 nm 80 nm 
Synthesis of gold nanorods of different aspect ratios 
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The nanorods are synthesized according to the seed-mediated growth method by Murphy 
(3) and Nikoobakht (4) with some modifications. The chemicals used for the synthesis 
are listed in Table 2-3. The synthesis of gold nanorods is divided into two steps (see 
Figure 2-4). 
Table 2-3: Chemicals used for synthesis of gold nanorods 
HAuCl4⋅ 3H2O 
Gold (III) chloride trihydrate, Sigma, Cat No: G4022-5g. 
CTAB  
cetyltrimethylammonium bromide, 98%, Sigma, Cat No: 855820-100g. 
BDAC  
Benzyldimethylhexadecylammonium chloride, 98%, Sigma, Cat No: B4136-100g. 
NaHBH4 
sodium borohydride, 99%, Sigma, Cat No: 213462-100g. 
L-ascorbic acid 
Sigma, Cat No: A7506-100g. 
AgNO3 
Silver Nitrate, Fisher Scientific Inc, Cat No: S181 78155, 453g.  
 
 
7.5 mL, 0.2 M CTAB
2.5 mL, 0.001M gold solution
600 µL, 0.01M
ice-cold NaBH4





50 mL, 0.001 M gold solution









             Rods start to form                     Rods solution 
Figure 2-4: Synthesis of gold nanorods of different aspect ratios. 
Step 2: Growth of nanorods 
Step 1: synthesis of seed solution 
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      Step 1: Seed (sphere) solution: 7.5 ml of 0.2 M CTAB solution is mixed with 2.5 ml 
of 0.001 M HAuCl4 in a 40 mL beaker and stirred. To the stirred solution, 0.6 ml of ice-
cold 0.01 M NaBH4 is added, which resulted in the formation of a solution with brownish 
yellow color. Vigorous stirring of the seed solution is continued for 2 minutes. After 
stirring, the solution is kept at room temperature.   
    Step 2: Growth of NRs (absorption maximum at 700 nm): 50 ml of 0.001 M HAuCl4 is 
added to 50 mL of 0.2 M CTAB in a 250 mL flat-bottom flask and the solution changed 
color from yellow (HAuCl4 dissolved in water) to orange (HAuCl4 dissolved in CTAB). 
1mL of 0.004 M AgNO3 solution is added and gentle mixed. Then 700 µl of 0.0788 M 
ascorbic acid is added to reduced the Au3+ ions to Au+ and the solution changed to 
colorless (Au+ color) from orange after swirling gently. To this solution, 80 µl of seed 
solution (make sure the seed solution is clear. Sometimes, the seed nanoparticles 
crystalize out of the solution which needs to be warmed up to dissolve the nanoparticles 
before use) is added to the center of the solution. After adding seed solution, the flask 
should be kept still and never shaken or stirred, so that the seed started to grow in the 
growth solution. Usually the color of the solution gradually changed within 30 minutes. 
For longer NRs, the color change took place slower.  After overnight, a lot rods are 
obtained (Optical density is about 0.8 at the longitudinal absorption band). With longer 
time growth, the rods would get shorter and the optical density would increase. All these 
experiments are done at room temperature. This pathway produced pure NR solutions 
with absorption maximum at 700nm.  
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    By changing the concentration of CTAB and BDAC and the amount of silver nitrate, 
the aspect ratios can be varied. Table 2-4 lists the concentrations used in my experiments 
in order to produce nanorods of different aspect ratios. (see Page 7, Figure 1-6 for the 
absorption and TEM spectra of the samples obtained by this mmethod). 
Table 2-4: The effect of the relative concentrations on the aspect ratio of gold nanorods: 
CTAB 0.2 M 0.12 M 0.2 M 0.12 M 0.2 M 0.12 M 0.2 M
BDAC 0 0.15 M 0.25 M 0.15 M 0.25 M 0.15 M 0.25 M
AgNO3 2 mL 1 mL 1.5 mL 1.5 mL 2 mL 2 mL 2.5 mL
Ascorbic acid 700 µL 700 µL 700 µL 700 µL 700 µL 700 µL 700 µL
Seed solution 80 µL 80 µL 80 µL 80 µL 80 µL 80 µL 80 µL
λmax 650 nm 700 nm 750 nm 800 nm 850 nm 900 nm 950 nm
Aspect ratio 2.4 2.9 3.5 4.0 4.6 5.2 5.7
 
2-3 Conjugation of gold nanoparticles to anti-EGFR antibodies 
Conjugation of gold nanospheres to anti-EGFR antibodies 
    The conjugation of anti-epidermal growth factor receptor (anti-EGFR) antibodies to 
gold nanospheres followed the method described by Sokolov (5). Basically, the gold NPs 
(40 nm) are diluted in 20 mM HEPES (4-(2-Hydroxyethyl)-1-piperazine-ethanesulfonic 
acid) buffer (pH 7.4, Sigma) to a final concentration with optical density of 0.8 at 530 nm. 
40 uL 6 mg/mL anti-EGFR monoclonal antibodies (host mouse; Sigma, clone 29.1) are 
added to 960 uL of the same HEPES buffer to form 1mL dilute solution. Then 10 mL of 
the gold solution prepared above is added dropwise to the dilute antibody solution while 
being stirred. After stirring for 5 mins, the solution is left to react for 20 mins. Right 
before centrifuge, 0.5 mL of 1% PEG 4000 (polyethylene glycol 4000, PEG 50% W/V, 
Boehringer Mannheimm, GmbH, 4 mL, 1243268) is added to the mixture to prevent 
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aggregation and the solution is centrifuged at 6000 rpm for 30 mins. The anti-EGFR/gold 
pellet is redispersed in PBS buffer (pH=7.4, Cellgro) and stored at 4oC.  
    It is well known (6) that antibody can be adsorbed onto gold nanoparticle surface at pH 
= 7.4 and still preserve its function and activity. The binding mechanism is still not quite 
known although it is suggested (6) that antibody is orientated perpendicular on the 











Figure 2-5: Conjugation of gold nanospheres to anti-EGFR antibodies. 
The isoelectric point (PI, zero net charge of the protein) of the antibody is near pH 7. 
Thus at pH = 7.4, the antibody has an overall small net negative charge. The exact PI 
value of anti-EGFR is not known. Sokolove (5) explained that the preparation of gold 
bioconjugates is based on noncovalent binding of the anti-EGFR IgG antibodies at their 
isoelectric point, but did not point out which kind of noncovalant interaction, such as 
electrostatic interaction or hydrophobic interaction. Gold nanoparticles are capped with 
citrate and that the surface of the nanoparticles is negatively charged. This suggests that 
the adsorption of antibody at pH = 7.4 to gold nanoparticles can not be explained by pure 
electrostatic attraction between the negatively charged citrate on gold surface and the 
positive segment of the antibody. The hydrophobic interaction of the antibody with the 
 61
hydrophobic three carbon region of the citrates (see structure in Figure 2-5) may play an 
important role.  
Conjugation of gold nanorods to anti-EGFR antibodies 
The original rods grown by the seed-mediated method are centrifuged at 14000 rpm 
twice to get rid of the extra free CTAB molecules in solution. The nanorods surface is 
coated with poly (styrenesulfonate) (PSS, MW=18,000, Polysciences Inc.) 
polyelectrolyte layers before antibody adsorption. This is done by adding 200 µL of 10 
mg/mL PSS to 10 mL stirred rods solution with optical density of 1.0 at the longitudinal 
absorption maximum. The mixture is let to react for about 15 mins to complete the 
adsorption process. The extra PSS in solution is separated by centrifuging the rod 
solution at 8000 rpm and the pellet is redispersed in HEPES solution (pH=7.4). Then the 
PSS capped nanorods are mixed with antibody solution which is diluted in the same 
HEPES buffer and left to react for 20 mins. The nanorods that are conjugated with the 
anti-EGFR monoclonal antibodies are centrifuged and redispersed into PBS (pH=7.4) to 
form a stock solution with an optical density of around 0.5 at 800 nm. The anti-
EGFR/nanorod conjugates are stored at 4oC until use at room temperature. 
The possible binding of antibody to the rods surface is shown as in Figure 2-6. The 
gold nanorod is capped by CTAB bilayers and is positively charged on the surface (7).  
PSS is a negatively charged polyelectrolyte. According to Lvov et al. (8) and Okahata et 
al. (9), negatively charged PSS has been used to adsorb the antibody at pH = 7.4 to 
assemble an immunosensing multilayer. They suggested that besides possible 
electrostatic interaction between the negative charged PSS and the positively charged  
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Figure 2-6: Conjugation of gold nanorods with anti-EGFR antibodies. 
segment of the antibody (the overall charge of the antibody should be negative charged at 
pH=7.4, as discussed before), the hydrophobic interaction between these two molecules is 
dominated. They also found that at pH = 6.0 (the antibody has a net positive charge), the 
antibody is strongly adsorbed onto PSS layer. We did not use pH = 6.0 condition because 
the neutralization of the positive charge of the CTAB on the surface of rods by negatively 
charged antibodies will cause the aggregation of the nanorod solution. Here we used the 
strong interaction of PSS and antibody to adsorb anti-EGFR antibodies to the nanorods 
surface. In this way, the outlayer of the nanorods is negatively charged by antibody 
molecules and thus stable in solution. The aryl portion of the PSS molecules (see 
structure in Figure 2-6) supports the explanation of the hydrophobic binding.  
2.4 Micro-absorption spectroscopy of gold nanoparticles on single cells 
    The quantification of gold nanoparticles inside or on the surface of single cells is 
carried out by using the micro-absorption spectrometer in Prof Mohan’s lab. This is a 
S.E.E. 1000 MSP visible-NIR micro-spectrometer running the SEEScope version 4.0.0 
software package (S.E.E. Inc, Middleboro, MA). The micro-spectrometer has a 
 63
wavelength range of 400-1100 nm thus the surface plasma absorption spectra of gold 
nanospheres and nanorods can be measured. The 20X objective used in these experiments 
has a sampling area of 8 µm squared. Since on average the cells grown on cover slips are 
usually larger than 10 µm, 20X objective is the best one to use. Also different areas on a 
single cell can be examined individually. All data taken is saved as .spc files and 
exported in ASCII format so that the data can be opened by Oringin or Excell software. If 
the baseline is to be subtracted, the data is saved as .spc files and opened in the ONMIC v 
5.2 software package (Nicolet Instrument Corp, Madison WI), where the baseline can be 
smoothed or subtracted easily. After subtraction, the data is saved as .csv files and 
opened with the Origin or Excell software for plotting. Since Sept 2005, the SEES 
Microscope software has changed to CRAIC software because SEE company has been 
shut down. A CCD color camera has been added to the microscope so that more than one 
spectrum can be recorded and identified. 
    Under 20X objective, the distance between the objective and the sample is very small 
(several mms) so the absorption spectra can not be measured in buffer, which means 
absorption spectrum can not be taken on living cells. So after colloidal nanoparticles or 
nanoparticle bioconjugates incubation, the cells needed to be fixed and sealed before 
measurement (see Figure 2-7).  This is carried out as follows: First, the cells on the 
coverslips are rinsed with PBS beffer, then several drops of 1% paraformaldehyde (the 
16% paraformaldehyde are obtained from Dr Ivan and then diluted with PBS buffer to 
1%) are added on top of the cells and left for at least 5 mins to fix the cells. The cells are 





Figure 2-7: Cell fixation and sealing. 
On a separate larger rectangular coverslip (50 x 24 mm), a small drop of glycerol is 
added. The small coverslip with cells on them is placed onto the rectangular coverslip 
with cells between the two coverslips and the glycerol homogenouly distributed between 
the two coverslips. Then the Hard as Nails glue is used to seal the edge of the two 
coverslips so that the glycerol did not leak out. In this way, the cells can be stored at 
room temperature for several months. 
2.5 Cellular imaging in bright and dark field 
    The pictures of cells are taken in both bright and dark field using a simple optical 
microscope. In our lab, the Inverted Olympus IX70 can realize both functions with a 
DP11 color camera (for bright field images) and an Olympus film camera (for dark field 
images, borrowed from Prof Robert Dickson at Department of Chemistry and 
Biochemistry, Georgia Tech).  
    Bright field images are taken when light from a tungsten lamp is focused by a bright 
field condenser at the sample, and the objective collected the transmitted light and 
focused at the camera (see scheme on the left in Figure 2-8). Bright field microscopy is 
used when there is enough contrast in the subject matter or if artificial staining techniques 
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are employed. In our lab, we have 10X, 60X and 100X objectives for bright field images. 
But under 100X, oil immersion is needed for better focus and resolution.  
    The dark field is very useful in revealing very fine details in the cells which are hard to 













                      dark field 
 
Figure 2-8: Scheme of bright (left) and dark (right) field imaging. 
than the objective. In our lab, a dark field condenser (U-DCW) with high numerical 
aperture (0.9-1.2) delivers a very narrow beam of white light from a tungsten lamp on the 
top of the sample. A 100x/1.35 oil Iris objective (UPLANAPO) is used to collect only the 
scattered not the transmitted light from the samples. When the focus is optimized, the 
center of illuminating beam is blocked from entering the light collection cone of the 
microscope objective and only the scattered light of the side beam is collected (see right 
half scheme of Figure 2-8). This presents an image of bright object in a dark background. 
This is most useful for samples with very higher scattering crossection as in the case for 
the plasmonic nanoparticles. Figure 2-9 shows an example of the pictures taken under 
bright and dark field. 
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Figure 2-9: bright (left, 50X) and dark field (right, 100X) images of HOC 
cancer cells incubated with anti-EGFR antibody conjugated gold nanoparticles.  
2.6 Laser irradiation of gold nanoparticle conjugated cells with cw lasers 
    For the laser irradiation experiments, the 514 nm line of the cw argon ion laser is used 
to heat up gold nanoparticles that have plasmon absorption at 520 nm. The argon laser at 
514 nm is reflected down to the sample direction by a reflection mirror. The laser beam is 
focused by a lens (f = 10 cm) to form a small spot with 1 mm in diameter on the sample 
position where the coverslip with the cells is placed (Figure 2-10). The coverslips with 




Petri dish with buffer in
Coverslip with cells on top side
and with drawed lines on back side
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Figure 2-10: Laser irradiatin experiment setup. 
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the ion ring of the ion station. The coverslip is previously marked with lines to form 
many frames by a lab marker on the back side so that each laser irradiation position can 
be differentiated. After one position is irradiated for 4 mins, the laser beam is blocked 
and the Petri dish is moved so that the next cell frame is exposed to the laser beam and 
the beam power is changed. In the same way, multiple regions on the coverslips are 
exposed to argon laser light of different power densities for 4 min each. After the laser 
irradiation, the coverslip is taken out of the buffer from the Petri dish and a few drops of 
0.4 % trypan blue (Sigma) solution is added on top of the cells and left to be stained for 
10 mins. The trypan blue dye is used to test cell viability. Dead cells accumulated the dye 
and stained blue while live cells pumped the dye out and remained clear. After staining, 
the cells are rinsed with buffer and immersed in buffer in a petrish for bright field 
imaging under 10X. 
    When the gold nanorods are used which have their longitudinal plasmon absorption at 
800 nm, a cw Ti: Sapphire laser at 800 nm is used (similar setup, with the help from Dr 
Wei in our lab). This wavelength is in the NIR region at which the tissue has low 
absorption. The red laser at 800 nm is also focused to a 1 mm diameter spot on the 
sample position. Multiple regions on the slides are exposed to the laser light at different 
power densities for 4 min each and then stained with 0.4 % trypan blue (Sigma) for 10 
min to test cell viability. After staining, the samples are imaged under 10X in bright field 
setup. 
2.7 Steady and time-resolved fluorescence spectroscopy of NADH, collagen and cells 
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    The fluorescence spectrum of NADH solution is excited at 325 nm with a Shimadzu 
RF-5301PC spectrofluorophotometer in a 1cm quart cuvete. For NADH solution with 
higher concentrations, a 2-mm quartz is used at an angle of 45o to the excitation beam so 
that the fluorescence came just from the front surface of the sample. The time-resolved 
fluorescence spectrum of NADH in the presence and absence of nanoparticles is obtained 
with a PTI fluorimeter with a nitrogen laser and PMT detector.  
    The fluorescence spectra of the living cell suspensions are obtained with the PTI 
fluorimeter in a 1-cm quartz cuvette. After each spectrum is taken, the cells are shaken 
strongly to make sure the cells do not settle at the bottom. Excitation is chosen to be at 
three wavelengths, one in the protein absorption region at 280 nm, another one at the 
NADH absorption region at 340 nm and the third at the flavor and other chromatins 
absorption wavelength at 370 nm. When the cells are extracted from the tissue culture 
dishes, the cells are put on ice and carried to our lab to measure the fluorescence 
immediately.   
2.8 Surface enhanced Raman spectroscopy of biomolecules and cells 
    The Surface enhance Raman experiments are carried out on a Holoprobe series 5000 
Micro-spectrometer (Kaiser optical systems, Inc, Ann Arbor, MI). The excitation 
wavelength is at 785 nm from a diode laser. The red laser does not damage the cells as 
the 514 nm argon ion laser does.  Focusing on single cells is set under bright field 
exposure of the microscope using the 10X objective or 50X objective. The bright field is 
turned off and the cell is kept on the stage of the Raman microscope in the dark for data 
collection. The Raman microscope is housed in a black felt-lined Plexiglass box to 
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prevent the entrance of stray light. When the 10X objective is used, the laser power at the 
sample position is 2-6 mW, the focus area is 15 µm in diameter and the power density is 
2800 W/cm2. When the 50X objective is used, the laser power at the sample position is 2-
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CHAPTER 3  
SURFACE PLASMON ABSORPTION STUDIES OF ANTI-EGFR 
CONJUGATED GOLD NANOSPHERES AND NANORODS ON 





    Gold nanospheres of various sizes and gold nanorods of various aspect rations are 
synthesized according to the citrate reduction and the seed-mediated growth methods, 
respectively. Gold nanospheres are directly bound to the anti-epidermal growth factor 
receptor (anti-EGFR) monoclonal antibodies. The gold nanorods are bound to the 
antibodies through poly (styrenesulfonate) (PSS) polyelectrolyte linker. The conjugation 
is characterized from the surface plasmon absorption spectra of the nanoparticles.  The 
anti-EGFR/Au nanosphere and nanorod conjugates are bound to one nonmalignant 
epithelial cell line, HaCaT (human keratinocytes) and two malignant epithelial cell lines, 
HOC 313 clone 8 and HSC 3 (human oral squamous cell carcinoma). The surface 
plasmon absorption spectra of gold nanoparticles on the single cells are measured to 
qualitatively and quantitatively characterize the binding of the conjugates with the 
healthy and cancer cells. The anti-EGFR/Au nanospheres are found to have a surface 
plasmon absorption maximum at 545 nm when bound to the cancer cells but at 552 nm 
when added onto the normal cells, suggesting that absorption spectroscopy can be used 
for cancer diagnostics with this technique in the visible region of the spectrum. Due to the 
broad nature of the gold nanorod spectrum, its absorption spectroscopy does not offer a 
clear method for cancer diagnostics. The work has been published in Nano Letters, 2005, 5 
(5), 829 and JACS, 2006, 128 (6), 2115.   
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3.1 Introduction 
    As we have learnt in Chapter 1, gold nanoparticles show a strong surface plasmon 
absorption band in the spectrum when the frequency of the electromagnetic field is in 
resonance with the coherent electron motion (see Chapter 1, Page 1-5). The wavelength 
maximum of the surface plasmon absorption band is dependent on many parameters 
including the size and shape of the metal nanoparticles. As the size increases, the 
absorption maximum red shifts. The surface plasmon absorption of gold nanoparticles is 
also dependent on the dielectric constant of the metals as well as that of the medium 
surrounding the particles. This provides a great possibility for the nanoparticle to be used 
as a sensitive biosensor.   
    The surface plasmon absorption band of gold nanorods splits into two bands: A strong 
long wavelength band due to the longitudinal oscillation of electrons and a weak short 
wavelength band around 520nm due to the transverse electronic oscillation (see Chapter 1, 
Page 5-9). The longitudinal absorption band shifts from the visible to longer wavelength 
as the rod’s aspect ratio increases. This tunable optical property of gold nanorods makes 
them useful in many biological applications such as photothermal cancer therapy. 
    Gold nanoparticles have been conjugated to many biomolecules such as DNA (1-4), 
proteins (5-9) and sugars (10). Chad Mirkin used surface absorption spectra of gold 
nanospheres to monitor the hybridization of complimental DNA. When thiolated DNA 
single strand DNA is bound to the surface of gold nanospheres, the absorption maximum 
is shifted from 519 nm to 524 nm due to the Au-S bond formation (See Figure 3-1, 
absorption spectra A). After being hybridized with another complimentary DNA which is 
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also conjugated to nanoparticles, the nanoparticles aggregate and the surface plasmon 
absorption band decreases in intensity and red shifts in position (See Figure 3-1, 






Figure 3-1: DNA assembly of gold nanoparticles (left) and comparison of 
UV-vis spectra during DNA assembly (right) (2).  
    Mann et al. uses the longitudinal absorption band of gold nanorods to monitor the 
hybridization of DNA (3). When complementary DNA is bound to rods in advance is 
duplexed, the longitudinal absorption band of gold nanorods decreases in peak intensity 
and blue shifts in peak position (see Figure 3-2). 
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Figure 3-2: UV–VIS spectra of a suspension of non-complementary 
DNAfunctionalised nanorods. (a) 0 s, (b) 10 min, (c) 1 h, (d) 2 h after 
duplex initiation arising from the addition of the third complementary 
strand. Sequences of the three oligonucleotides are shown in the insert (3). 
 
    Gold nanoparticles have been conjugated to various antibodies for biological 
applications such as staining studies since 1950s’ (11). The conjugates are simply formed 
by noncovalant interactions between the citrate capping molecules and the antibodies (see 
Figure 3-3). The binding is in such a way that the bioactivity of the antibodies are 
preserved and thus the conjugates can be used for further biofunctional studies such as 
imaging cancer biomarker (12) and probing pathologic bacteria (13).  Very recently,  
 
Figure 3-3: The binding of antibody to gold nanoparticles (14). 
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gold nanorods have been reported to be bound to antibodies and characterized for 
biological applications (15) (see Figure 3-4).  
 
Figure 3-4: The binding of antibody to gold nanorods (15). 
They replace the stabilized surfactant bilayer by thiol terminated methoxypoly(ethylene 
glycol) so that the nanorods are stable in buffer solutions free of surfactant. Nanorod 
bioconjugation is accomplished with a heterobifunctional cross-linker, LC-SPDP. 
Nanorod bioconjugates are characterized by independent measurements of the nanorod 
and antibody concentrations. 
    In the present study, anti-EGFR monoclonal antibodies are conjugated with gold 
nanospheres using the method describe by Sokolov et al (12). The nanorods are firstly 
coated with a negatively charged PSS layer and then bound to antibodies. All these 
conjugates are incubated with the HaCat (human keratinocytes) healthy cells and HOC 
313 and HSC 3 (human oral squamous cell carcinoma) cancer cells. The absorption 




    Gold nanospheres and nanorods in different sizes are synthesized according to the 
procedures described in detail in Chapter 2, Page 54-59. The sizes are determined from 
their absorption spectrum and TEM (see Page 4, Figure 1-3, Page 7, Figure 1-6). Three 
sizes of gold nanospheres with the absorption maximum at 519, 529 and 535 nm and one 
size of gold nanorods with longitudinal absorption maximum around 800 nm arechosen 
for the conjugation with the anti-epidermal growth factor receptor (anti-EGFR) 
monoclonal antibodies (House, clone29.1, Sigma).  
    The conjugation procedure of gold nanoparticles with anti-EGFR antibodies is 
described in detail in Chapter 2, Page59-62. The success of binding of the antibody to the 
gold nanospheres which is capped by citrate is not only confirmed by the red shift of the 
absorption maximum (discussed later), but also by the fact the antibody bound gold 
nanospheres are stable in PBS buffer (while the bare gold nanospheres are very unstable 
and aggregate in the same buffer). The success of binding of the gold nanorods is 
confirmed by the fact that the conjugates can be centrifuged down (before conjugation, 
the nanorods have been centrifuged twice to get rid of free CTAB molecules) and 
dispersed in buffer while the bare gold nanorods can not be centrifuged at the third time 
and they are not stable in buffer. 
    After the gold nanoparticles are conjugated with the antibodies, they are dispersed in 
PBS buffer at some concentration for their incubation with the living cells. For 
nanospheres, the optical density at the absorption maximum is adjusted to a value 
between 1.5 to 2.0. For gold nanorods, the optical density at the longitudinal absorption 
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maximum is adjusted to a value between 0.8 to 1.0. The use of lower concentration for 
the nanorods might be due to the higher affinity of antibody to nanorods which is due to 
the contribution of the hydrophobic interaction of the PSS and the antibody (16, 17). 
After the cells are grown on coverslips (see Chapter 2, Page 49-54, cell culture for detail 
procedure) for 2 or 3 days, the cells are taken out from Prof Edmonds’ lab to our lab, 
rinsed with PBS buffer and then a few drops of the nanoparticles are added on top of the 
cells and wait for 40 mins.  For gold nanorods, 30 mins incubation is found to be 
sufficient. For the nanorods, you can see the cells are stained red within 5 mins which is 
due to the binding of gold nanorods onto the cells. After the incubation, the free 
nanoparticles are rinsed out with PBS buffer and the cells are fixed with 
paraformaldehyde and coated with glycerol and sealed with glue. Then the cells are taken 
to Prof Mohan’s lab to measure absorption spectra of gold nanoparticle on single cells. 
   For comparison, the gold nanospheres are also incubated into cells by putting the 
nanoparticles (several drops of nanopsrticles with optical density at 3.5 at the absorption 
maxiumum in the well of the 12-well plates) in the medium while the cells are growing 
(the coveslip is put in the well and the cells are grown on the coverslip). In this way the 
nanoparticles diffuse into cells by endocytosis. The absorption spectra of the 
nanoparticles inside the cells are compared with the nanoparticles bound on the cell 
surface. 
3. Results and discussion 
3.3.1 Gold nanospheres 
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    By just changing the citrate amount, various sizes of gold nanoparticles from 15 nm to 
100 nm can be prepared (see Chapter 2, Page 55-56). Figure 3-5 shows the absorption 









































Figure 3-5: Gold nanospheres of different sizes obtained by changing citrate 
amount. Left: absorption spectra, right: TEM of the samples with absorption 
maximum at 519nm (top, 15 nm), 529 nm (middle, 35 nm) and 535 nm 




     The surface plasmon absorption maxima of the anti-EGFR antibody conjugated 
gold nanoparticles are shown in Figure 3-6. Among all the three sizes, the absorption 
maximum shows obvious red shift. For the 15 nm (λmax = 519 nm), the absorption 
maximum shifts by 6 nm, for the 35 nm gold nanoparticles (λmax = 529 nm), the 
absorption maximum shifts by 7 nm and for the 50 nm gold nanoparticles (λmax = 
535 nm), the absorption maximum shifts by 12 nm. This red shift is due to the 
change in the dielectric constant of the medium around gold nanoparticles. Antibody 
binding changed the local environment and thus the surface plasmon absorption of 
the nanoparticles is changed.  
    For binding the cells, the sizes of 35 nm are chosen after experimental determination of 
the cellular labeling efficiency and the light scattering experiment of the nanoparticles 
(describe in the next Chapter). Smaller nanoparticles have smaller light scattering 
crossection than larger nanoparticles. They also give more greenish scattered color which 
cannot be easily resolved from the scattered green light of the cellular organelles. Larger 
nanoparticles have higher scattering crossection but have smaller labeling efficiency 
possibly due to steric hindrance. 
    Figure 3-7 shows the absorption spectra of conjugated gold nanoparticles after binding 
to cells. Statistically 25 cells are measured. Each spectrum is from the sample area of 8 
µm in diameter. The cells are over 10 µm. So each spectrum is from part of a cell. From 
Figure 3-7 we can see that the nanoparticles bound to all types of cells red shift greatly 
compared to the conjugated nanoparticles in solution in Figure 3-6.  
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Figure 3-6: The absorption spectra of gold nanoparticles and the 





























































Figure 3-7: The absorption spectra of anti-EGFR antibody conjugated 




    HOC and HSC cancer cells have similar absorption maxima at around 545 nm which is 
9 nm red shifted compared to the isolated anti-EGFR/Au solutions at 536 nm. This red 
shift could be due to the specific binding of the anti-EGFR antibodies on the gold surface 
to EGFR on the cell surface. One can use the maximum at 545 nm to characterize the 
conjugated nanoparticle binding to the EGFR on the cell surface. For HaCaT 
noncanerous cells, the nanoparticles have their maximum at 552 nm. The maximum 
difference indicates the difference in the dielectric constant of the local environment 
around gold nanoparticles of the healthy cells compared to cancer cells. The well 
organized nanoparticles on the cancer cell surface have a different environment than that 
on the noncancerous cell surface which has a heterogeneous environment.   
    For comparison, the nanoparticles inside the cells is also measured. Figure 3-8 shows 
the absorption spectrum of the nanoparticles in the three types of cells. To statistically 
characterize the surface plasmon absorption of the gold nanoparticles inside the cells, 25 
cells of each kind are measured. The NPs inside all cells have a major peak around 545 
nm characteristic of the surface plasmon absorption of the individual nanoparticles inside 
the cytoplasm of the cells. This is red shifted by 16 nm compared from that of the colloid 
nanoparticles suspension (at 529 nm). This suggests that the nanoparticle surface has a 
different dielectric environment when present inside the cells. The broad absorption 
around 700 nm of the gold nanoparticles inside the cells is characteristic of the 
aggregated gold nanoparticles. Aggregation of the nanoparticles is likely induced by the 
salts in both the growth medium and the cytoplasm of the cells. The capping material of 
citrate molecules could be dissolved inside cells and thus leads to aggregation of the 
resulting metallic nanostructures. 
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Figure 3-8: The absorption spectra of colloidal gold nanoparticles 
inside single cells.  
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In HSC cells, the aggregates have the absorption maximum at 715 nm. In HaCaT cells, 
the size of these large aggregates is smaller as concluded from the shorter wavelength 
surface plasmon absorption maximum. The absorption of the aggregates inside HOC is 
not as resolved due to the shorter wavelength (679 nm) which is close to the absorption 
maximum of the surface plasmon absorption of the individual nanoparticles. The 
different sizes of the aggregates inside different kinds of cells may reflect the difference 
in the cell cytoplasm medium. The ability to resolve aggregates within cells by SPRA 
spectroscopy suggests that different capping agents could be utilized to monitor 
intracellular processes as the aggregates are formed. 
3.3.2 Gold nanorods 
    By changing the silver amount during the rod preparation process (see Chapter 2, Page 
57-59 for details), the aspect ratios of gold nanorods can be changed (see Page 7, Figure 
1-6 for the absorption spectra and TEM images). 
    The nanorods with aspect ratio of 3.9 is chosen for the conjugation with antibodies and 
with cells due to the overlapping of the absorption longitudinal maximum of the rods 
with the NIR Ti:Sapphire laser wavelength (800 nm) which will be used for the 
photothermal therapy (describe later). Figure 3-9 shows the absorption spectra during the 
change of the surface charge by PSS and the antibody binding process. From Figure 3-9, 
we can see that there is no shift in the absorption maximum after PSS coating. After the 
antibody binding to the PSS laser, there is 10 nm blue shift of the longitudinal absorption 
maximum, while there is no shift in the absorption maximum of the transverse band 
during the whole process. The intensity of the transverse absorption maximum increased 
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slightly after PSS coating and antibody binding. When PSS is bound, it does not affect 
the gold nanoparticle absorption much due to the covalently capped thick bilayer of the 
CTAB molecules (see structure in Figure 3-9). When antibody is bounded, it may cause 
conformation changing in the PSS and the CTAB layers and thus shifts the absorption 
maximum. 



























Figure 3-9: The absorption spectra of bare gold nanorods, PSS coated 
nanorods and antibody bounded nanorods (left) and the structure of the 
conjugates (right). 
 
    Figure 3-10 shows the absorption spectra of conjugated gold nanorods after binding to 
the three types of cells. Compared to the conjugates in solution (Figure 3-9), the peak 
maximum of the longitudinal absorption band is red shifted by about 80 nm. This is 
probably due to the interparticle interaction resulting from the assembly of nanoparticles 
on the cell surface. This interplasmon interaction of nanorods has also been observed on 
carbon nanotube surfaces and in solution (16-18).   
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Figure 3-10: The absorption spectra of anti-EGFR antibody conjugated 
gold nanorods on single cells. 
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Due to the broadening of the longitudinal absorption band, its peak position can not be 
used to differentiate the cancer and noncancer cells. However, the transverse band is 
sharper and shows difference in the wavelength maximum.  In the cancer cells, the 
maximum is at 530 nm while in the noncancer cells it red shifts to 535 nm and is broader. 
Compared to the spheres shown in Figure 3-7, the optical density of the nanorods are 
much higher for each type of cells. This might be due to the higher affinity of antibody to 
the PSS molecules on the nanorods than that between antibodies to citrate molecules. The 
higher affinity of PSS with antibody is due to the strong hydrophobic interaction between 
antibody and the aryl portion in the PSS molecules. Another reason might be that the 
nanorods have higher absorption coefficient (~ 109) than spheres (~108) so they giver 
higher optical density for the same amount of nanoparticles between nanorods and 
nanospheres. 
    From Figure 3-10 we can also see that statistically the amount of gold nanorods on the 
two cancerous cells is about double of the amount of nanorods on the noncancerous cells. 
This is due to the specific binding of the antibodies to the overexpressed EGFR on the 
cancerous cells. But the nanorods amount can not be attributed to the amount of EGFR 
amount on the cancerous and healthy cells because of the nonspecific binding of 
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CHAPTER 4  
BRIGHT AND DARK FIELD IMAGING OF CANCEROUS 






    Bright field (light transmission mode) and dark field (light scattering mode) imaging of 
HaCat normal cells, HSC and HOC cancer cells with and without gold nanospheres and 
nanorods incubation are discussed. Two methods are used to incubate the gold 
nanospheres with the cells: One is to add colloidal gold to the cell growth medium and 
the cells are left to grown for overnight in the presence of the nanospheres. In this way, 
the nanospheres enter into cells by endocytosis process. The other method is to incubate 
anti-EGFR antibody conjugated gold nanospheres with the cells for 40 mins and the 
nanospheres are bound to cells through EGFR on the cell surface. For incubation with 
gold nanorods, only anti-EGFR/Au nanorod conjugates are incubated with the cells and 
located on the cell surface by specific binding between antibody and the EGFR on the 
cell surface. Both transmission and light scattering imaging are used to characterize the 
gold nanoparticles inside the cells or on the surface of the cells. From the light scattering 
images, the cancer cells are clearly distinguishable from the healthy cells by using either 
gold nanospheres or nanorods. This is due to the specific binding of the anti-EGFR/Au 
conjugates to the overexpressed EGFR on the cancer cell surface. The work has been 




    Cellular and tissue imaging is one of the most important ways for the detection of 
pathosis in biology and medicine. Radiographic imaging modalities such as CT scan and 
MRI can delineate the deep extent of carcinomas (1). But they are not sufficiently 
sensitive to detect small, earlier intraepithelial lesions which are more readily cured.  
Cellular imaging utilizing microscope techniques provides anatomic details of cells and 
tissue architecture important for cancer diagnostics and research. Currently used optical 
probes include chemiluminescent, fluorimetric and colorimetric techniques (2). Optical 
imaging is a relatively new modality which enables real time, non-invasive, high 
resolution imaging of epithelial tissue (3-7).Optical imaging systems are inexpensive, 
robust and portable because of advances in computing, fiber optics and semiconductor 
technology. 
    Imaging the molecular features of cancer requires molecular specific contrast agents 
which can safely be used in vivo as well as cost-effective imaging systems to rapidly and 
noninvasively imaging the uptake, distribution and binding of these agents in vivo. One 
of the earlier contrast agents is the conventional organic dyes (8-9). They are bright and 
can be used for both cytoplasmic and nuclear labeling due to the small size molecules. 
But one of the problems is that they are not photostable. After one minuets irradiation 
with a laser, they are totally bleached and can not be used anymore (10).  Thus, the 
fluorescent semiconductor nanoparticles emerged, which is called quantum dots (11-13). 
Quantum dots have wide absorption ranges and unique size dependent fluorescence 
properties. They are highly fluorescent and photobleach resistant. They can provide 
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single excitation for multicolor images which is not possible for molecular fluorophors 
because of their narrow excitation spectra.  
    Another kind of contrast agents is metal nanoparticles which use the bright light 
reflectance properties (14-17). Metal nanoparticles have the ability to resonantly scatter 
visible and near infrared light upon the excitation of their surface plasmon oscillation. 
The scattering light intensity is extremely sensitive to the size and aggregation state of the 
particles. Preliminary studies have reported their use as contrast agents for biomedical 
imaging using confocal scanning optical microscopy (17), multiphoton plasmon 
resonance microscopy (15), optical coherence microscopy (18) and third-harmonic 
microscopy (19).  
    In the present work, we use a very simple and inexpensive conventional microscope 
with proper rearrangement of the illumination system and the light collection system to 
imaging cells which are incubated with colloidal gold or with anti-epidermal growth 
factor receptor (anti-EGFR) antibody conjugated gold nanoparticles. The optical 
properties of the gold nanoparticles incubated in single living cancerous and 
noncancerous cells are compared for different incubation methods.  
4. 2 Experimental 
    The detail bright and dark field procedures as well as their principles have been 
described in detail in Chapter 2, Page 64-66.  In bright field imaging, the light goes 
through the samples and the transmitted light is detected. In dark field imaging, the light 
is scattered by the samples and the transmitted light is blocked and only scattered light is 
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detected. In this way, the background is dark and the sample which scatters strongly gives 
very bright images. Under the illumination with a beam of white light, multicolor images 
can be seen due to the differently scattered light wavelength. Both the bright and dark 
field images are taken with our inverted Olympus IX70 microscope (some dark field 
pictures are taken with Olympus IX70 in Prof Robert Dickson’s lab).  
    The nanospheres are incorporated with living cells (grown on coverslips) with two 
methods. One is to add 40 nm colloidal gold into the cell growth medium and the cells 
are left to grown overnight in the presence of the nanoparticles. In this way, the 
nanoparticles are incorporated inside cells by endocytosis process during cell division 
and proferlitation. In the other method, gold nanospheres are conjugated anti-EGFR 
antibodies and then incubated with living cells in buffer at room temperature outside 
incubator for 40 mins (see Chapter 2, Page 59-61 for detail information). In this way, the 
nanoparticles are mostly stay at cell surface due to the short incubation time and the 
specific binding of anti-EGFR to the EGFR on the cell surface. Then the cells with gold 
nanoparticles incorporated are fixed and sealed with another coverslip with a layer of 
glycerol filled between and then used for bright and dark field imaging. 
    The nanorods are incorporated with cells only after conjugation with antibodies. The 
nanorods are coated with PSS polyelectrolyte and conjugated with anti-EGFR antibodies 
(see Chapter 2, Page 61-62 for detail information). The conjugated nanorods are 
incubated with living cells at room temperature for 30 mins in buffer outside incubator. 
The cells are then fixed, sealed and then used for bright and dark field imaging. The 
nanorods have problems to be incorporated inside cells because the nanorods aggregate in 
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the cell growth medium and mess up the cell growth environment. Thus the cells can not 
grow. The cell death is also caused by the cytotoxicity of the free CTAB molecules in the 
nanorods solution. The cytotoxicity of the free CTAB molecules has been reported by 
some other group (20). 
4.3 Results and discussion 
4.3.1 Bright field imaging (light transmission mode) 
    The nanoparticles we used for both incubation inside cells and conjugation with 
antibodies are 40 nm in diameter. Figure 4-1 shows the absorption spectrum and the TEM 
images of the nanoparticles. 
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Figure 4-1: Absorption spectrum (left) and TEM image (right) used for the 
treatment of gold nanospheres with cells. 
    Figure 4-2 shows the bright field images of both cancer and healthy cells without gold 
nanoparticle (control cells, top row), with colloidal gold incubated (middle row) and with 
anti-EGFR/Au nanosphere conjugates incubated (bottom row). In the bright field, the 
camera detects the transmitted light trough the sample, the coverslip background shows 
very bright color and thus the fine structures of the cells can not be recognized. 
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    From this figure we can see that the three types of cells have different structure 
character. HOC cancer cells are almost 4 times larger than HaCaT or HSC cells. HaCaT 
and HSC cells show almost homogenous diamond shapes while HOC cells have other 
shapes. The HaCat normal cells grow in a different way. They like to grow in a clump 
style. Usually no individual cells are observed during HaCat grow process while the other 
two cancer cells can grow individually.     














Figure 4-2: The bright field images of HaCaT normal cells (left column), HSC cancer 
cells (middle column) and HOC cancer cells (right column) without gold (top row), with 
colloidal gold incubated inside cells (middle row) and with anti-EGFR/Au nanosphere 
conjugates (bottom row) bound on the cell surface.  Magnification: 50x. 
10 µm
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    When incubated in the presence of nanoparticles, the cells grow as usual and the 
nanoparticles are accumulated inside the cells. The gold nanoparticles can be seen clearly 
under 50x as red spots inside the cells. It can be seen that gold nanoparticles are 
predominantly accumulated inside the cytoplasm of the cells. It is well known that gold 
nanoparticles enter into cells by endocytosis process. In most HaCaT noncancerous cells 
(middle, left image) the gold nanoparticles demonstrate a spotted pattern inside the 
cytoplasm while the nanoparticles are homogenously distributed in the cytoplasm of HSC 
(middle image) and HOC (middle, right image) cancer cells. The difference of the 
distribution of nanoparticles inside cells may reflect the difference of the cell 
differentiation and proliferation processes. It can also be seen that the HOC cancer cells 
take less nanoparticles than the other two types of cells. This could be due to the slower 
growth speed of this type of cells than the HaCat and HSC cells.  
    When anti-EGFR antibodies (optical density of 2.5 at 530 nm) are conjugated to gold 
nanoparticles, the nanoparticles can not be recognized in bright field. The HaCaT 
noncancerous cells could not be identified individually (bottom left image). This is due to 
the poor labeling of the cells by the nanoparticles. The HSC (bottom middle image) and 
HOC (bottom right image) cancerous cells show better contrast than the control cells, 
which is due to the binding of the anti-EGFR/Au conjugates to the surface of the cancer 
cells. This contrast difference between the normal and cancer cells is due to the specific 
binding of overexpressed EGFR on the cancer cells with the anti-EGFR antibodies on the 
gold surface.  
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    Figure 4-3 shows the absorption spectrum and TEM image of the gold nanorods used 
in the experiment. The nanorods have an absorption maximum of the longitudinal band at 
800 nm with an aspect ratio of 3.9.    
























Figure 4-3: Absorption spectrum (left) and TEM image (right) used for the 
incubation of gold nanorods with cells. 
    Figure 4-4 shows the bright field images of both cancerous and noncancerous cells 
without gold nanoparticle and with anti-EGFR/Au nanorod conjugates incubated. For 
better comparison, we choose 10x and 60x to image the cells. The top two rows show the 
images of the control cells. The middle two rows show the images after incubated with 
anti-EGFR/Au nanorod conjugates with optical density of 0.6 at 800 nm (the absorption 
maximum of the longitudinal band). The bottom two rows show the images after 
incubation with anti-EGFR/Au nanorod conjugates with optical density of 1.2 at 800 nm. 
From this figure we can see that at lower concentration of the conjugates, the HaCat 
healthy cells can not be clearly identified individually but the two cancer cells can be 
seen clearly. This is consistent with the results when using gold nanospheres. When the 
concentration of the conjugates doubled, the HaCat normal cells can be recognized, but 
































Figure 4-4: The bright field images of both cancer and health cells without gold 
nanoparticle treatment and with anti-EGFR/Au nanorod conjugates. row 1: 10x; 
row 2: 60x; row 3: lower concentration of conjugates (OD800 = 0.6), 10x; row 4: 
lower concentration of conjugates, 60x; row 5: higher concentration of 
conjugates (OD800 = 1.2), 10x, row 4: higher concentration of conjugates, 60x. 
The nanorods on the two cancer cells show deeper and smooth red color than the healthy 
cells. Also on the edge of the cells (cell cytoplasmic membrane) the nanorods show 
higher concentration on the cancer cells so that the cells look like rings. This contrast 
difference of gold nanorods on the cancerous and noncancerous cells is due to the 
specific binding of anti-EGFR antibodies to the overexpressed EGFR on the cancer cell 
surface. Due to the nonspecific binding, the nanorods heterogenously distributed on the 
surface of the HaCat healthy cells. This indicates that when anti-EGFR/Au nanorod 
conjugates are used, the simple bright field images can be used to distinguish the cancer 
cells from the healthy cells.   
    It is well known that citrate-capped gold nanospheres have no cytotoxicity for the cells. 
But the toxcicity of CTAB-capped gold nanorods is not known. So after we incubate the 
rod conjugates with cells, we stained with trypan blue dye to test the cell viability. The 
dead cells accumulate trypan blue dye and stained blue while the live cells get rid of the 
dye and stain colorless. For comparison, the conjugates are incubated with the cells in 
several different ways (Figure 4-5). First, the cells are incubated with nanorods (with 
PSS- capped) in buffer at room temperature for 30 mins (using HSC cancerous cells for 
this experiment) and then stained with trypan blue (see the image on the first row). The 
cells are stained blue and the rods (without antibody) also go to the cell surface. In 
addition the nanorods attachment on the cells caused the cell dislodgment from the cover 
slips. 
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in medium for 15 mins at 
37oC, TB 8 mins.  
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Figure 4-5: The cell viability after binding anti-EGFR/Au nanorod 
conjugates in different ways. 
This indicates that the nanorods without antibody also bind to the cells but they injure the 
cells. If the rods (with PSS- capped) are incubated with the cells in medium at 37oC for 15 
mins, the cells are not stained blue and no cell dislodgement (second row images) but the 
nanorods aggregate on the cells so that the cells can not be individually recognized. This 
indicates that when the cells are taken out from incubator, the cells are getting unhealthy 
due to lack of medium and the lower temperature (cells need 37oC for grow).  
   For the incubation of antibody conjugated gold nanorods, four methods are tried. One is 
to incubate the rods in buffer at room temperature for 30 mins (third row images). 
Another method is to incubate the rods in buffer at 37oC for 20 mins (fourth row). The 
third way is to incubate the rods in buffer at RT for 30 mins (this is the usual way we 
incubated the conjugates with cells, fifth row images) and the last one is to incubate the 
rods in buffer at RT for 30 mins and then immerse the cells in medium and put back into 
incubator and let cells grow for 2 hrs (bottom row images). From the results of these four 
incubation ways, we can see that again the cells are getting unhealthy when taken out of 
their incubator environment. Another point we can see is that the cells are best labeled 
with the conjugates in buffer at RT. Either the medium or the temperature affects the 
labeling of the rods on the cells. In addition, after the incubation of the conjugates, if the 
cells are put back into its growth environment (immersed in medium) and let them grow 
for several hours in incubator, the cells will recovered totally and become healthy again 
(not blue stained). This indicates that the anti-EGFR/Au nanorod conjugates have no 
cytotoxcity to the cells.  
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4.3.2 Dark field imaging (light scattering mode) 
    Figure 4-6 shows the dark field (light scattering) images of the HaCaT noncancerous 
cells, HOC cancerous cells and HSC cancerous cells without nanoparticles (A), with 
colloidal gold nanospheres incubated inside cells (B), with lower concentration of anti-
EGFR/Au nanosphere conjugates incubated (OD530 = 1.0, C) and with higher 
concentration of anti-EGFR/Au nanosphere conjugates incubated (OD530 = 2.5, C). All 
the cells without gold nanoparticles show dim greenish light. This green light is due to 
autofluorescence and scattered light from the cell organelles in cell cytoplasm and 
membrane. The cell morphogy is much clearer than the bright field images (Figure 2, top 
row images). We can see obviously that the three types of cells have different structure 
characteristics. HOC cancer cells are larger than the other two types of cells.   
    The incorporated gold nanoparticles scatter strong yellowish light and make individual 
cells easily identifiable. It is very clear that gold nanoparticles are predominantly 
accumulated inside the cytoplasm of the cells. In most HaCaT and HSC noncancerous 
cells (left column) the gold nanoparticles demonstrate a spotted pattern inside the 
cytoplasm while the nanoparticles are homogenously distributed in the cytoplasm of 
HOC cancerous cells. The HaCat and HSC specimens give stronger scattering light 
which is due to the large amount of accumulated gold nanoparticles.  
    The light scattering pattern of gold nanoparticles is significantly different when anti-
EGFR antibodies are conjugated to gold nanoparticles. When the conjugates 
concentration is lower (OD530 = 1.0), almost no nanoparticles are bound to the healthy 
cells (C row, left image). But a lot of nanoparticles are accumulated on the surface of 
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Figure 4-6: The dark field (light scattering) images of the HaCaT noncancerous 
cells, HOC cancerous cells and HSC cancerous cells without nanoparticles (A), 
with colloidal gold nanospheres incubated inside cells (B), with lower 
concentration of anti-EGFR/Au nanosphere conjugates incubated (OD530 = 1.0, C) 
and with higher concentration of anti-EGFR/Au nanosphere conjugates incubated 
(OD530 = 2.5, C).    
the two cancer cells (C, right two images). When the conjugates concentration increases 
(OD530 = 2.5), some nanoparticles are bound to the healthy cells (D row, left image). And 
even more nanoparticles are accumulated on the surface of the two cancer cells (D, right 
two images). At this time, some gold nanoparticles also stick to the coverslip background 
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(the coverslip is coated with collagen). This is due to the nonspecific binding of gold 
nanoparticles to the collagen background. The nanoparticles are also bound to the healthy 
cells due to part of the specific binding, but mostly due to the nonspecific interactions 
between the antibodies and the proteins on the cell surface and thus the nanoparticles are 
randomly distributed on the whole cells. This predominant nonspecific interaction makes 
the cells not be identified individually. This contrast difference in both conjugate 
concentrations is due to the specific binding of overexpressed EGFR on the cancer cells 
with the anti-EGFR antibodies on the gold surface.  
The nanorods scatter strongly orange to red light due to their strong longitudinal 
surface plasmon oscillation with a frequency in the NIR region (Figure 4-7). As the 
nanosphere conjugates, the anti-EGFR/Au nanorod conjugates bind specifically to the 
two types of malignant cells (right two columns) and give them distinguished imaging 
difference from the noncancerous cells. The individual noncancerous cells are hardly 
identified due to the predominant nonspecific interactions between the nanoparticles and 
the cells. The light scattering images with higher concentration of conjugates (OD800 = 
1.6) as shown in the bright field images is not shown here. Because too much nanorods 
accumulated on the cells make the focus very difficult. The nanoparticles located at 
different part of the cells can not be focused at the same time because they are not on the 
same focus layer while in the dark field imaging (100x) only a very thin layer of particles 
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Figure 4-7: The dark field (light scattering) images of the HaCaT noncancerous cells, 
HOC cancerous cells and HSC cancerous cells without nanoparticles (top row), and 
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CHAPTER 5  
PHOTOTHERMAL CANCER CELL THERAPY IN VISIBLE 






    Two oral squamous carcinoma cell lines (HSC 313 and HOC 3 Clone 8) and one 
benign epithelial cell line (HaCaT) are incubated with anti-epithelial growth factor 
receptor (EGFR) antibody conjugated gold nanoparticles and then exposed to continuous 
visible argon ion laser at 514 nm. It is found that the cancer cells require less than half the 
laser energy to be photo-destructed than the benign cells after incubation with anti-EGFR 
antibody conjugated Au nanoparticles. No photothermal destruction is observed for all 
types of cells in the absence of nanoparticles at four times energy required to destroy the 
malignant cells with ant-EGFR/Au conjugates bonded. By oven-heating the cells (either 
cancerous or noncancerous cells), it is found that the cells are thermally destructed 
between 70-80°C. This temperature range is in agreement with the local temperature rise 
calculated by Prashant (another member in our group) from the amount of gold loading at 
the threshold laser power. The work has been published in Cancer Letters, in press and 






    It is known that the tradition cancer treatment includes surgery, radiation, hormone 
therapy and more recently chemotherapy, immunotherapy and combines strategies (1). 
Surgery is limited to tumors that are known to be surgically respectable and accessible. 
Chemotherapy may have significant side effects (2) and is subject to the development of 
resistance by the tumor, rendering agents ineffective. Radiotherapy can cause damage to 
healthy tissue close to the tumor or in the path of the radiation beam (3). Rapid advances 
in immunology suggests the potential of immunotherapy as a promising treatment, 
however its development is still in the nascent stage (4). Thus the searching for more 
effective cancer therapy is still underway. 
        Photodynamic therapy (PDT) is an attractive alternative to the traditional treatment 
methods with less morbidity and can preserve the anatomic and functional integrity of 
many organs such as the tongue or larynx (5). PDT uses molecules that are preferentially 
taken up by the tumor cells. Light delivered to tumor site to convert the molecules into 
singlet oxygen that chemically injures the cell.  However, these agents are only relatively 
selective and risk of severe burns over the entire body when exposed to light for long 
time. 
    Thermal therapies (hyperthermia) for cancer have been widely investigated as a 
minimally invasive alternative (6). Thermal therapies induced cellular injury/death above 
40°C appears due to protein denaturation (7-9). A variety of heat sources have been used 
including ultrasound (10), microwaves (11, 12), magnetic heating (13, 14) and radio 
frequency (11, 15). However, the thermal therapy affects both healthy and cancerous 
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tissue. In order to attain success as a sole therapeutic agent, the thermal heat must be 
specifically targeted to the tumor with much less heat produced in the surrounding tissue.  
    The use of lasers for thermal treatment of tumors can target the tumors by fine cable 
(16-18). However, pigments in healthy tissue absorb energy in the light path, thus 
reducing the speed and effectiveness of the heat deposition within tumor cells and 
increasing nonspecific injury of adjacent healthy tissue. Photosensitizers such as dyes (19, 
20) located within a tumor allow for increased heat production within the tumor at lower 
incident energies.  
    Nanotechnology has engendered a range of novel materials with unique properties 
unlike their bulk counterparts and raised the possibility of designing molecularly targeted 
photothermal agents. Recently, silica coated gold nanoshells with a tunable absorption in 
the near infrared (NIR) region have been used as both imaging and therapy agents (21-
24). Nanoshells have generated considerable interest as a photothermal agent due to its 
wavelength selectivity, strong near infrared absorption efficiency and photo-stability 
compared to the conventional dyes. By adjusting the relative gold layer thickness and the 
size of the silica core, the absorption band can be tuned to NIR wavelength, a region of 
light where optical penetration through tissue is optimal.  
    Metallic noble nanoparticles devoid of any coating have received widespread interest 
in their use in biotechnological systems for diagnostic application and biological imaging 
due to its easy preparation, ready bioconjugation and highly controlled optical properties 
(25-31). Colloidal gold nanoparticles are well known safe and their safety in human cells 
have been characterized (32). The absorption maximum of Au nanoparticles is tunable 
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from the mid visible region into the infrared region based on the size, shape, and material. 
Our group has determined that the absorbed light by Au nanoparticles is converted into 
heat on the picosecond time scale (33, 34). Thus Au nanoparticles are potential very 
practical and efficient phothermal agents in therapeutic applications.  
   In this work the efficiency of gold nanospheres as photothermal agent near its plasmon 
resonance absorption (530 nm) is demonstrated in vitro by selectively delivering gold 
nanoparticles to oral squamous carcinoma cells that overexpress EGFR, a clinically 
related cancer biomarker. Thermal therapy by oven heating is also carried out for 
comparison. 
5.2 Experimental 
    Au nanoparticles are prepared by the citrate reduction of HAuCl4 as described in 
Chapter II, part 2. The measured absorption maximum of the nanoparticles is 530 nm. 
TEM showed the average particle size of 40 nm. The anti-EGFR/gold conjugates are 
prepared according to the method described in Chapter II, part 3.  Briefly, the gold NPs 
are diluted in 20 mM HEPES buffer (pH = 7.4, Sigma) to a final concentration with 
optical density of 0.8 at 530 nm. 50 uL anti-EGFR monoclonal antibodies (host mouse; 
Sigma) are diluted in 500 uL of the same HEPES buffer. Then 10 mL of the Au solution 
prepared above are mixed with the dilute antibody solution for 20 mins. 0.5 mL of 1% 
polyethyleneglycol (MW = 4000, Boehringer Mannheim) is added to the mixture to 
prevent aggregation and the solution is centrifuged at 6000 rpm for 18 mins. Then the 
anti-EGFR/Au pellet is redispersed in PBS buffer (pH = 7.4, Cellgro) and stored at 4oC. 
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    One benign epithelial cell line, HaCaT (human keratinocytes), and two malignant 
epithelial cell lines (human oral squamous cell carcinoma) , HOC 313 clone 8 and HSC 3, 
are cultured on 18 mm diameter glass cover slips in a 12-well tissue culture plate in 
DMEM plus 5% FBS at 37°C under 5% CO2. The cover slips are coated with collagen 
type I (Roche) in advance for optimum cell growth.   
    For the laser irradiation experiment the CW argon laser is chosen due to wavelength 
overlapping with the absorption band of the nanoparticles. The cell monolayer is 
immersed into the conjugated nanoparticles solution (~ 0.2 nM) for 40 min, rinsed with 
PBS buffer and then exposed to argon laser light at various power densities. The argon 
laser at 514 nm is focused by a lens (f = 10 cm) to form a round spot with 1 mm in 
diameter on the sample position. Multiple regions on the slides are exposed to argon laser 
light at different power densities for 4 min each and then stained with 0.4 % trypan blue 
(Sigma) for 10 mins to test cell viability. Dead cells will accumulate the dye and stain 
blue while live cells will pump out it and remain clear. After staining, the samples are 
imaged under 10x in a transmission mode. 
    In the thermal destruction experiment, cells without any gold nanoparticles are heated 
in an oven at different temperatures ranging from 50-90˚C with intervals of 10°C. After 7 
mins, the cells are taken out, cooled down to room temperature and stained with trypan 
blue for 10 mins. The cells are then rinsed with PBS buffer and imaged under a 
microscope. 
5.3 Results and discussion 
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5.3.1 Photothermal Therapy 
    Control cells (without nanoparticles) have been exposed to laser light at several power 
values to test the photothermal stability of the cell themselves as controls. Laser power 
energy of 600 mW (76 W/cm2), 500 mW (64 W/cm2), 400 mW (50 W/cm2), 300 mW(38 
W/cm2), 200 mW (25 W/cm2) and 150 mW (19 W/cm2) are used to irradiate cells at 
different regions for 4 mins each and then stained with trypan blue. After staining, no 
blue cells are observed for all of the area exposed to laser irradiation. Figure 5-1 shows 
the pictures of the cells irradiated at 600 mW. It is obvious that even at high laser 
energies, no death is observed for both cancer and healthy cells. 
HaCaT healthy cells  HSC cancer cells   HOC cancer cells 
 
Figure 5-1: HaCaT benign cells, HSC malignant cells and HOC 
malignant cells without nanoparticles treatment irradiated at 600 
mW (76 W/cm2) and then stained with trypan blue. No cells are 
killed up to this laser power. Scale bar: 60 µm. 
 
    After incubation with anti-EGFR antibody conjugated gold nanoparticles, cells are 
exposed to laser power value from 600 mW to 250 mW at an interval of 50 mW at 
different regions for 4 mins each to test their photothermal stability. After exposure to the 
argon laser at and above 450 mW, cells within the laser spots became blue while at lower 
energy values only a few or no blue cells are detected. Figure 5-2 shows the pictures 
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60x, dead cells 60x, live cells 
Figure 5-2: HaCaT noncancerous cells irradiated at different laser 
powers and then stained with trypan blue. Scale bar:  60 µm for 10x 
images and 10 µm for 60x images. 
 
It is obvious that the HaCaT cells after incubation with anti-EGFR antibody conjugated 
gold nanoparticles suffered photothermal destruction when the laser has density at or 
higher than 450 mW in a 1mm laser spots (57 W/cm2). This is due to the introduction of 
the Au nanoparticles which binds to EGFR on the cell surface. The Au nanoparticles 
served as a photo-absorbers due to the overlapping of its absorption band (λmax = 530 nm) 
and the argon ion laser wavelength at 514 nm.  From Figure 5-2 we can also see that even 
at energy equal and higher than 450 mW, some cells are still colorless. This means some 
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cells are not killed by the laser although majority of cells are photodamaged. This 
indicates that the gold nanoparticles do not homogeneously distribute on the cell 
monolayer. Some cells take nanoparticles, some not. Some cells may take more 
nanoparticles and some cells take less. This is because that although part of nanoparticles 
are bound to the cells by EGFR on the cell surface, but  mostly the nanoparticles are 
bound to cell surface by nonspecific interactions of the antibody on the surface of gold 
nanoparticles and the proteins on the surface of healthy cells.     
    The malignant HSC cells suffered irreversible photothermal injury at a much lower 
power density (see Figure 5-3). Cell death occurred within the laser spots after exposure 
to laser at and above 200 mW while no cell death are observed at lower power density 
than 150 mW.  The energy threshold to cause death of the HSC cells is about half that 
which caused the photothermal death of the benign HaCaT cells. This indicates that the 
gold amount on the HSC cancer cells are much more than that on the healthy cells, which 
results in the lower laser energy required to cause the cell destruction. 
    The HOC malignant cells also undergo photothermal destruction at a much lower 
power density than that required for HaCaT noncancerous cells (Figure 5-4). Cell death 
within the laser spots is observed at the laser power of 250 mW (19 W/cm2) and no cell 
death is observed at lower power density than 100 mW (13 W/cm2). The transmission 
images at 60x reveal that more Au nanoparticles (reddish color) are bound to the surface 
of the HOC cell surface allowing for the lower energy required to cause cell death than 
HSC cells. This indicates that HOC may have more EGFR on their cell surface than HSC 
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Figure 5-3: HSC cancer cells irradiated at different laser powers and then 
stained with trypan blue. HSC cancer cells are killed at and above 200 mW 
(57 W/cm2). Scale bar:  60 µm for 10x images and 10 µm for 60x images. 
growth processes by binding with EGF. Before bound to EGF, EGFR change its 
conformation and form an activated state so that EGF can bind to EGFR (35). Upon 
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Figure 5-4: HOC cancer cells irradiated at different laser powers 
and then stained with trypan blue. HOC cancer cells are killed at and 
above 150 mW (19 W/cm2). Scale bar:  60 µm for 10x images and 
10 µm for 60x images. 
the EGFR receptor pairs, or ‘dimerizes’, with another ErbB family members. So at the 
time of gold nanoarticles bound to the EGFR, EGFR might be in an unactivated 
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monomer state, might be in an activated state and might be in dimmer state. It is not 
known when the antibody on the gold surface bound to EGFR. Does it bound to all the 
states or some states? These factors will affect the amount of gold nanoparticles 
eventually adsorbed on the cell surface. So at different phase of cell growth, the binding 
of antibody to EGFR may vary at some extent. 
5.3.2 Thermal destruction of cells by oven heating 
    Figure 5-5 shows images of the cells which are heated in the oven at 70°C and 80°C 
for 7 min. These results indicate that for all three cell lines, cell damage began at 70°C 
while the cell samples underwent complete destruction at 80°C. The error in the 
temperature measurement is 5°C. Thus a threshold temperature in the range of 70-80°C is 
required for the thermal destruction of cells of all three lines. 
HaCaT noncancerous cells HSC cancerous cells HOC cancerous cells 
   
   
 
Figure 5-5: HaCaT noncancerous cells (top row), HSC cancerous cells (middle row) and 
HOC cancerous cells (bottom row) heated in an oven at 70˚C (left column) and 80˚C 
(right column). For all three lines, the cell damage began at 70˚C while complete cell 





    Using a numerical model, Prashant, another member in our lab, calculated the 
relationship of the minimum local temperature rise on the cells with the laser power 
values according to the gold loading on each type of cells (36). He found that the 
temperature rise is lineally dependent on the laser power. At the threshold power value 
for the photothermal destruction of each type of cells (see results in 5.3.1), he found that 
the local temperature rise for HaCat cells is 77oC, 73oC for HSC cancer cells and 74oC 
for HOC cancer cells. These results indicate that the minimum temperature to cause cell 
phothermal destruction is between 70o and 80oC, which is in great agreement with the 
temperature range to cause cell thermal destruction. It is also interesting to notice that 
that Hirsch et. al. (22) has reported that a temperature of ~ 74oC (measured by MRTI 
analysis) is reached in the photothermal destruction of breast tumor in vivo using gold 
nanoshells. Although the heating dissipation in photothermal and thermal therapy of 
cancer cells in vitro as well as in the photothermal therapy of tumor tissue in vivo might 
be different, a similar threshold temperature in the range of 70-80°C is required for the 
destruction of the cells.  
    This study demonstrates that Au nanoparticles are a novel class of photothermal agents 
causing cell injury and death through conversion of the strongly absorbed light to thermal 
energy. After exposure of these cells treated with anti-EGFR antibody conjugated Au 
nanoparticles to a visible CW argon laser at 514 nm, different laser power densities are 
observed to cause photothermal destruction among these three types of cells. The two 
malignant cells require less than half the energy needed to kill the benign cells incubated 
with gold nanoparticles and more than four times energy required to kill the cells in the 
absence of nanoparticles. Thermal destruction by oven-heating showed that a threshold 
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temperature in the range of 70-80˚C is required to destroy cancerous as well as 
noncancerous cells. This temperature range is in great agreement with the calculated 
minimum temperature rise to cause the photothermal destruction of cells which is done 
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CHAPTER 6  
PHOTOTHERMAL CANCER CELL THERAPY IN NEAR-
INFRARED REGION USING ANTI-EGFR ANTIBODY 




    Due to strong electric fields at the surface, the absorption and scattering of 
electromagnetic radiation by noble metal nanoparticles are strongly enhanced. These 
unique properties provide the potential of designing novel optically active reagents for 
simultaneous molecular imaging and photothermal cancer therapy. It is desirable to use 
agents that are active in the near infrared (NIR) region of the radiation spectrum to 
minimize the light extinction by intrinsic chromophores in native tissue. Gold nanorods 
with suitable aspect ratios (length divided by width) can absorb and scatter strongly in the 
NIR region (650-900 nm). In the present work, we provide an in vitro demonstration of 
gold nanorods as novel contrast agents for the photothermal cancer therapy. Nanorods are 
synthesized and conjugated to anti-epidermal growth factor receptor (anti-EGFR) 
monoclonal antibodies and incubated in cell cultures with a nonmalignant epithelial cell 
line (HaCat) and two malignant oral epithelial cell lines (HOC 313 clone 8 and HSC 3). 
The anti-EGFR antibody conjugated nanorods bind specifically to the surface of the 
malignant type cells with a much higher affinity due to the overexpressed EGFR on the 
cytoplasmic membrane of the malignant cells. After exposure to continuous red laser at 
800 nm, it is found that malignant cells require half the laser energy to be photothermally 
destroyed than the nonmalignant cells. Thus selective photothermal therapy is realized in 
the NIR region. The work has been published in JACS, 2006, 128 (6), 2115. 
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6.1 Introduction 
     Reducing a material’s size to the nanometer length scale (which is the length scale 
of the electronic motion that determines the material’s properties) makes it sensitive to 
further reduction in size or a change in shape. In semiconductor nanoparticles, the 
property change results from quantum confinement of the electronic motion (1). In metals 
the properties of the surface become dominant and give nanoparticles new properties (2). 
In noble metals the coherent collective oscillation of electrons in the conduction band 
induces large surface electric fields which greatly enhance the radiative properties of gold 
and silver nanoparticles when they interact with resonant electromagnetic radiation (3). 
This makes the absorption crossection of these nanoparticles orders in magnitude 
stronger than the strongest absorbing molecules (4) and the light scattering crossecction 
orders in magnitude more intense than organic dyes (5). Thus these particles act as 
excellent sensors and novel contrast agents for optical detection due to their enhanced 
absorption and scattering, respectively. In addition, when it is realized that the strong 
absorbed radiation is converted efficiently into heat on a picosecond time domain due to 
electron-phonon and phonon-phonon processes (6), their potential use in photothermal 
therapy becomes obvious.  
     The use of nanoparticles in medicine is one of the important directions that 
nanotechnology is taking at this time. Their applications in drug delivery (7-9), cancer 
cell diagnostics (10-13), and therapeutics (14) have been active fields of research. The 
scattering properties of gold nanospheres have been used for cancer cell imaging using 
confocal microscopy (13, 15) and simple dark field microscopy (16). Recently 
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photothermal therapy using the absorption properties of antibody conjugated gold 
nanoshells (17) and solid gold nanospheres (18) have been demonstrated to selectively 
kill cancer cells leaving the healthy cells unaffected. 
     In order to use long wavelength laser irradiation that penetrates tissue optimally (can 
be over 10 cm in penetration depth depending on tissue types) for in vivo photothermal 
treatment (650-900 nm) (19, see Figure 6-1), the absorption band of the nanoparticles has 
to be in the near infrared region. The absorption band of core-shell particles has been 
 
 
Figure 6-1: NIR window (19). 
tuned by adjusting the ratio of the thickness of the gold shell to the diameter of the silica 
core (about 120 nm in diameter) and thus enables photothermal therapy in this region. 
Carbon nanotubes absorb naturally in this region and have recently been proposed as 
near-infrared therapy agents (20). It is important to mention that surface plasmon field 
enhancement of the absorption of nanorods is predicted to be the strongest of all the 
different shapes of gold and silver nanoparticles (21, 22). By changing the shape of gold 


















wavelength from visible to the NIR region, but also increase their absorption and 
scattering crossections.  
     In the present work, we demonstrate the potential use of gold nanorods as a novel 
contrast reagent for selective photothermal therapy of cancer cells using a near infrared 
low energy cw laser. Solid gold nanorods have several advantages over other 
photothermal contrast agents. The synthesis of gold nanorods with various aspect ratios 
which enables tunable absorption wavelength in the near infrared region (4, 23, 24) is 
quite simple and well-established. The appropriate size of the nanorods is quite small and 
is potentially useful in applications such as drug delivery and gene therapy. In addition, 
the biosafety of metallic gold is well known and they have been used in vivo since the 
1950’s (25) and recently the noncytotoxicity of gold nanoparticles in human cells has 
been studied in detail by Wyatt et al (26).  
6.2 Experimental 
The nanorods are synthesized according to the seed-mediated growth method described 
in Chapter 2, page 57-59. The nanorods with aspect ratio of 3.9 are chosen for this 
experiment due to the efficient overlapping of the longitudinal absorption maximum 
which overlapped the red laser wavelength at 800nm. The nanorods prepared above are 
coated with poly (styrenesulfonate) (PSS, MW=18,000, Polysciences Inc.) and then 
conjugated with the anti-EGFR antibodies according to the methods described in Chapter 
2, Page61-62. The nanorods conjugated with anti-EGFR monoclonal antibodies are 
centrifuged and redispersed into PBS (pH=7.4) to form a stock solution with the optical 
density around 1.0 at 800 nm.    
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HaCaT healthy cells and HOC and HSC 3 cancer cells are cultured in DMEM 
(Dulbecco's Modification of Eagle's Medium, Cellgro) plus 10% FBS (Fetal Bovine 
Serum, Gem Cell) at 37°C under 5% CO2.  Then the cells are cleaved by trypsin and 
replated onto 18 mm glass coverslips in a 12-well tissue culture plate and are allowed to 
grow for 3 days. The cover slips are coated with collagen type I (Roche) in advance for 
optimum cell growth. The cell monolayer on the cover slips is taken out of the medium 
from the incubator and rinsed with PBS buffer and then immersed into the anti-EGFR 
conjugated nanorods solution for 30 min at room temperature. After the nanorods 
incubation, the cell monolayer is rinsed with PBS buffer, and immersed in PBS buffer in 
a 60x15mm Petri dish for the photothermal experiments.  
    For the laser irradiation experiment, a cw Ti: Sapphire laser at 800 nm is used. This 
wavelength is in the NIR region at which the tissue has low absorption. It also overlaps 
efficiently with the longitudinal absorption band of the nanorods. The cell monolayer is 
immersed into the conjugated nanoparticle solution (OD800nm = 0.5) for 30 min, rinsed 
with PBS buffer and then exposed to the red laser light at various power densities. The 
red laser at 800 nm is focused to a 1 mm diameter spot on the sample. Multiple regions 
on the slides are exposed to the laser light at different power densities for 4 min each and 
then stained with 0.4 % trypan blue (Sigma) for 10 min to test cell viability. Dead cells 
accumulated the dye and are stained blue while living cells got rid of it and remained 
clear. After staining, the samples are imaged under 10x in bright field. 
6.3 Results and Discussion 
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Our previous work (see Chapter 5) demonstrates that antibody conjugated gold 
nanospheres of 35 nm in diameter act as efficient and selective photo thermal absorbers 
for destroying cancer cells with a visible argon ion laser without affecting the 
surrounding nonmalignant cells (18). The laser wavelength at 514 nm overlaps the 
surface plasmon absorption of the spherical nanoparticles which has an absorption 
maximum at 520 nm. By conjugation with anti-EGFR monoclonal antibodies that 
specifically target the molecular marker EGFR, the malignant cells can be destroyed with 
less than half the laser energy required to kill the normal cells due to the overexpresssion 
of the EGFR on the surface of malignant cells. However, at this wavelength, tissue 
penetration of the light is very low (less than 500 µm, (19)). While this may be useful for 
superficial lesions, to treat cancer in vivo it is desirable to have deeper tissue penetration. 
The near infrared region of the spectrum provides maximal penetration of light due to 
relatively lower scattering and absorption from the intrinsic tissue chromophores. In this 
region, the light penetration depth is up to ten centimeters depending on the tissue types 
(19). 
     Since the absorption band of metallic noble nanoparticles is tunable by altering the 
nanoparticle shape or size, designing photothermal absorbing agents in the near infrared 
region is possible. Other shapes of gold nanoparticles, such as branched (27), pentagon 
(28) and large prisms nanoparticles (29) have the surface plasmon absorption in near 
infrared region. Nanorods are better candidates for this application due to the accurate 
control of the absorption maximum to the required wavelength by changing the aspect 
ratio, which can be realized by simply changing the silver ion concentration during the 
gold nanorod growth process. However, other properties such as binding affinity of 
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different nanoshapes and their capping molecules to the antibodies should also be 
considered in the future. 
 Figure 6-2 shows the absorption spectrum (left) and TEM image (right) of the gold 
nanorods used for the selective photothermal therapy of cancer cells in this work. 
Nanorods with an aspect ratio of 3.9 are chosen due to their absorption overlapping with 
a region of minimum extinction of the human tissues. The absorption band of the 
nanorods also overlaps the cw Ti:Sapphire red laser wavelength at 800 nm which we used 
in our lab.  
























Figure 6-2: Absorption spectrum (left) and TEM image (right) of the gold 
nanorods with aspect ration of 3.9 used for the selective photothermal therapy of 
cancer cells. Scale bar: 60 µm. 
After incubation with anti-EGFR antibody conjugated gold nanorods for 30 minutes, 
cells are exposed to cw Ti:Sapphire laser irradiation at power values of 40, 80, 120, 160, 
and 200 mW with a  focus spot of 1 mm in diameter  for 4 minutes each. The cells are 
then stained with trypan blue to test for their photothermal stability. Figure 6-3 shows 
images of irradiated HaCat healthy cells at different laser energies.   
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Exposure to the red laser at 800 nm at and above 160 mW (20 W/cm2) caused 
photodestruction of all HaCat normal cells, which is detected by the cell viability test 
with trypan blue. Cell death is shown as a blue spot in a circular region that matches the 
laser spot size. The cells outside the laser spot are viable as indicated by their ability to 
get rid of the trypan blue. This also indicates that the anti-EGFR/Au nanorods themselves 
are not cytotoxic. Reducing the laser energy to 120 mW decreases the proportion of blue 
cells in the laser spot. At this energy, only the laser spot center contains a sufficiently 
high enough energy density to cause cell destruction. The energy density at the edge of 
the laser spot is not high enough to cause cell injury and thus the blue death cell spots 





Figure 6-3: HaCat noncancerous cells irradiated at different laser 
powers and then stained with trypan blue. HaCatC noncancerous cells 
are killed at and above 160 mW (20 W/cm2). Scale bar: 100 µm. 
160 mW 120 mW 
80 mW 40 mW 
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     Figure 6-4 shows that the malignant HSC cells suffer photothermal injury at a lower 
laser power. Cell death occurs within the laser spots after exposure to the laser at and 
above 80 mW, which corresponds to 10 W/cm2. The energy threshold for cell death of 
the HSC cells is about half that needed to cause cell death of the nonmalignant HaCaT 
cells. The dim blue color shown in the HSC cell images outside the laser spot is due  





Figure 6-4: HSC cancer cells irradiated at different laser powers and 
then stained with trypan blue. HSC cancer cells are killed at and above 
80 mW (10 W/cm2). Scale bar: 100 µm. 
160 mW 120 mW 
100 mW 80 mW 
60 mW 40 mW 
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to cells that died from prolonged exposure of the cells in buffer solution outside the cell 
incubator.  
    The HOC malignant cells also undergo photothermal destruction at and above 80 mW 
while no cell death is observed at lower power (Figure 6-5). The two malignant cells 
require less than half the energy needed to kill the nonmalignant cells, which is due to the 
overexpression of EGFR on the cancer cells and the corresponding higher amount of anti-
EGFR antibody conjugated gold nanorods which absorb the light and convert it into heat 
at the cell surface. From the absorption spectra of the three types of cells in Figure 6-3, it 
can be seen that the amount of nanorods on the two malignant cells is over 2 times higher 
than that on the nonmalignant cells. The photothermally hot nanorods thus deliver more 
heat to the malignant cell membrane leading to cell death at lower energy than that for the 
nonmalignant cells.  
  The above results suggest that nanorods conjugated to antibodies can be used as a 
selective and efficient photothermal agent for cancer cell therapy using low energy 
harmless near infrared laser. Thus, for further in vivo applications, it is expected that the 
tumor tissue will be selectively destroyed at laser energies which will not harm the 
surrounding normal tissue due to the higher concentration of nanorods selectively bound 
to the tumor tissue. The threshold energy to kill the cancer cells in our work is found to 
be 10 W/cm2, which is lower than that needed in the case of the core-shell particles (14). 
This difference can result from either higher absorption crossection, higher binding 
affinity constant of the gold nanoparticles to the antibody or higher affinity constant of 
the antibody to the cancer cell surface used.  
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Figure 6-5: HOC cancer cells irradiated at different laser powers and 
then stained with trypan blue. HOC cancer cells are killed at and above 
80 mW (10 W/cm2). Scale bar: 100 µm. 
It is known that many solid tumors including brain, bladder, stomach, breast, lung, 
endometrium, cervix, vulva, ovary, esophagus, stomach, prostate, renal, pancreatic, 
glioblastoma, and squamous cell carcinoma cells, overexpress EGFR on the cell 
cytoplasm membrane to different degrees (30). Targeting this specific molecule on the 
cell surface allows selective delivery of the nanorods with much higher concentrations to 
200 mW 160 mW 
100 mW 120 mW 
80 mW 40 mW 
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carcinoma cells and allow for selective photothermal therapy with a near infrared laser 
for many types of cancer cells. The strong scattering of gold nanorods enables them to be 
imaging contrast agents as well. Thus gold nanorods offer a new dual diagnostic 
imaging/therapy method in biomedical sensing and cancer therapy tunable to be used in 
the visible and near infrared region. 
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CHAPTER 7  
CATALYTIC PROPERTY OF GOLD NANOPARTICLES  





    Nicotinamide adenine dinucleotide is an important coenzyme involved in the 
production of ATP, the fuel of energy, in every cell. It alternates between the oxidized 
form NAD+ and the reduced form dihydronicotinamide adenine dinucleotide (NADH) 
and serves as a hydrogen and electron carrier in the cellular respiratory processes. In the 
present work, the catalytic effect of gold nanoparticles on the oxidization of NADH to 
NAD+ is investigated. The addition of gold nanoparticles is found to quench the NADH 
fluorescence intensities but had no effect on the fluorescence lifetime. This suggested that 
the fluorescence quenching is not due to coupling with the excited state, but due to 
changing the ground state of NADH. The intensity of the 340 nm absorption band of 
NADH is found to decrease while that of the 260 nm band of NAD+ is found to increase 
as the concentration of gold nanoparticles increases. This conversion reaction is further 
supported by nuclear magnetic resonance and mass spectroscopy. The effect of the 
addition of NADH is found to slightly red shift and increase the intensity of the surface 
plasmon absorption band of gold nanoparticles at 520 nm. This gives strong support that 
the conversion of NADH to NAD+ is occurring on the surface of the gold nanoparticles, 
i.e. NADH is surface catalyzed by the gold nanoparticles. The catalytic property of this 
reaction might have important future applications in biological and medical fields. The 




    Nicotinamide adenine dinucleotide is one of the most important coenzymes found in 
every cell. It is involved in the production of energy in all cells, and is needed to oxidize 
all foods including carbohydrate, fats, and amino acids to produce ATP which is used by 
every cell in the body (1). It serves as a hydrogen and electron carrier and alternates 
between the oxidized state NAD+ and the reduced state – dihydronicotinamide adenine 
dinucleotide (NADH) in cellular respiratory and metabolic processes (2). The extra 
hydrogen on position 4 of the planar pyridine ring in NADH results in the significant 
spectral differences between NADH and NAD+ (Figure 1). In contrast with oxidized 
NAD+, the reduced coenzyme NADH absorbs strongly around 340 nm and fluoresces in 
the blue spectral region with a maximum around 460 nm (3). This reduced fluorescent 
form is one of the major endogenous fluorophores on cellular fluorescence (4) and the 
absorption and fluorescence of which have been widely used to monitor enzymatic 






















































































Figure 7-1: Structure of NADH and NAD+. 
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    Metal nanoparticles have been shown to catalyze some redox reactions such as the 
electron transfer reaction of hexacyanoferrate(III) ions and thiosulfate ions catalyzed by 
platinum nanoparticles (7) and the Suzuki reaction between phenylboronic acid and 
iodobenzene catalyzed by PVP-Palladium nanoparticles (8). The large surface to volume 
ratio and the enhanced surface atomic catalytic activity make metallic nanoparticles 
attractive catalysts compared to bulk materials. In this paper, the effect of gold 
nanoparticles on NADH is systematically investigated by following the change in the 
UV/Vis absorption and fluorescence spectroscopy, 1H nuclear magnetic resonance and 
mass spectroscopy. A catalytic function of gold nanoparticles to the biologically 
important reaction of NADH to NAD+ is found. This catalytic property of gold 
nanoparticles to NADH might have future importance in biochemical and medical 
applications. 
7.2 Experimental 
    NADH disodium salt is obtained from CALBIOCHEM Co. Gold nanoparticles are 
prepared by the citrate reduction of HAuCl4 (9, 10). Briefly, 10mL of 38.8 mM sodium 
citrate is quickly injected into 100 mL of 1 mM HAuCl4 vigorously stirred in a 250 mL 
round-bottom flask equipped with a condenser. The color is quickly changed from pale 
yellow to burgundy. The heating is continued for 10 min. Then the solution is kept 
stirring for 15 min without heating. After it reached room temperature, the solution is 
filtered through a 0.45 µm Gelman Nylon filter. The gold nanoparticles made in this way 
have the absorption maximum at 520 nm. TEM showed the average particle size of 15 
nm. A series of Au and NADH mixed solution are prepared by simply adding 1.0 to 2.5 
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mL of the stock gold solutions (OD = 1.0) and 0.03 mL to 0.9 mL of the stock NADH 
solution (1mM) as well as water to form a final solution in a total volume of 3.0 mL. The 
final concentrations of gold nanoparticles are calculated according to the extinction 
coefficient calculated by Stephan Link (ε = 7.2 × 108 for 15 nm gold nanoparticles) (11). 
The Au nanoparticle and NADH mixed solution is kept in dark for later NMR and MS 
measurements and time experiments. The mixed solutions are stable for about one week 
in cold and dark.  
    The absorption spectrum of each sample is measured on a Shimadzu UV-3101PC 
spectrometer in a quartz cell. The fluorescence spectrum excited at 325 nm is measured 
on a Shimadzu RF-5301PC spectrofluorophotometer. For NADH with higher 
concentrations, a 2-mm quartz is used at an angle of 45o to the excitation beam so that the 
fluorescence just came from the front surface of the sample. PTI fluorimeter with a 
nitrogen laser and PMT detector is used to obtain the time-resolved fluorescence 
spectrum. Mass spectrum is obtained from a LCQ Advantage mass spectrometer in a 
negative mode with electrospray ionization (ESI). The NADH (0.2 mM) or the NADH-
Au mixed solution (0.2 mM NADH are mixed with 0.46 nM Au solution and let sit in 
dark for 3 days before measurement) is diluted by about a factor of 5 using 
water/acetonitrile/ammonia before injection. Nuclear magnetic resonance spectra are 
obtained from a Varian Inova 600MHz NMR spectrometer equipped with a chili 
cryoprobe. 225 µl of NADH (1.0 mM) or NADH-Au mixed solutions (1.0 mM NADH 
are mixed with 2.0 nM Au solution and let sit in dark for 3 days before measurement) are 
mixed with 25 µl of D2O and then used for NMR experiment. 
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7.3 Results and discussion 
7.3.1 Fluorescence results      
    The spectra effect of Au nanoparticles on NADH is followed by the change of 
fluorescence intensities of NADH when different concentrations of Au nanoparticles are 
just mixed with NADH solution, shown in Figure 7-2. Figure 7-2(a) shows that when Au  
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Figure 7-2: (a) Fluorescence spectra of NADH (0.08 mM) at different concentrations of 
gold nanoparticles (λexci = 325 nm). Inset is the time-resolved fluorescence decay spectra 
of NADH at 460 nm at different concentrations of gold nanoparticles. The lifetime of 
NADH fluorescence obtained by a monoexponential fitting is about 0.85 ns which is the 
same for all samples; (b) The quantitative relationship of the fluorescence intensity of 
NADH at 460 nm with the concentration of gold nanoparticles. 
nanoparticles are added into NADH, the fluorescence of NADH with a maximum at 460 
nm (λexci = 325 nm) is quenched. The quenching effect is increased with the increasing of 
the concentration of Au nanoparticles. The same quenching effect is also observed at 
other concentrations of NADH. Figure 7-2 (b) shows a quantitative relationship of the 
fluorescence intensities at 460 nm with the concentration of Au nanoparticles at different 
concentrations of NADH. It can been seen that for 0.03 mM NADH, 0.92 nM Au 
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nanoparticles (the final concentration of gold nanoparticles when 2.0 mL gold (OD = 1.0) 
are mixed with 0.09 mL of 1mM NADH solution and 0.91 mL water) induced the 
fluorescence to be totally quenched while for 0.08 and 0.15 mM NADH more Au 
nanoparticles are needed to lead to the same effect. To find out the reason for the 
quenching effect, the fluorescence lifetime of pure NADH as well as NADH in Au 
solutions is measured. The normalized fluorescence decay in inset of Fig. 2(a) shows that 
the fluorescence lifetimes for these three samples are the same as that of pure NADH.  
This suggests that the quenching effects are not due to the coupling of Au nanoparticles 
with the excited states of NADH, but due to the change of their ground states. So the 
absorption spectra of NADH should change. By a monoexponential fitting of the 
fluorescence decay of NADH, the fluorescence lifetime is about 0.85 ns. There exists 
variation on the absolute value of the life time as the instrument is most sensitive to time 
scale of over nanosecond region. 
7.3.2 Absorption results         
    The absorption spectra are measured right after Au nanoparticles are added into NADH 
solution. Figure 7-3(a) solid line shows that NADH has three absorption bands at UV-Vis 
region. The band at 340 nm is from the n-π* transition of the dihydronicotinamide part 
which has a coplanar conformation with the carboxamide moity and thus the electrons are 
conjugated between these two parts (12, 13). The stronger band at 260 nm is from the π-
π* transition of the adenine ring.  The strongest band around 205 nm is from the π-π* 
transition of the dihydronicotinamide part. From Figure 7-3 we can see that when the 
concentration of Au nanoparticles are linearly increased, the absorption  
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Figure 7-3: Absorption spectra of the mixed solutions of NADH (0.08 mM) and gold 
nanoparticles at different concentrations; (b) The absorption spectra of NADH after 
subtraction of the absorption contribution from gold nanoparticles; (c) The quantitative 
relationship of the absorption intensity of NADH at 340 nm with the concentration of 
gold nanoparticles; (d) The absorption spectra of NADH (0.08 mM) at different time after 
gold nanoparticles (0.46 nM) are added. 
intensities of both 260 nm of NADH and 520 nm of Au nanoparticles linearly increased 
while the intensities of the 340 nm band didn’t change much. The intensities of 205 nm 
band are too strong to be resolved. Due to the contribution of Au nanoparticles, the 
absorption of the mixed solution is subtracted by the absorption of pure Au nanoparticles 
at the same concentration as in the mixed solution on considering of no obvious change 
on the gold absorption spectra and thus the change only from NADH absorption can be 
resolved, as shown in Figure 7-3(b).  It is obvious that when Au nanoparticles are added, 
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the intensity of the 340 nm band greatly decreased while the intensity of the 260 nm band 
slightly increased. More Au nanoparticles induced further decrease on the former band 
and further increase on the latter band. Since the 340 nm band is from the electron 
transition on the coplanar structure of dihydronicotinamide and carboximate, the intensity 
decrease of this band suggests that the structure of this part is changed due to the addition 
of gold nanoparticles, i.e NADH must be converted to some other species. The intensity 
increase of the 260 nm band which is due to the adenine ring indicates that the adenine is 
not destroyed by the Au nanoparticles, but conversely this band has higher extinction 
coefficient than that in NADH. It has been reported that NAD+, the oxidized state of 
NADH has larger extinction coefficient at 260 nm (18×10-3) than that of NADH (14.4 
×10-3) due to the contribution of oxidized nicotinamide (14). It doesn’t have the 340 nm 
band due to a twisted and cisoid conformation between the oxidized nicotinamide and 
carboxamide (15). So the changes of the absorption spectra of NADH due to the effect of 
Au nanoparticles indicate that NADH might be oxidized to NAD+, and thus the decrease 
of the 340 nm band could be due to the decrease of the amount of NADH and the 
increase of the 260 nm band is due to the production of NAD+ which had higher molar 
extinction coefficient than that of NADH. Further experiments are carried on other 
NADH concentrations. The quantitative relationship of the absorption intensities at 340 
nm with the concentration of Au nanoparticles are shown in Figure 7-3(c).  Since the 340 
nm band is specific for NADH, the absorption intensity of this band represents the 
amount of NADH. From Figure 7-3(c) we can see that 0.92 nM Au nanoparticles can 
lead to the complete reaction of 0.03 mM NADH according to the absorption intensity of 
the NADH. This is consistent with the fluorescence results shown in Figure 7-2 that 0.92 
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nM Au nanoparticles lead to the complete reaction of 0.03 mM NADH according to the 
fluorescence intensity of NADH.  
    The effect on the absorption spectra of NADH by the addition of Au nanoparticles also 
depended on time, which is shown in Figure 7-3(d). Figure 7-3(d) shows that as the time 
increased, the intensity of 340 nm band decreases while that of the 260 nm band increases. 
The band at 340 nm totally disappeared after overnight and the band at 260 nm became 
strongest among all the time. This suggests that more and more NADH is reacted with 
gold nanoparticles until complete reaction after overnight.  
7.3.3 Mass spectra and nuclear magnetic resonance results 
    If NADH is converted into NAD+, then the mass spectra of pure NADH and NADH in 
Au solutions should shown the differences of their molecular ion peak and NMR of these 
two samples should shown the difference of the chemical shifts of protons from the 
oxidized and reduced nicotinamide rings. A soft ionization mode - Electron Spray 
Ionization is used in the mass spectra measurement and the signals are detected in a 
negative mode. The strongest peak in NADH in Figure 7-4 represents the molecular ion 
of NADH (FW = 663). Due to the two negative charges on the NADH (see Figure 7-1), a 
proton is added to the molecule to form a single negative charged ion. So the molecular 
ion appeared at 664.2. The peak at 686.2 is from the NADH ⋅ Na ion. And the double 
charged NADH ion is detected at 331.7. While in the NADH and Au mixed solution, 
only one peak is detected in the range from 250 to 700. This peak at 661.9 represented 
the molecular ion peak of the product. While NAD+ (FW = 662, single negative charged) 
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should have a molecular ion at 662, the product is possibly NAD+. As electron spray 





Figure 7-4: ESI - MS of pure NADH (0.2 mM) and NADH with gold nanoparticles 
mixed (0.46 nM) using a negative detection mode. The peak at 664.2 is the molecular ion 
of NADH (FW = 663) plus a proton for the detection in the negative mode. The peak at 
661.9 is the molecular ion of NAD+ (FW = 662).  
    Figure 7-5 shows the 1H NMR of NADH and NADH-Au mixed solutions. The Au 
nanoparticles are mixed with NADH solution for three days and absorption spectra had 
shown that there are no NADH left. The signals between 4.0 to 5.8 ppm are cut off due to 
the strong and broad peak from water. The peak assignments of protons on the carbons of 
the nicotinamide, adenine and ribose C1’ are listed in the Table 7-1. The chemical shifts 






















the same condition in our samples) are also listed for comparison. The results of NADH 
agree very well with those from Catterall et.al.   
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Figure 7-5: 1H NMR of NADH (1.0 mM) and NADH with gold nanoparticles (2 nM) 
mixed (10% D2O) at the region from 9.5 to 5.8 ppm (a) and the region from 4.2 ppm to 
zero (b). The region between 4.2 to 5.6 ppm is not shown due to the strong signals from 
water. The inset in NADH spectrum from 6 to 9.5 ppm is the enlarged signals between 
8.5 and 9.5 ppm in NADH. The assignments of the labeled peaks are listed and compared 





Table 7-1: Some of the 1H-NMR peak assignments of NADH and NADH in gold 
nanoparticle solutions. The data reported by Catterall et al (16) are listed for comparison. 
 









a N-C-2-H 6.90 6.98 9.30 9.32 
b N-C-6-H Buried by 
H2O peak 
- 9.10 9.17 
c N-C-4-H 2.75 2.8 8.80 8.84 
d A-C-8-H 8.44 8.45 8.39 8.41 
e A-C-2-H 8.19 8.20 8.14 8.11 
f N-C-5-H 4.04 - 8.15 8.21 
g Ribose-C-1’-H 5.95, 6.08 6.09, 6.12 6.00, 6.04 6.05, 6.13 
 
    By the comparison of the chemical shifts of the protons on NADH in Au solutions with 
those of protons on NAD+, we can see that they are in a great agreement. These indicate 
that the NADH in Au solutions is actually NAD+. The oxidization at the C-4 position of 
NADH (c peak in Fig. 5) led to the far down shift of the chemical shift of the protons at 
this position from 2.8 ppm to 8.8 ppm in NAD+. And the oxidization of the 
dihydronicotinamide to nicotinamide also resulted in the big change of the chemical 
shifts of other protons on the nicotinamide rings (a,b and f peaks). The chemical shifts of 
the protons on adenines are the same in NADH and NAD+ (d and e peaks). The chemical 
shift of the ribose C-1’ which is bond to the adenine ring (g, left peak) didn’t change, but 
the chemical shift of the ribose C-1’ which is bond to the nicotinamide ring (g, right peak) 
of NAD+ is obviously down shifted. From the zoom-in region between 8.5 and 9.5 ppm 
in the NADH spectrum, we can see that those peaks in the mixed solution also showed up 
in the pure NADH solution in which there are no Au nanoparticles at all. This means that 
there is about 1% NAD+ impurities in the pure NADH stock solution. 
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7. 3.4 Explanation of the oxidation reaction 
    So why the oxidation reaction of NADH to NAD+ happens after the addition of Au 
nanoparticles? What induces this redox reaction? Since Au nanoparticles are obtained by 
sodium citrate reduction of HAuCl4, there might some HAuCl4 molecules left and they 
could cause the reaction. But this reason is excluded because it is also found that Au  
nanorods synthesized by the electrochemical method (no HAuCl4 acid is added and gold 
metal is converted from the anode to from gold nanoparticles) shows the same 
spectroscopic changes as induced by the Au nanoparticles although in a much slower 
reaction speed, shown in Figure 7-6 (a). This indicates that it is not HAuCl4 inducing the 
conversion of NADH to NAD+ in the Au nanoparticle solution. The slower reaction 
speed in Au nanorods than in nanospheres could be due to their differences in the shape, 
size and surface capping materials of the nanoparticles. Another possibility might be the 
HAuCl2 left in solution which is due to the incomplete reduction of HAuCl4. This reason 
is also excluded because the reduction of HAuCl2 solution (0.17 mM) by NADH (Figure 
7-6 (b)) is much slower than that caused by Au nanoparticles (the HAuCl2 is obtained by 
reduction of HAuCl4 in CTAB solution with ascorbic acids. The HAuCl2 concentration is 
selected by assuming 100% HAuCl4 is converted to HAuCl2 during the synthesis of gold 
nanoparticles).  
    From the absorption spectra of Au nanoparticles in Figure 7-6 (c) we can see that after 
24 h the gold surface plasmon band red shifted by 3 ~ 4 nm and the intensities increased 
about 4%. This indicates that Au nanoparticles are involved in the reactions. From Figure 
7-6 (d), it can be seen that the initial reaction rate determined by using the absorption 
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intensity of NADH at 340 nm depends on Au concentration linearly in the range used 
(0.23 to 1.17 nM). This, together with the absorption changes of the Au surface plasmon 
band, suggests that the catalytic reaction occurs at the surface of Au nanoparticles. 
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Figure 7-6: Absorption spectra of NADH (0.05 mM) at different time after gold 
nanorods (0.3 nM) are added. The gold nanorods are synthesized by the electrochemical 
method. Inset is the absorption region of gold nanorods between 400 to 800 nm; (b) 
Absorption spectra of NADH (0.05 mM) at different time after HAuCl2 solution (0.17 
mM) is added. The HAuCl2 solution is obtained by reduction of HAuCl4 in CTAB 
solution with ascorbic acids; (c) Absorption spectra of gold nanoparticles (0.46 nM) at 
different time after NADH (0.05 mM) is added; (d) Initial reaction rate of the NADH 
oxidization vs concentration of gold nanoparticles. The reactions are taken at the same 
initial NADH concentration (0.08mM). The initial reaction rates are determined by the 
decreased amount of NADH within the first one minute after gold nanoparticles are 
added. 
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The Au+ on the surface of Au nanoparticles could be one reason due to the incomplete 
reduction of Au3+. The Au nanoparticles must catalyze the reduction of Au+ on the 
surface of Au nanoparticles if this is the case because much higher concentration of 
HAuCl2 (assuming 100% HAuCl4 is converted to HAuCl2 in the synthesis of Au 
nanoparticles) solution shows slower reduction (Figure 7-6 (b)). Thus the oxygen 
molecules adsorbed on the surface of Au nanoparticles is the possible reason due to the 
high surface-to-volume ratio of the Au nanoparticles. It has been reported that many 
important reactions involving oxygen as the oxidant are catalyzed by Au nanoparticles, 
such as the low-temperature CO oxidation (17-19), propylene epoxidation (20, 21), 
combustion of hydrocarbons (22, 23), NOx reduction (24, 25), hydrogenation reactions 
(26), etc.  
    In our work, the fact that oxygen is involved as the oxidant and Au nanoparticles as the 
catalyst for the NADH oxidation reaction is supported by the nitrogen flush experiment. 
When Au nanoparticles are flushed with nitrogen gas for several minutes before they are 
mixed with NADH solution, the reaction speed (the slope of the fitting curves) is 
obviously slowed compared to the reaction in oxygen (Figure7-7). So the addition of Au 
nanoparticles simultaneously introduced the catalysts and the oxidant. 
    In this work it has been shown that Au nanoparticles catalyze the oxidation reaction of 
the biofluorophore nicotinamide adenine dinucleotide which is one of the most important 
coenzymes in every cell. The decrease of the absorption intensities at 340 nm is due to 
the decrease of the NADH amount and the increase of the absorption intensities at 260 
nm is due to the formation of NAD+. As NAD+ is not fluorescent, the conversion reaction 
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induces the quenching of the fluorescent intensities of NADH. The change of the surface 
plasmon absorption band of Au nanoparticles indicates NADH is surface catalyzed by the 
Au nanoparticles. The oxygen on the surface of Au nanoparticles possibly reacts with 
NADH and produces NAD+. This catalytic effect of Au nanoparticles on NADH could 
have future importance in biochemical and medical applications. 
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Figure 7-7: Comparison of the reaction speed of NADH oxidation 
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CHAPTER 8  
FLUORESCENCE STUDIES OF THE INTERACTION OF GOLD 




    The fluorescence properties of collagen and whole cells are studied with and without 
the presence of gold nanospheres and nanorods. The fluorescence of collagen solution is 
quenched by the addition of Au nanospheres and nanorods due to the re-absorption of the 
fluorescence by the Au nanoparticles. The protein fluorescence of HaCat healthy cells, 
HSC and HOC cancer cells are the same but the NADH fluorescence of the three types of 
cells are different, which makes the diagnostics of the cancer cells possible by using 
fluorescence spectroscopy. When the nanospheres and nanorods are incorporated into 
cells or by mixing with the cell solutions, the fluorescence of both protein and NADH 
bands are quenched by the nanoparticles. This is due to the re-absorption of the cellular 




    Fluorescence spectroscopy is a widely used tool in biochemistry and molecular biology 
as a novel minimal-invasive method. It is a well established analytical technique that can 
be used to provide chemical sensing in dilute nonscattering samples. It is very helpful to 
provide information about biochemical, structural and functional changes of biomolecule 
related complexes (1-3). It is becoming a dominant method in medical diagnostics such 
as cancer detection. In fluorescence spectroscopy, absorption of light by a molecule 
excites it from a vibrational level in the electronic ground state to one of the many 
vibrational levels in the electronic excited state, usually a singlet state. Collisions with 
other molecules cause the excited molecule to lose vibration and electric energy and fall 
to the lowest vibrational level of this state. Fluorescence occurs when the molecule 
returns to the electronic ground state, from the excited singlet state, by emission of a 
photon. The molecule will also partition the excess energy to other possible modes (see 
Figure 8-1, (4)) of vibration and rotation if in the gas phase. 
 
 
Figure 8-1: Fluorescence process (4).   
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    Tissues contain a lot of different intrinsic fluorophores which are characterized by their 
absorption and emission spectra. Table 8-1 lists the Endogenous fluorophores in tissue 
(5). Figure 8-2 shows the absorption and emission spectra of some of the important 
autofluorophores in tissue (6). These endogenous fluorescences are very important for 
optical assessment of the tissue metabolic status. Among those autofluorophores, NADH, 
collagen, elastin and flavins plays dominant roles due to their strong fluorescence upon 
excitation between 335 nm and 360 nm. Protein fluorescence is contributed by amino 
acids including tryptophan, tyrosine and phenylalaine (7, 8). 




(a) Excitation spectra of some biomolecules 
 
(b) Emission spectra of some biomolecules 
Figure 8-2: Excitation (a) and emission (b) spectra of some biomolecules (6). 
    Collagen is a fibrous component of bone, teeth, cartilidge, tendons, blood vessels and 
matrix of skin. It contains 3 protein chains forming triple helix (see Figure 8-3, (9)). All 
the three helix contains GLY-X-Y-repeating sequence (X often Pro, Y often Hyp). 
Collagen fluorescence is associated with two types of cross-links. One is hydroxylysyl 
pyridinoline (HP) and another is lysyl pyridinoline (LP) (Figure 8-4, 10). Both are 
autofluorescent with emission maximum at 400 nm at excitation of 325 nm. 
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Figure 8-3: Structure of collagen (9). 
 
Figure 8-4: Fluorescence components in collagen (10). 
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    With the wide application of nanotechnology in biology and biomedine, the use of 
metal surfaces to manipulate the spectral properties of fluorophores has gained increased 
interests due to their effects on the fluorophores such as increasing or decreasing the rates 
of radiative decay and the rates of resonance energy transfer (RET) (11,12). Au 
nanoparticles have been applied to biomedine for cancer cells diagnostics and 
photothermal therapy (13-16). But there is no report on the research on its interaction 
with the fluorescence of cellular compoents. In order to understand the potential 
application of Au nanoparticles in fluorescence studies as an optical diagnostic tool, we 
characterized the interaction of Au-NP’s with the optical properties of the component 
fluorophores and whole cells of an oral squamous cell carcinoma cell culture model.  
8.2. Experimental  
    Acid soluble type I collagen (White rabbit skin, Sigma-Aldrich) is dissolved in 0.5 M 
acetic acid. Collagen is mixed with Au nanospheres with 15 nm in diameter and AU 
nanorods with aspect ratio of 2.4 in various concentrations and put in a 1cm (for dilute 
specimen) and/or 5 mm quartz cuvette for absorption and fluorescence experiments. The 
concentration of collagen is held constant as the nanoparticle concentrations are increased 
over several trials.   
    The effect of 15 nm Au nanospheres on whole cell fluorescence is characterized using 
two malignant oral squamous cell lines (HOC 313 clone 8 and HSC 3) and one non-
malignant epithelial cell line (HaCat).  HSC 3 is a malignant, aggressive, metastatic line 
of oral carcinoma.  HOC 313 clone 8 is a less aggressive malignant oral carcinoma with 
less metastatic potential.  HaCat is a line of nonmalignant line of epithelial tissue origin. 
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    Au NPs are applied in two ways.  First they are added directly to cell suspensions and 
compared to control cells without nanoparticles from the same suspension that are 
equally diluted with Dulbeccos’ buffered phosphate saline (DPBS). The cells are spun 
down at 1000 rpm and 0oC C for 5 mins to get rid of DMEM medium which will 
interference the fluorescence signals of cells. The cell pellets are reconstituted with 
DPBS and then centrifuged two more times in DPBS to remove all DMEM. Second, they 
incubated into cells for 12, 24 and 48 hours and compared to control cells derived from 
the same sample and incubated concurrently. 
    The absorption spectrum of each sample of NADH and collagen are measured in 1cm 
(for dilute solutions) or 5mm quartz cuvette on a Shimadzu UV-3101PC spectrometer. 
Fluorescent spectra of collagen are obtained using a PTI fluorimeter with a Xenon lamp 
and PMT detector. Spectra of cell suspensions are measured in a 5mm quartz cuvettte on 
a Molecular Devices Spectramax M5 fluorimeter.  Data of cellular fluorescence is 
recorded into Soft Max Pro 4.8 software and transferred to Microsoft Excel 2002 
database on Windows XP for data processing.     
    Preliminary spectra from whole cell suspensions are evaluated at several excitation 
wavelengths over several trials to identify optically active areas and peak maximum 
values is graphed out by cell type and length of incubation and analyzed visually for 
consistency. The optical density and cell count are compared to ensure data integrity.  
Clumping of the cells during specimen preparation could decrease the fluorescence by 
removing cells from the light path. Data is evaluated for differences among the cell types 
and by method of nanparticle application. The average difference of fluorescence 
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between untreated and treated cells is determined and graphed using Micorsoft Excel as a 
proportion of the total fluorescence of the control cells without the nanoparticles.  The 
mean value of fluorescence of the two groups (with and without nanoparticles) is 
calculated and the significance determined using the paired T test for the matched 
samples.   
8.3 Results and discussion 
8.3.1 Interaction of gold nanoparticles with the collagen suspension  
    Figure 8-5 shows the results of the effect of Au nanospheres on the absorption and 
fluorescence of collagen solution. Figure 8-5(a) shows that the addition of Au 
nanospheres did not affect the absorption spectra of collagen.  Figure 8-5 (b) shows that 
the absorption spectra did not change with the time when Au nanospheres are mixed with 
the collagen solution. Figure 8-5 (c) shows that Au nanoparticles quench the fluorescence 
of collagen. As the concentrations of Au nanoparticles increase, the quenching of the 
fluorescence increases. The time-resolved fluorescence spectra in Figure 8-5 (d) show 
that the presence of Au nanospheres does not affect the fluorescence decay of collagen 
solution. 
    This is unlike the effect of Au nanoparticles on NADH fluorophore. As discussed in 
Chapter VII, Au nanoparticles catalyzed the oxidation of NADH to NAD+. But when Au 
nanospheres are mixed with collagen solution, the absorption spectra of collagen do not 
change. This indicates that collagen is not converted to other species. The fluorescence 
decrease after addition of Au nanoparticles indicates that Au nanoparticles quenched  
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Figure 8-5: Interaction of collagen suspension with Au nanospheres. (a) 
Absorption spectra of collagen in various amount of Au nanospheres 
(OD=1.0); (b) Absorption spectra of collagen with Au nanospheres at 
different time; (c) Fluorescence spectra of collagen in various amount of 
Au nanospheres (OD=1.0). λexci = 280 nm. (d) The fluorescence decay of 
collagen at 390 nm in different amount of Au nanospheres (λexci = 280 nm). 
The lifetime of collagen fluorescence obtained by a monoexponential 
fitting is about 2.4 ns which is the same for all samples. 
 
the fluorescence of collagen. This could be due to the filter effect of the gold 
nanoparticles, the re-absorption of collagen fluorescence by Au nanoparticles or due to 
energy transfer from collagen molecule to the Au nanoparticles. The same fluorescence 
decay of collagen is not affected by the addition of Au nanoparticles suggesting that there 
is no energy transfer process taking place between collagen and the nanoparticles. Thus 
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the fluorescence quenching is caused by the simple absorption of the fluorescence of 
collagen or the exciting light by Au nanoparticles. 
    The gold nanorods have similar effects on the collagen absorption and fluorescence 
spectra, shown in Figure 8-6. Au nanorods quenched the fluorescence of the collagen  
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Figure 8-6: Interaction of collagen suspension with Au nanorods. (a) 
Absorption spectra of collagen in various amount of Au nanorods 
(OD=1.6); (b) The absorption spectra of collagen with Au nanorods at 
different time; (c) Fluorescence spectra of collagen in various amount of 
Au nanorods (OD=1.6). λexci = 280 nm; (d) The fluorescence decay of 
collagen at 390 nm in different amount of Au nanorods (λexci = 280 nm. 
The lifetime of collagen fluorescence obtained by a monoexponential 
fitting is about 2.4 ns which is the same for all samples.  
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solution, but they did not change the absorption spectra or the fluorescence decay of the 
collagen solution. The fluorescence quenching effects is due to the re-absorption of the 
fluorescence or the exciting light by Au nanorods. 
8.3.2 Interaction of gold nanoparticles with the cell suspension 
    The absorption and fluorescence spectra of cells without nanoparticles are shown in 
Figure 8-7. For comparison, all data are normalized. All three types of cells have 
absorption maximum at 280 nm which is from the protein absorption (Figure 8-7(a)).  





































































Figure 8-7: Absorption (a) and fluorescence spectra (b, c) of different 
types of cells without nanoparticles. (b): λexci = 280 nm, (c): λexci = 340 nm. 
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The protein fluorescence profile is similar for all three cells lines after normalization. 
When excited at the protein absorption maximum of 280 nm, the cells show a very strong 
and similar fluorescence band around 336 nm (Figure 8-7 (b)). When excited at the 
NADH absorption maximum around 340 nm, they show a weaker band around 450 nm 
compared to their protein fluorescence bands (Figure 8-7 (c)). From Figure 8-7 (c) we 
can see that the normalized profile for each type of cells is different. The normal HaCat 
cells have higher fluorescence at wavelength shorter than 400 nm and higher wavelength 
over 480 nm regions. HSC cancer cells have higher fluorescence intensity from 420nm to 
450 nm. Collagen fluorescence (380nm region) and flavin (520nm region) in HaCaT 
noncancerous cells are stronger than that in HOC and HSC cancerous cells.  Elastin 
fluorescence (420nm region) is stronger in HSC cancerous cells than that in HaCaT 
noncancerous cells and HOC cancerous cells. Upon mixing NPs with cell suspension, 
NPs quenched both protein and NADH fluorescence of all three cell lines. After 
incubation inside the cells, NPs quenched the protein fluorescence of all three kinds of 
cells. Interestingly, NPs also quenched the NADH fluorescence of HaCaT noncancerous 
cells, but enhanced the NADH fluorescence of HOC and HSC cancerous cells.  
    The effects of Au nanoparticles on the absorption and fluorescence of all three type of 
cells are shown in Figure 8-8 (Au nanoparticles are mixed with cell suspension).   From 
Figure 8-8 it can be seen that Au nanoparticles quenched the fluorescence of cells at their 
protein and NADH bands when they are mixed with the cell suspensions. 
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Figure 8-8: The comparison of fluorescence spectra of whole cells with 
and without nanospheres mixed in solution.  λexci = 300 nm for (a), (c) and 
(e); λexci = 330 nm for (b), (d) and (f). (a) and (b): HaCat cells; (c) and (d): 
HSC cells; (e) and (f): HOC cells. 
 
 169
    The effects of Au nanoparticles on the absorption and fluorescence of HSC cells 
incubated with nanoparticles are shown in Figure 8-9 (data are obtained by Ivan H. EL-
Sayed at University of San Francisco). From Figure 9 it can be seen that Au nanoparticles 
quench the cellular fluorescence at their protein and NADH bands.  Other types of cells 
have similar results and thus not shown here. Further review of the data revealed there is 
no obvious difference if the gold nanoparticles incubated for longer times (12 to 48 
hours).  
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Figure 8-9: Representative fluorescence spectra of whole cells incubated 
with nanospheres using HSC 3 in solution. λexci = 280 nm. Au nanospheres 
decrease the fluorescence of cells. The pilot data is similar for all 3 cells 
both for those incubated with and without nanoparticles, and for those 
mixed in suspension with nanoparticles (Obtained by Ivan H. EL-Sayed, at 
University of San Francisco). 
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     Statistically many samples are run for checking the data of reproduction. A similar 
number of cells have a wide range of fluorescence. This may be attributable to varying 
metabolic conditions of the cells.  However, each test sample and control is paired as they 
are seeded with the same starting cells and grown under equal conditions. Overall, Dr 
Ivan H. EL-Sayed’s student, Fema checked 32 samples. He grouped the cells together 
and the mean fluorescence of the two groups is compared (Figure 8-10). There are not 
enough specimens to perform subgroup analysis. Thirty eight specimens are obtained 
overall. Two specimens are excluded due to technical difficulties with sample preparation 
and clumping of cells determined visually along with abnormal OD and cell counts. A 
box and whisker plot is created determining two outliers in either direction of the mean, 
and these 4 samples are removed from analysis. Twenty six of 32 samples demonstrated a 
decrease in fluorescence. Comparison of the mean fluorescence value at the peak 
maximum of 333 nm revealed a mean relative value unit of 1244 (no nanoparticles) and 
1059 (nanoparticles). The difference between means revealed an average quenching of 
15% (p<.00005). Thus from this percent decrease fluorescence analysis, statistically Au 
nanopartices quench the fluorescence of living cells. This is the first report we know of to 
characterize the effect of Au NPs on the cellular autofluorescence.  While Au NPs effects 
on fluorescence in many dry processes is a field of active investigation, the addition of a 
physiologic fluidic environment introduces many unknown variables to the system that 
have not been well studied. Many variables exist that may effect the optical properties of 
Au NP such as the acidity, the ions in solution, enzymes, and proteins. Therefore, any 
effects of Au nanoparticles in these conditions must be characterized experimentally. We 
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demonstrate that Au NPs decrease the fluorescence of two of the main fluorophores of 
cancer (NADH and Collagen) and also of whole cells (excitation at 280 nm).   
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Figure 8-10: Percent of fluorescence decreased for all samples (no 
incubation and incubation). No difference is observed for samples 
incubated with particles and mixed with particles in solution just prior to 
measurements with sample size. Some samples demonstrate increased 
fluorescence. With this small sample size, no difference can be determined 
between cell types or incubation times with nanoparticles. (Obtained by 
Ivan H. EL-Sayed, at University of San Francisco). 
    Much research has been conducted on the florescence of oral cancer.  While LIFE (17) 
is FDA approved for pulmonary and GI screening, the oral cavity and upper aerodigestive 
tract stand to benefit tremendously by improved screening methods. While the UADT is 
generally accessible for visual inspection, the eye lacks sensitivity and specificity.  
Further, at risk patients, including those with a previously diagnosed cancer, often have 
abnormal areas of dysplastic or scarred tissue from prior surgery and radiation, which is 
followed clinically. An accurate noninvasive technique to diagnose cancer and dysplasia 
in these patients would guide the treating physician tremendously. In conjunction with 
our prior work, we have now demonstrated that Au NPs effect three optical parameters 
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useful for spectroscopic cancer diagnostics; absorption, scattering, and fluorescence.   
These may be useful as optical probes for application with confocal endoscopy in the 
scattering or fluorescent mode, TMS, or LIFE. 
    Current fluorescent based techniques are not specific, but are capable of being coupled 
with camera imaging technology for screening wide areas. Thus fluorescent technology 
complements the fiberprobe technologies which offer specific diagnosis. Despite 
consistent changes in tissue fluorescence, many variables exist in the oral mucosa that 
affects interpretation of the spectra. The tissue thickness and keratinization varies with 
each site in the oral cavity, and factors such as increased vascularity or inflammation may 
create extra signals from porphyrins in hemoglobin or bacteria.  Thus, many investigators 
have stressed that baseline florescence must be determined on a patient to patient basis.  
This complicated process could be bypassed by developing a agent that could be applied 
to mucosa and stick to malignant cells. Measurements of fluorescence before and after 
can be imaged and significant decrease in fluorescence identified by comparing images.  
Au nanoparticles are easily conjugated to a variety of chemicals, proteins and antibodies 
to allow for molecular targeting which should increase the fluorescence quenching 
significantly.   
    This pilot study suggests a potential role for Au nanoparticles as an optical probe to be 
used in conjunction with optical biopsy techniques employing fluorescence spectroscopy.  
In combination with its other optical properties, Au nanopoarticles represent a unique 
multifunctional particle to increase sensitivity of detection, specificity of diagnosis, and 
tumor destruction with photothermal therapy via heat conversion of absorbed light.  
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Further, this work raises the possibility of new avenues of optical sensing in vivo using 
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CHAPTER 9  
SURFACE ENHANCED RAMAN SPECTROSCOPY  





    Surface enhanced Raman spectroscopy (SERS) are carried out on several different 
systems using a micro-Raman spectrometer with a NIR excitation laser at 785 nm. 
Colloidal Au nanoparticles (Au NPs) are incubated inside cells and Raman spectra from 
both single cells and cell pellet are collected. Colloidal Au NPs are also mixed with the 
cell suspension and the cell pellets. The HaCat healthy cells, HSC and HOC cancer cells 
are measured and compared.  SERS are also measured on mercaptoacetic acids and anti-
EGFR antibodies which are adsorbed onto monolayer of prismatic gold nanoparticles 
assembled on quartz substrate. The SERS of R6G and BSA molecules are recorded on a 




    Raman spectroscopy has been used for biological application since the first 
interpretable laser-excited Raman spectrum of a native protein is obtained from lysozyme 
by Lord and Yu at the MIT Spectroscopy Laboratory in 1970 (1). Raman spectroscopy 
can provide the most detailed information about the chemical composition of the tissue 
under study among the molecular level optical spectroscopy such as absorption, 
fluorescence, reflectance and Raman scattering (2). But most biological molecules have 
small Raman scattering cross-section which results in very weak signals, possibility of 
sample damage and the strong fluorescence background from cells and tissues (3). The 
problem of sample damage and strong florescence background can be addressed by 
shifting the excitation laser wavelength from UV-Visible to NIR region.  The 
enhancement of Raman signals mostly relies on the surface-enhancement Raman 
spectroscopy. 
    In 1974, surface-enhanced Raman spectroscopy (SERS) are observed by Fleischmann 
on pyridines adsorbed on an Ag electrode roughed by oxidation-reduction cycles (4). But 
they attribute the signal enhancement to the big surface area of the electrode. In 1977, 
Van Duyne (5) and Creighton (6) firstly recognized the large intensity is due to the 
electromagnetic field effect. Now it is believed that SERS is due to two major 
enhancements: the electromagnetic field enhancements and the chemical enhancement. 
When molecules are adsorbed to metallic nanostructures, resonances of the applied 
optical fields with the surface plasmon oscillation of the nanostructures, the local optical 
fields of these structures are greatly enhanced and results in the enhanced Raman signals 
 178
(7-11). This electromagnetic field enhancement plays the most important role in the 
SERS. In addition, the electronic interaction of the adsorbed molecules and the metal 
surface can results in an increase in the Raman cross-section of the molecules (12-15). In 
many experiments on metal surfaces this “chemical or electronic” effect provides a very 
small contribution compared to the electromagnetic enhancement. 
    In early 1980’s, SERS are observed on small and large biomolecules such as DNA and 
protein. Three groups, Koglin and Sequaris (16), Cotton et al. (17-19) and Nabiew (20) 
and coworkers have lead to a great development of SERS on the biomolecules during this 
period. Later many researchers have continued to demonstrate the great potential of 
SERS applications in the fields of biochemistry, biophysics, and molecular biology.  
    In early 1990’s, SERS are performed using metallic nanoparticles on living cells (21-
24). In these experiments, colloidal silver nanoparticles are incorportated inside cells and 
used to probe the interaction of drugs and DNA complex. But only drug signals are 
observed. In 2002, Field et al. directly incorporated 60 nm colloidal gold nanoparticles 
into living cells and observed the celluar constitutes (25). Figure 9-1 shows the SERS 
signals of the cell DNA and proteins and the signal mapping. On the cell monolayer, 
different spectra are obtained on different spots. These distinct spectra reflect the 
inhomogenorosity of the cell composition. But also the nanoparticles aggregated inside 
cells, which might also results in the signal difference due to different degree of 
aggregation. Recently, Kneipp et al used indocyanine green dye conjugated gold 
nanoparticles as probe to determine the cellular components (26). When indocyanine 
green dye conjugated gold nanoparticles are incorporated into cells, 
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Typical unprocessed surface-enhanced 
Raman spectra measured with 1-mm spot 
size at different places on a cell monolayer 




Phase contrast image of two living cells (top) and 
the image of the total SERS signal (bottom) (25). 
 
Figure 9-1: SERS from single living cells using gold nanoparticles incorporated inside 
cells (left) and the images of the total SERS signals (right) (25). 
 
the probe not only gave Raman signals of indocyanine green molecules, but also signals 
from cell constitutes (Figure 9-2). In this way, nanoparticle aggregation is avoided and 
the data is more consistent. But they did not compare the difference between cancer and 
healthy cells. 
   In the present work, 60 nm colloidal gold nanoparticles are also incorporated inside 
both healthy and cancer cells and Raman signals from single cells are obtained and 
compared between the noncancerous and cancerous cells. Due to the signal difference 
from different laser focus spots, the cells pellet after incorporation of the gold 
nanoparticles are also used to obtain SERS of whole cells. In addition, gold nanoarray 
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and gold nanorods film are also used to obtain SERS of small molecules, large 
biomolecules and living cells.  
 
Figure 9-2: (a) Examples of SERS spectra measured in single living cells incubated with 
the ICG-gold nanoprobe. Trace A represents the ICG signature. Assignments of major 
bands in spectra B-E are given below spectrum E. ICG bands are marked with an asterisk, 
while an asterisk in parentheses indicates contribution of both ICG and cell. Trace C 
shows the difference between spectra B and A and displays only Raman lines of the cell. 
(b) Spectral map of the ICG-gold nanoprobe in a cell based on 1147-cm-1 ICG line and 




    Au nanoparticles of 60 nm in diameter are synthesized by the citrate reduction method 
as described in Chapter 2, Page 55-56. Then several drops of these nanoparticles are 
added in the medium in a well of a 12-well plate in which cells are grown on a cover slip. 
The nanoparticles are incubated with the cells for 2 days. Then the cells on coverslips are 
take out of the incubator and fixed with 1.6% paraformaldehyde and sealed with another 
coverslips and used for Raman measurement. 
    To make the cell pellet for Raman experiment, the cells are grown in 60x15mm tissue 
culture dishes. The 60 nm Au nanoparticles are added into the medium and let incubate 
with the cells for 2 days. The cells are then cleaved with trypsin and centrifuged at 1000 
rpm for 5 mins to get cell pellet. The cell pellet is resispersed in DPBS buffer and 
centrifuged again to rinse out the medium which might interfere the Raman signals.  
Then the cell pellet on the bottom of the centrifuge tubes is placed on the ice and carried 
to Raman lab for Raman experiment. The cell pellet are taken out by a glass pipette and 
placed onto a foil film and used for Raman measurement.   
    60 nm Au NPs are also mixed with cell suspension and shaken for 30 mins and then 
centrifuged down to get cell pellet. In this way, the NPs are adsorbed onto the surface of 
the cells and SERS signals from the cell surface protein can be obtained. 
    Au nanoarray is also used for SERS of adsorbed molecules. The nanoarray is prepared 
by Wenyu Huang, a member of our group. Different molecules are adsorbed onto the 
nanoarray for SERS measurement. Nanoarray is also autoclaved and used a substrate for 
cell growth. The Raman experiment of the cells grown on Au array is carried out in PBS 
buffer.  
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    Au nanorods film is also prepared on which molecules are adsorbed for the SERS 
experiment. The procedure to make the rod film is similar to that described by Yamada et 
al. (27) and shown in Figure 9-3. Briefly, 10 mL hexane is added to 10 mL rod solution 
(λmax = 2.0). Then 2.5 mL acetonitrile is added dropwise on top of the hexane. During the 
addition of the acetonitrile, the nanorods are adsorption onto the interface of the hexane 
and nanorod solution. After the acetonitrile is completely added, a thick layer of nanorod 
film is formed at the interface. The film is then lifted up by inserting a quartz plate and 
the film is transferred onto the quartz plate.     
 
 
Figure 9-3: The preparation of nanorods film (27). 
    Rrodmine 6G, Bovine Serum Album and anti-EGFR antibodies are drop added on the 
film for Raman measurement. After 2 mins of R6G addition on the film, Raman spectra 
are collected. After overnight of BSA and anti-EGFR antibodies are added, Raman 
spectra are collected.  
9.3 Results and Discussion 
    Since Au nanoparticles are capped with and mostly close to citrate molecules, it is 
important to know the citrate Raman SERS signals. Figure 9-4 shows the Raman spectra 
of a drop of 60 nm Au NPs concentrated solution on a foil film and a dried 60 nm Au 
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NPS film. From this Figure, we can see that very strong SERS signals of citrate on the 
surface of Au NPs are observed. And also the signals from monodispersed Au NPs and 
aggregated dried film are different. These Raman bands from citrate should be considered 
when molecules or cells are adsorbed onto the surface of Au NPs. The assignment of the 
bands can be obtained from reference 28. The major bands at 890, 1126, 1266, 1446 and 
1492 cm-1 are possibly assigned for υ (C4-O), υ (C-C), υa (OCO), υs (COO) and υas 
(COO), respectively. 
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Figure 9-4: Citrate SERS signals adsorbed on Au NPs. 
9.3.1 Colloidal gold incubated inside cells – SERS from single cells 
    Colloidal Au are incubated inside cells, fixed and used for Raman measurement. But 
the problem is that the spectra are not quite reproducible. Different age of Au NPs used 
and different incubation time gave different Raman signals. Figure 9-5 shows the SERS 
from part of single cells (8 µm in diameter) obtained by different time. The NPs are 
incubated inside cells for 2 days for all samples. 
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Figure 9-5: SERS signals from single cells. 60 nm Au NPs are incubated inside cells. 
    From Figure 9-5 we can see that the Raman signals for each type of cells are different 
when the experiments are done at different time. This is mostly due to the different 
patches of Au NPs used. The Au NPs used on May 26 are the same patches of NPs used 
on May 20, but aged 6 more days. The Au NPs used on June 1 is different patches of Au 
NPS used on June 8. As we have seen from Figure 9-4 that for nanoparticles themselves, 
aggregation give different spectrum. So it is obviously that the degree of Au NPs 
aggregation affects the signals observed from cells. Each time, Au nanoparticles are 
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incubated inside cells, the NPs are aggregated. Different aggregation will get different 
signals. Even in the solution of Au NPs before addition to the medium, there might also 
aggregation of NPs. And also compared to Figure 9-4, most signals from cells are 
actually from citrate molecules. So it is hard to get a consistent conclusion what are the 
difference between the cancer and healthy cells. 
    If the cells are not fixed, the living cells are immersed into PBS buffer and measure 
signals from single cells, the signals from each spot from one cell are different. And also 
the signals on one spot are changing even after several seconds under 50x. We originally 
thought that this is due to the laser damaging the cells. However, if the cells are fixed, the 
signals are not changed within mins. This indicates that the change in the signal with time 
is due to the motion of the living cells in the buffer. Under each second, the cell 
molecules are moving and the Au nanoparticles inside cells are also moving. So it is hard 
to reproducible signals from each part of the cells.  
9.3.2 Colloidal gold incubated inside cells – SERS from cell pellet 
    Since it is hard to get reproducible results from signals on single cells, the cell pellet 
after incubated with Au NPs solution is used. In this way, each cell pellet gives one 
spectrum from a lot of cells under the focused spot (10x, 15 µm focus area). Since the 
aggregation of Au NPS affects the signals, the Raman spectra from samples of different 
incubation time are also measured for comparison. Figure 9-6 shows the Raman signals 
from cell pellets pre-incubated with 60 nm Au NPs. It can be seen that the Raman profile 
are quite reproducible for each type of cells. Also the changes of the signals due to 
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aggregation of the Au NPs (long time incubation) are consistent for the three types of 
cells. The assignments of the peaks are listed in Table 9-1 according to references (29-32). 
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Figure 9-6: Raman spectra of cell pellet incubated with NPs at different time. From up to 
bottom the incubation time increases. Right spectra are the time peaked for 2 days, 4 days 
and 6 days incubation and normalized at 670 cm-1 for comparison. 
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Table 9-1: Peak assignment of the bands in Figure 9-6 according to references (29-32). 
510: Au-S 1026: Phe 
670:  cys and or T, G 1140: trp 
755: T 1303: phe, try, trp and/or A, P: CH def 
836: DNA: RP, try 1337: trp and/or A, P: Ch def 
897: DNA Bkb: C-C str 1384: T, A, G? 
1000: Phe ring vib  
    From Figure 9-6 and Table 9-1 we can see that some differences between the three 
types of cells are observed. The phe contents in HaCat normal cells are higher than that in 
HSC and HOC cancer cells. At 6 days incubation, there is a peak at 1267 cm-1 (try 
and/or citrate molecules) in HaCat normal cells while this peak is absent in the other two 
cancer cells. At 6 days incubation, the Au-S band in HOC cancer cells is extremely 
strong compared to the other two types of cells. Also the intensity ratios of the two peaks 
around 500 nm are different for each type of cells. These differences might be useful in 
the diagnosis of the different types of cells. 
9.3.3 Colloidal gold mixed with cell suspension 
    Another method to measure the SERS of cells is to mix colloidal Au with the cell 
suspensions in buffer. In this way, the Au NPs aggregate in the buffer and also are 
adsorbed onto the cell surface. Some of the NPs enter into cells by endocytosis. The 
mixture is centrifuged down and the cell pellet is used for the Raman experiment. Figure 
9-7 shows the results of the three types of cells and Table 9-2 lists the assignment of the 
major peaks according to reference (29-32). One issue need to be pointed out is that the 
ratio of the cell numbers and the Au NPs amount determine the intensity of the observed 
signals. Too much Au NPs give mostly citrate signals and too many cells give too weak 
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SERS signals to be detected. Figure 9-7 is the optimum signals obtained. From Figure 9-7 
we can see that the 1263 cm-1 peak (tyr) in HOC is very strong while it is absent in 
HaCat and HSC cells. The largest difference is due to the two peaks at 1546 (trp) and 
1586 (trp, phe) cm-1. The intensity ratio of the 1546 cm-1 to 1586 cm-1 is in the 
following order: HOC > HSC > HaCat. This might be a fingerprint for differentiation of 
the three cells from.  
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Figure 9-7: SERS of cell pellets with Au NPs mixed. 
  Table 9-2: Peak assignments of the bands in Figure 9-7 according to references (29-32). 
493: Au-S 1263: tyr and/or citrate 
708: trp 1306: phe, try, trp  
733: cys 1436: phe  
995: Phe  1546: trp 
1150: trp 1586: trp, phe 
9.3.4 SERS using gold nanoarray 
    The reason we use array is try to see anti-EGFR SERS signals. We have tried to bind 
anti-EGFR antibodies onto the Au nanosphere solution and did not see the antibody 
 189
signals due to the interference from the strong citrate signals. So it is better to use 
nanoarray since the gold nanoparticles are made without capping materials under the 
method of nanosphere lithograpy on a quart substrate. These adsorbed molecules onto the 
surface of the nanoprisms would give strong Raman signals.  We have tried different 
molecules and also cells grown and dropped onto the array surface. Figure 9-8 is SERS of 
the mercaptoacetic acid chemically adsorbed onto the Au array. 
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Figure 9-8: SERS of the mercaptoacetic acid adsorbed onto the Au array. 
The mercaptoacetic acid (MPA) is chemically bound to the Au surface via Au-S bound 
and thus strongly enhanced by the Au nanoarray. Even the Au nanoarray is exposed to 
the vapor of the acids, the thiol molecules will be adsorbed onto the Au array and strong 
Raman peaks are observed. 
    After MPA are adsorbed onto Au surface, anti-EGFR antibodies are adsorbed onto the 
MPA surface by electrostatic interaction between the negatively charged acid surface on 
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the MPA and the positively charged antibodies. The Raman spectra after addition of 
antibodies are shown in Figure 9-9.  From this Figure, it can be seen that there is no more 
peaks observed after addition of the antibodies. The increase of the intensity around 954 
cm-1, 676 cm-1, 800 cm-1 and 1138 cm-1 may also indicate the antibody signals, but it is 
weak and can not be confirmed. This might be because the antibody molecules are far 
away from the Au surface and thus they are not enhanced. Thus we tried to directly put 
the antibodies onto the array surface and Raman signals are observed. 
 










 MPA+IgG on Au array
 
 
Figure 9-9: SERS of mecaptoacidic acid as well as after addition 
of anti-EGFR antibodies. 
      Figure 9-10 shows the Raman spectrum of antibodies on the Au array. From Figure 
10 we can see that some peaks such as 674 cm-1, 1150 cm-1 and 1264 cm-1 showed up 
after addition of antibodies, which indicate the signals from antibody. The array is 
immersed into the antibody solution (10 µM) overnight. So the antibody is adsorbed onto 
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the Au array by some chemical bounds and physical adsorption between the amino acids 
on the antibodies and the Au surface.  











1 0 0 0
1 1 0 0





R a m a n  s h if t  ( c m -1 )
 A r ra y
 A r ra y  +  A n t i-E G F R  a n t ib o d ie s
 
Figure 9-10: The SERS of antibodies on the Au array. The 
background signals from array itself are also shown for comparison. 
 
9.3.5 SERS of R6G dye using gold nanorod film 
    To obtain the SERS of the antibodies, gold nanorods are also used. In this method, 
gold nanorods film is prepared on quartz plates. To test the SERS of the rod film,     R6G 
molecules are drop added onto the film and Raman spectrum are measured. I used R6G 
because the molecules would not evaporate when they are dropped onto the film and also 
many people use R6G as a test of Raman enhancement. Figure 9-11 shows the Raman 
spectra of the Rods themselves and the rods with different concentration of R6G 
adsorbed. 
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Figure 9-11: The SERS of R6G on Au nanorods film. 
*: R6G signals enhanced by the gold nanorods. 
    In Figure 9-11 green and blue curves show the Raman signals of R6G on the rod film. 
The 3mM R6G in ethanol is checked for comparison. It can be seen that the Raman 
intensity of 3mM R6G on nanorods is much stronger than that of 3mM R6G film. When 
the R6G concentration decreased to 3 µm, the R6G signals are still strong and the 
intensity is similar to the 3mM R6G film. So the nanorods definitely enhanced the R6G 
signals. Compared to literature using gold nanospheres (33), which hardly give signals 
when R6G increased to 10 -6 M, the rod film give much better enhancement. 
    Then Bovine Serum Album molecules are drop added onto the rod film to see if the 
rod can enhance the Raman signals of big biomolecules. 15 µM BSA are added onto rod 
film and let it sit for 4h before checking Raman signals. The Raman signal is shown in 
red in Figure 9-12. Compared to the Rod film itself shown in black at the bottom, it 
seems some very weak peaks are observed such as the peak at 1426 cm-1. To see if these 
peaks are from BSA protein, the concentration of the BSA and the time of the Rod film 
 193
immersed into the protein solution are increased. When the rod film is immersed in the 
BAS solution for overnight in 5 mg/mL (75 µM) concentration, some new peaks are 
obvious: 500cm-1, 550cm-1, 890 cm-1, 960 cm-1 and 1426 cm-1.  To immerse the rod 
film into the BSA at 10mg/mL for 3 days, these peaks slightly increased. It indicates that 
after overnight incubation, the absorption of BSA onto rod film is saturated. The peak at 
500 cm-1 is from phe Au-N bond and 550 cm-1 is from tryp Au-N bond.  
4 5 0 6 0 0 7 5 0 9 0 0 1 0 5 0 1 2 0 0 1 3 5 0 1 5 0 0
*
***
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Figure 9-12: Surface Enhanced Raman Shift of bovine serum album on 
gold nanorod film. *: R6G signals enhanced by the gold nanorods. The 
nanorods are capped with CTAB. 
 
    This is first time that large protein SERS is observed on gold nanorod films. So this 
means that if cells can be ruptured (just by immerse the cells into water, the membrane 
ruptures and the nucleaus and proteins inside cells can flow out), the Raman signals of 
the protein and DNA could be enhanced by the rod film. In this way, the data will be very 
reproducible because the rods form a monodispersed film. They are not aggregates. I 
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have tested that from different spots of a nanorod film, the signals from both capping 
materials and adsorbed moelucles (R6G and BSA), they are almost the same. And also 
the signals do not change upon laser exposure. In addition, the anti-EGFR antibody SERS 
on the nanorods film should also be detected. But unfortunately, the Raman instrument is 
broken and the antibody Raman experiment can not be done. 
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CHAPTER 10  
NUCLEUS TARGETING OF GOLD NANOPARTICLES BY 




    Gold nanoparticles are targeted into the nucleus of humam epithelial HaCat cells by 
the sonication after incorporation of the nanoparticles inside cytoplasm by incubation of 
the nanoparticles in the cell medium during the cell growth process. In addition, gold 
nanoparticles are formed inside both nucleus and cytoplasm part of the cells by the 
reduction of auric acid with the cellular reducing proteins. The gold nanoparticles 
formation inside cells are more efficient by using the paraformaldehyde or glycerol 
reducing agents after the accumulation of gold ions inside cells. Light scattering imaging 
and micro-absorption spectroscopy are used to identify the nanoparticles in the cells. 
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10.1 Introduction 
    Nuclea rtarget of nanoparticles is very important because of the genetic information 
inside nucleus (1, 2). But nuclear targeting is a difficult task because the nanoparticles 
have to pass both cytoplasmic membrane and the nuclear membrane. Most of studies of 
intracellular tracking by metal, semiconductor and polymer nanoparticles are on the 
cytoplasmic entry (3-6). Some studies realize nuclear targeting by microinjection or 
chemical modification of cells (7, 8).  
     Feldheim et al. (9, 10) have tried to use several different peptides to modify gold 
nanoparticles and found that the nanoparticles modified with peptide from both 
adenovirus RME and adenovirus NLS went into nucleus efficiently when they are 
incubated with intact HepG2 cells in the cell culture medium (See Figure 10-1). 
 
 
Figure 10-1: Nanoparticle-peptide complexes incubated with HepG2 cells for 2 h: #2 (A), 
#3 (B), #4 (C), and #2/#3 (D).  
1: CGGGPKKKRKVGG, origin: SV40 large T NLS;  
2: CGGFSTSLRARKA, origina: adenoviral NLS;  
3: CKKKKKKSEDEYPYVPN, origina: adenoviral RME;  
4:  KKKKKKKSEDEYPYVPNFSTSLRARKA, origina:adenoviral fiber protein. (8). 
 200
    In our work, when we incubate colloidal gold nanoparicles with cells in the cell culture 
medium, the majority of nanoparticles go into the cytoplasm of the cells which are 
identified by the light scattering imaging. It is well known that nanoparticles can also 
enter into cells by sonication which ruptures the cell membrane and then the membrane 
will be recovered after the nanoparticle entry. Thus from this idea, it is interesting to see 
if nanoparticles can go into the nucleus by the sonication if the nanoparticles are already 
present inside the cytoplasm of the cells. By the sonication, the nucleus membrane may 
also rupture and allow nanoparticle incorporation. 
    In addition, recent reports have shown that gold and silver nanoparticles can be formed 
inside cells by mixing the auric acid or silver nitrate solution with the cell suspension 
(11-17). As shown in Figure 10-2 when auric acid is added to the bacteria biomass, the 
Au nanoparticles are formed after 24 hours. The particles distribute inside both 
cytoplasmic and nuclear part of the cells (Figure 10-3). In this manner, the nanoparticles 
can be directly formed inside the nucleus. In our work, we try the method for incubation 
the nanoparticles inside the nucleus of both cancer and healthy human cells. 
    
Figure 10-2: (A) Rhodococcus sp. biomass after removal from the culture 
medium. (B) Rhodococcus sp. actinomycete cells after exposure to 10−3 M 




Figure 10-3: (A)–(C) Representative TEM micrographs recorded at different 
magnifications from thin sections of stained Rhodococcus cells after reaction 
with AuCl−4 ions for 24 h. (D) A particle size distribution histogram 
determined from the TEM micrograph shown in figure 3(C). 
10.2 Experimental 
    15 nm gold nanoparticles are added to the DMEM cell culture medium and incubated 
with cells in culture dishes for 2 days. Then the cells is cleaved with trypsin and 
dispersed in DMEM in the centrifuge tube and carried to our lab for sonication. The 
sonication time is 20s, 40s and 60 s to see find out the best time for the nuclear entry of 
the nanoparticles. In too long time the cells might be killed due to the rupture of the 
membrane and too short time the nanoparticles entry might not be efficient. Right after 
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sonication, the cells are taken back and replated onto cover slips and let them grow at 
least for 4 hours.  Then the cells are fixed and sealed and used for dark field imaging. 
    To try to see the distribution of small nanoparticles (3nm), nanoparticles are made by 
the reduction of auric acid using NADH solution. These small nanoparticles are tried 
because they might directly penetrate into nucleus due to their small sizes. Equal amount 
of NADH solution (10 mM) and auric acid (5 mM) are mixed together. The solution 
became dark red immediately. The nanoparticles are left sit overnight to allow for the 
complete capping of the nanoparticles, probably by NAD+. The absorption spectrum 
show that the nanoparticles have an absorption maximum at 523 nm and the TEM show 
that the nanoparticles are about 3 nm (Figure 10-4). If the nanoparticles are allowed to sit 
for longer time, the absorption maximum red shifted about several nanometers due to the 
aggregation and growing of the nanoparticles.  















Wavelength (nm)      
 
Figure 10-4: Absorption and TEM of NADH made Au nanoparticles. 
    The intracellular formation of Au nanoparticles are carried out according to the method 
by Pradeep et al (11) who synthesizes Au nanoparticles inside human cells. Briefly, the 
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cells are grown on cover slips for 3 days. Then the medium are rinsed out and immersed 
with DPBS buffer with 1 mM auric acid. The cells with 1mM auric acid in the buffer are 
put back in the incubator for 7 days. The cells are then taken out and fixed and used for 
micro-absorption spectrum measurement and dark field imaging. 
10.3 Results and discussion 
10.3.1 Nucleus entry of gold nanoparticles by sonication   
    According to our previous experience, gold nanoparticles go mostly into cytoplasma 
portion of the cells. We do not see much or did not see at all gold nanoparticles inside 
nucleus. One simple experiment is to sonicate the cells after incubation of gold 
nanoparticles. Figure 10-5 shows the comparison before and after sonication for 40s.   
(a) before sonication 
 
(b) sonication for 40 s 
(c) sonication for 40 s 
 
(d) sonication for 40 s 
 
Figure 10-5: Comparison of gold nanoparticles inside cells without (a) 
and with sonication (b), (c), and (d). 
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From this Figure it can be seen that before sonication, the nanoparticles aggregate 
together and are located in someplace inside the cytoplasm. After sonication, the 
nanoparticles are more dispersed and widely distributed everywhere in the cytoplasm (b), 
(c) and (d). Also they are located inside the nucleus. The cells are viable after sonication 
and continue to grow in the growth medium and in the incubator. 
    Another interesting experiment is to incubate NADH made Au nanoparticles with cells.         
Au nanoparticles of different sizes can be prepared by reduction of NADH. No citrate is 
required to cap the nanoparticles. So NAD+ must cap the nanoparticles and the 
nanoparticles are very stable up to several weeks. Since NADH and NAD+ are more 
biocompatible and also NADH made Au nanoparticles do not aggregate in buffer, so the 
nanoparticle distribution must be different from the colloidal citrate capped nanoparticles. 
The light scattering pictures and micro-absorption spectra after incubation with NADH to 
make gold nanoparticles are shown in Figure 10-6.  
   
                       (a)                                         (b)                                               (c) 
Figure 10-6: Au NPs made by the NADH reduction incubated into cells. Au 
nanoparticles are distributed homogeneously inside cytoplasm of the cells. Some Au 
nanoparticles go into nucleus (a). 
Compared to the colloidal nanoparticles, it can be seen that the nanoparticles are 
homogenously distributed inside the cytoplasm part of the cells and the dark nucleus can 
be clearly seen. In this picture, the nanoparticles are about 30nm because the 
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nanoparticles are aged for 3 days after preparation. From the picture (a) it can be seen 
that some of nanoparticles went into nucleus. Compared to the citrate made Au 
nanoparticles, the NADH made nanoparticles do not aggregate. So the monodispersed 
NADH made nanoparticles went into cells more easily than the aggregated citrate made 
nanoparticles.  
10.3.2 Nucleus entry of gold nanoparticles by intracellular formation   
    Recently it has been reported that gold nanoparticles can be formed inside cancer and 
noncancer human cells by adding auric acid in the buffer solution (11). We follow this 
method for the HaCat healthy cells. In order to imaging cells, the cells need be taken out 
and sealed with another coverslips. So fixation and glycerol are needed for general 
procedures. But unfortunately, fixation solution-paraformaldehyde and glycerol are both 
reductive and so they might reduce Au3+ inside the cells and form gold nanoparticles. 
Thus a series of experiments are carried out to exam this possibility. The data are shown 
in Figure 10-7.  
    Figure 10-7 (A) is the image of the cells incubated only with 1mM auric acid for 7 
days and taken out of incubator and imaged immediately. No paraformadehyde or 
glycerol is used. Figure 10-7 (B) is the image of the cells incubated with 1 mM auric acid 
for 2 days and then paraformaldehyde is used to fix the cells and then wait for 2 days for 
cell imaging. So only paraformaldehyde is used. Figure 10-7 (C) is the image of the cells 
incubated with 1 mM auric acid for 2 days and then paraformaldehyde is used to fix the 
cells, glycerol is used to seal the cells and then wait for 2 days for cell imaging. So both 






























Figure 10-7: Au nanoparticles formation inside the cells. A: Cells 
incubated with 1 mM Au3+ for 6 days and take out for bright field imaging 
immediately. B: Cells incubated with 1 mM Au3+ for 2 days, them take out 
fixed with paraforaldehyde and sealed with water and measured their 
bright field images; C: Cells incubated with 1 mM Au3+ for 2 days, then 
take out fixed with paraforaldehyde and sealed with glycerol and then 
imaged. D: the light scattering image of D; E: cells without auric acid; F: 
the micro-absorption spectra of Au NPs from nucleus and cytoplasm of a 
typical single cell in sample C.   
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paraformaldehyde and glycerol are used, a lot of gold nanoaprticles are formed (red color 
in the bright field images), but if no paraformaldehyde and glycerol are involved, it is 
hard to see nanoparticles (Figure 10-7(A)). The cells look more yellowish, which means 
that a lot of Au3+ ions are accumulated inside cells (at Au3+ ion solution is yellow). Only 
under dark field, some gold nanoparticles can be seen inside cells (Figures not shown). 
So it means that gold nanoparticles can be formed inside cells by the cellular reducing 
agents. By using paraformaldehyde and glycerol, the Au3+ ions inside cells are reduced 
very quickly to forma nanoparticles. But the nanoparticles must be very small because 
they can not be identified under dark field. The absorption spectra show that the 
nanoparticles amount inside nucleus is almost double those in the cytoplasmic portion. 
This indicates that Au3+ contents (AuCl4- actually) are much higher inside nucleus than 
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